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Abstract 
The two last decades have witnessed the appearance and the successful development of 
magnetic resonance imaging (MRI) contrast agents (CAs). Though MRI, which has become 
an essential medical diagnostic tool, can be performed without contrast agents, its rather low 
sensitivity implies long and tedious examination times. This time can be considerably reduced 
by the use of CAs. Paramagnetic ion complexes, and particularly gadolinium (III) complexes, 
can thus significantly accelerate the longitudinal relaxation rate 1/T1 of the water proton, one 
of the most common parameters measured in MRI experiments. The relaxivity, the property 
describing the paramagnetic relaxation enhancement, or PRE, is mainly affected by four 
parameters : the number of water molecules in the inner coordination sphere of the complex, 
the proton exchange rate in this inner sphere, the rotational correlation times, related to the 
size of the molecule, and the electron spin relaxation rates. 
 
This work deals with the development of four new types of compounds designed as potential 
MRI T1 contrast agents. The four compounds have different properties and were therefore 
developed to observe different effect on the relaxivity. High-field CAs, medium-field CA 
aggregates, linear polymeric and nanoparticular CAs, and targeted CAs are the four different 
specificities studied in this work.  
 
The first compound, presented in Chapter II, is the tricephalous complex 
{Mes[Gd(DO3A)(H2O)2]}. This mid-size molecule was designed as a potential high-field CA. 
The standard complexation method does not lead to the complete complexation, most 
probably due to an intramolecular folding of the compound. The complexation is therefore 
performed in two steps : a complete pre-complexation with magnesium (II) followed by a 
transmetallation to replace Mg2+ by Gd3+ in the three complexation sites. This newly 
developed complexation method can be really useful to achieve complete complexation of 
mid-size molecules, where complexation shared by two neighboring chelating units can 
occur. 
 
Chapter III deals with another mid-size trimeric complex, the {Ph4[Gd(DTTA)(H2O)2]-3}. The 
central core of this compound, composed of four phenyl rings, was designed to favor 
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aggregation. The relaxivities of the big entities formed is expected to increase significantly in 
the medium resonance frequency range, i.e. between 10 and 200 MHz. The dynamic 
aggregation is observed by the concentration dependence of the relaxivity. The parameters 
obtained by fitting the experimental data allow the estimation of the number of molecule in 
the entities, ranging from the monomer in diluted solution to a few units for more 
concentrated solutions. 
 
Chapter IV presents Gd3+ chelate complexes conjugated to the linear polysaccharide 
chitosan. The coupling reaction, performed directly with the Gd3+ complex, is achieved 
through the condensation of a carboxylate uncomplexing arm on the chelating unit with the 
free amine of the chitosan. The ratio of modified chitosan units in the compound 
{Chi[Gd(DTTA-N’but)(H2O)2]-} is determined by ICP-MS and elemental analysis. Porous 
hydrogels nanoparticles, or nanogels, are subsequently formed from the modified linear 
chitosan by the ionic gelation method. As the material becomes bigger and more rigid, the 
relaxivities of the formed nanogels were expected to become higher than that of the linear 
chain. This does unfortunately not occur, most probably because of a partial complexation of 
the anion triphosphate, used for the formation of the particles, or by limited water diffusion 
inside the nanogels. 
 
The final chapter of results, Chapter V, presents a family of four compounds designed as 
target CAs for a specific kind of malignant tumor, such as prostate, breast or some lung 
cancer cells, which overexpress bombesin receptors. The four studied compounds are 
therefore composed by the peptide bombesin conjugated to a Gd3+ chelate complexe. In order 
to optimize the peptide-receptor interaction, two bombesin analogues, the Lys3-bombesin and 
the Ahx-bombesin(4-14), are used for the synthesis of the monovalent and the divalent 
peptide conjugates. The relaxometric properties of the four compounds are measured and 
compared. 
 
Key words :  aggregation, bombesin, chitosan, complexation, contrast agent, gadolinium 
(III), high-field, longitudinal relaxation, magnetic resonance imaging, 
nanogels, relaxivity, targeted, transmetallation. 
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Résumé 
Les deux dernières décennies ont vu l’apparition et le développement efficace d’agents de 
contraste pour l’imagerie par résonance magnétiques (IRM). Bien que cette technique, 
devenue un outil incontournable pour le diagnostique médical, puisse être exécutées sans 
agent de contraste, sa relativement basse sensibilité implique des temps d’examen longs et 
fastidieux. Ces temps peuvent être considérablement réduits par l’utilisation d’agent de 
contraste. Les complexes d’ions paramagnétiques, et particulièrement ceux du gadolinium 
(III), accélèrent ainsi significativement la vitesse de relaxation longitudinale 1/T1 du proton de 
l’eau, l’un des paramètres les plus mesurés lors d’examens IRM. La relaxivité, propriété 
décrivant l’augmentation de la relaxation paramagnétique, est modulée principalement par 
quatre paramètres : le nombre de molécules d’eau dans la première sphère de coordination du 
complexe, la vitesse d’échange du proton dans cette première sphère de coordination, le temps 
de corrélation rotationnel et les vitesses de relaxation du spin électronique. 
 
Ce travail traite du développement de quatre nouveaux types de composés, conçus comme de 
potentiels agents de contraste T1 pour l’IRM. Ces quatre composés, présentant des propriétés 
différentes, ont été développés pour observer différents effets sur la relaxivité. Les agents de 
contraste pour hauts champs, des agrégats pour champs moyens, des agents de contraste 
nanoparticulaires, ainsi que des agents de contraste ciblés sont les quatre spécificités étudiées 
dans ce travail. 
 
Le premier composé, présenté dans le Chapitre II, est le complexe tricéphalique 
{Mes[Gd(DO3A)(H2O)2]}. Cette molécule de taille moyenne a été développée comme un 
agent de contraste potentiel pour haut champs magnétiques. La méthode de complexation 
standard ne permet pas la complexation totale, probablement à cause d’un repliement 
intramoléculaire du composé. La complexation doit alors être effectuée en deux temps : une 
pré-complexation totale avec du magnésium (II) suivit d’une transmetallation pour remplacer 
Mg2+ par Gd3+ dans les trois sites de complexation. Cette nouvelle méthode de complexation 
peut être réellement utile pour obtenir une complexation totale de molécules de taille 
moyenne, où la coordination partagée par deux unités de chélation voisines peut se produire.  
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Le Chapitre III traite également d’une molécule de taille moyenne portant trois complexes, le 
{Ph4[Gd(DTTA)(H2O)2]-3}. Le centre de ce composé, formé de quatre cycles phényles, a été 
conçu pour favoriser l’agrégation de molécules. On attend de la relaxivité de ces grandes 
entités formées une augmentation importante dans la région des moyennes fréquences de 
résonance, c’est-à-dire entre 10 et 200 MHz. L’agrégation dynamique est observée par la 
dépendance de la relaxivité à la concentration. Les paramètres obtenus par le fit des données 
expérimentales permettent l’estimation du nombre de molécule dans les agrégats, allant du 
seul monomère dans les solutions diluées à quelques unités pour les solutions plus 
concentrées.  
 
La Chapitre IV présente le polysaccharide linéaire chitosan sur lequel sont conjugués des 
complexes de Gd3+. La réaction de couplage, accomplie directement avec le complexe de 
Gd3+, est réalisée par la condensation d’un carboxylate non complexant de l’unité de chélation 
avec l’amine libre du chitosan. Le taux de modification des unités du chitosan modifié 
{Chi[Gd(DTTA-N’but)(H2O)2]-} est déterminé par ICP-MS et analyse élémentaire. Des 
nanoparticules poreuses d’hydrogel, ou nanogels, sont ensuite formées avec le chitosan 
linéaire modifié par la méthode de gélation ionique. Comme le composé devient plus grand et 
plus rigide, on s’attend à ce que les relaxivités des nanogels formés soient plus élevées que 
celles de la chaîne linéaire. Cela n’est malheureusement pas observé, probablement à cause 
d’une complexation partielle de Gd3+ par l’anion triphosphate, utilisé pour la formation des 
particules, ou d’une diffusion limitée de l’eau à l’intérieur des nanogels.   
 
Le dernier chapitre de résultats, le Chapitre V, présente une famille de quatre composés 
conçus pour cibler un type spécifique de cellules tumorales malignes, telle que celles des 
cancers de la prostate, du sein ou des poumons, qui surexpriment des récepteurs de 
bombésine. Les quatre composés étudiés sont donc composés du peptide bombésine conjugué 
à des chélates de Gd3+. Dans le but d’optimiser l’interaction peptide-récepteur de peptide, 
deux analogues de la bombésine, le Lys3-bombésine et le Ahx-bombésine(4-14), sont utilisés 
pour synthétiser les conjugués monovalents et divalents. Les propriétés relaxométriques des 
quatre composés sont mesurées et comparées.  
 
Mots clés :  agent de contraste, agrégation, bombésine, chitosan, ciblé, complexation, 
gadolinium (III), haut-champ, imagerie par résonance magnétique, nanogels, 
relaxation longitudinale, relaxivité, transmétallation.  
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I.1  Nuclear Magnetic Resonance 
The theoretical introduction of this work will frequently refer to many Nuclear Magnetic 
Resonance (NMR) concepts. This phenomenon is therefore briefly introduced to define 
properly the introduced notions.1-4 
 
I.1.1. Zeeman effect  
The principle of the nuclear magnetic resonance is based on the interactions between nuclei 
and a magnetic field. Numerous elements, or more precisely isotopes, have an intrinsic 
nuclear spin angular momentum. Though it is a purely quantum mechanical concept, the spin 
of a particle can be represented in a classical model as an angular momentum due to its 
rotation around an axis. The spin angular momentum I is a vector quantity, whose magnitude 
is given by the equation I.1. The spin quantum number I of the nucleus, a positive multiple of 
1/2, is an intrinsic property of a given nuclei. The components of this angular momentum 
vector are also quantized and there are 2I+1 possible values for a spin-I nucleus with respect 
to a given direction. The projection of this vector Iz on an arbitrary chosen z-axis is given by 
equation I.2. 
 
( 1)I I= +I   I.1 
 
zI m=   I.2 
 
The magnetic quantum number m has 2I+1 values in integral steps from -I to I (-I, -I+1, …, I). 
This means that the spin-1/2 particles, such as the most commonly studied nuclei in NMR 1H, 
13C, 19F or 31P, have two permitted orientations (m = ± 1/2). Nuclei with I = 1, like 14N, have 
three possible directions, while nuclei with I = 0, like 12C or 16O, have no angular momentum 
and can consequently not be observed by NMR. From this angular momentum results a 
magnetic moment μ directly proportional to I by a factor γ, a constant characteristic for each 
magnetic isotope and known as the gyromagnetic ratio (equation I.3). 
 
 = γμ I  I.3 
 
Chapter I 
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Unsurprisingly this magnetic moment interacts with magnetic fields. The 2I+1 orientations of 
a I-spin nuclei, degenerated in the absence of a magnetic field, split into different energy 
levels when a magnetic field B0 is applied. This phenomenon is called the Zeeman effect, and 
the energy gap is given by equation I.4. By defining the z-axis along the magnetic field, this 
leads to equation I.5, using I.2 and I.3, with B0 the magnitude of the magnetic field B0. 
 
0E = − ⋅μ B   I.4 
 
0 0zE B m B= − = − γμ   I.5 
 
The energy levels of the 2I+1 states are equally spaced and the gaps are equal to 0Bγ . The 
frequency for electromagnetic radiation ν0 corresponding to these energy gaps can be 
expressed by equation I.6. 
 
0 0E h BΔ = ν = γ    00 0 0 or 2
B Bγν = = γ
π
ω  I.6 
 
I.1.2. Excitation process  
With magnetic fields used in NMR, the frequency corresponding to the energy difference 
between the nuclear spin states corresponds to the radiofrequency (RF) region of the 
electromagnetic spectrum. The principle of NMR is based on the energy absorption of a 
provided radiofrequency wave with a very precise energy. For a typical magnetic field of 9.4 
T used in NMR, this gives a frequency of 400 MHz for protons (with the 1H gyromagnetic 
ratio γΗ = 2.675 · 108 T-1s-1), 100.6 MHz for 13C (with γC = 6.73 · 107 T-1s-1) or 54.3 MHz for 
17O (with γΟ = -3.63 · 107 T-1s-1). 
 
As the angular momentum I forms an angle with B0 different from 0°, the magnetic moment μ 
experience a torque F trying to align it along B0 (equation I.7). By definition, this torque is 
the time derivative of I (equation I.8). 
 
= × 0F μ B  I.7 
 
d
dt
=
I F  I.8 
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The equation I.3, I.7 and I.8 are combined to describe the motion of the magnetic moment μ 
(equation I.9). This motion is a revolution, or precession, around B0 and perpendicular to both 
μ and B0. The angular frequency ω0 of the precession is given by equation I.10. 
 
0
d
dt
= γ ×μ μ B  I.9 
 
0 0= −γω B  I.10 
 
I.1.3. Macroscopic magnetization  
The probability of inducing a transition from the lower to the upper energy level is nearly 
equal to the probability of inducing the reverse transition. The net energy absorption, meaning 
the intensity of the NMR signal, can be observed thanks to the small population difference of 
the different energy states. The spin populations of the different energy states follow a 
Boltzmann distribution (equation I.11). 
 
0
e
e
m
B
n
B
E
k T
m E
n I k T
n I
N N
−
−
=
=−
=

 I.11 
 
Where Nm is the population in the state m, Em is the energy of the state m, N0 is the total 
number of spins, T the absolute temperature and kB the Boltzmann constant. For a spin-1/2 
nucleus such as 1H, the population ratio of two energy states, called spin up and spin down for 
the low and high energy states respectively, is given by equation I.12. The difference of 
population depends on the strength of the applied magnetic field and the temperature. For the 
proton at 9.4T and 25°C, this ratio is equal to 1.000065, indicating that only one nucleus in 
about 15000 can be observed.  
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The macroscopic magnetization M is defined as the vector sum of all individual microscopic 
moments μ of all nuclei in the magnetic field. The spins are randomly distributed around the 
z-axis and precess around it in an incoherent way, which averages to zero the magnetization in 
the xy-plane. However, the small population difference between the unlike energy level 
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induces a non-zero magnetization component along the z-axis. This magnetization Mz can be 
calculated from equations I.5 and I.11, using the approximation e 1x x≈ +  (for x << 1). The 
resulting relation between the magnetization and the magnetic field strength is known as the 
Curie’s law (equation I.13). 
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N I IM B
k T
γ +
=

 I.13 
 
I.1.4. Rotating frame  
The motion of the magnetization M in a magnetic field B is a precession around it with an 
angular frequency ω = γB (equation I.10). In an NMR experiment, the field Beff is actually 
composed of two magnetic fields, the strong static field B0 and a weak field B1(t) produced by 
the radiofrequency field applied along the x-axis and oscillating along it with the angular 
frequency Ω. This linear oscillation can be considered as the sum of two rotating vectors B1cw 
and B1ccw, rotating in opposite directions with frequencies –Ω and Ω (equation I.14). 
 
1 1 1
1 1 1 1 1
cos( ) cos( ) 2 cos( )
sin( ) sin( ) 0
00 0
cw ccw
B t B t B t
B t B t
                        
−Ω Ω Ω
= + = −Ω + Ω =B B B  I.14 
 
The complex motion of the magnetization in an oscillating field can be simplified by 
considering a new Cartesian coordinates system (x’, y’, z’) rotating around the z-axis in phase 
with the rotating vector B1cw with the angular frequency –Ω. In this new frame, called the 
rotating frame, B1cw will appear static, while B1ccw will seem to rotate with an angular 
frequency of 2Ω.  The time derivative of the magnetization in both the laboratory frame 
( /d dtM ) and the rotating frame ( / t∂ ∂M ) are related by equation I.15. 
 
( )ddt t
∂
= + ×∂
M M Ω M  with 
0
0
     
=
−Ω
Ω  I.15 
 
The dynamics of the magnetization M, described by the equation I.16 in the laboratory frame 
(from equation I.9), becomes therefore equation I.17, where Beff is defined as the effective 
field, i.e. the sum of B0, B1 and Ω/γ (Figure I.1). 
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The two fields Ω and B0, in opposite directions, compensate if Ω = γB0. The resulting Beff 
becomes equal to B1, composed by the static B1cw–field and the rotating B1ccw–field. The latter 
rotates with the fast angular frequency of 2Ω and will have no effect when averaged in time. 
An applied radiofrequency field will therefore result in a precession of the magnetization 
around the B1cw-component with the angular velocity ω1 = – γ B1. The so-called flip angle     
β1 = ω1t corresponds to the angle of rotation of the magnetization M around the x-axis 
resulting from a B1 application during a time t. 
 
 
Figure I.1   –  The effective magnetic Beff in the rotating frame resulting from the 
static B0 and the RF fields components B1 and Ω / γ. 
 
I.1.5. Free Induction Decay 
After B1 is turned off, the magnetization M will have a component in the xy-plane, Mxy, and 
will continue to rotate around B0 (equation I.16). This rotating magnetization in the xy-plane 
can be observed thanks to the induced current in a detector coil. This signal, known as the 
FID for Free Induction Decay, allows the determination of the resonance frequency, or 
Larmor frequency (Figure I.2). The Larmor frequencies of distinctive nuclei and their 
respective contribution are obtained by Fourier transform of this signal. The intensity of the 
signal decreases due to relaxation as will be explained in Chapter I.2. 
x 
y 
z 
B0 Ω / γ
 
B1 
Beff 
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Figure I.2   –  FID generated by a single Larmor frequency (A) and by two 
Larmor frequencies of equal intensities (B). 
 
I.1.6. Chemical shift  
In a molecule, all the nuclei of a magnetic isotope do not have exactly the same resonance 
frequency. This phenomenon arises from the magnetic field B actually experienced by a 
nucleus, that differs slightly from the applied field B0. The experienced magnetic field 
depends on the environment of the nucleus, determined by the local electronic distribution on 
the atom. The motion of electrons within their molecular orbitals generates a small magnetic 
field that affects the local magnetic field. This effect, known as the chemical shift, allows 
discriminating the different types of an isotope and is used to characterize molecules. 
 
The chemical shift δ is always defined by the frequency difference of the signal with respect 
to the frequency of a reference nucleus (equation I.18). The order of magnitude of this 
frequency difference is about one million times smaller than the reference frequency νref and 
is therefore expressed in part per million (ppm). The non-dependence of the chemical shift to 
the applied magnetic field is an appreciable advantage of this notion. 
 
( )ref6
ref
10
ν − νδ =
ν
 I.18 
 
I.1.7. Diamagnetism and paramagnetism 
When placed in a magnetic field, any substance induces a magnetic moment. This 
phenomenon is known as the magnetic induction. This magnetization M0 is related to the 
applied field B0 through a proportional constant χv, called the volume magnetic susceptibility, 
representing the magnetization capability of the compound (equation I.19). The specific molar 
A  
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magnetic susceptibility χM is obtained by multiplying the volume magnetic susceptibility χv 
by the molar mass M, divided by the density d (equation I.20). 
 
0 0v= χM B  I.19 
 
d vM
Mχ = χ  I.20 
 
Diamagnetism is characterized by a negative volume magnetic susceptibility χv < 0, indicating 
an induced magnetization opposed to the external field. This effect arises from the 
interactions between the magnetic field and the movement of the electrons in their orbitals. It 
is systematic and present in any compound. 
 
Paramagnetic compounds are characterized by a positive magnetic susceptibility (χv > 0). The 
induced magnetic moment is now parallel to the field and reinforces it. This effect is 
generated by one or more unpaired electrons and is therefore present either in free organic 
radicals or in metal complexes. The interaction of the unpaired electron spins with nuclear 
spins is strong, and it influences the nuclear magnetic resonance in two ways. First it changes 
the resonance frequency of the nucleus, i.e. its chemical shift. Secondly, it reduces 
tremendously the time for the system to recover the equilibrium, known as the relaxation time 
(see Chapter I.2). The latter point will be discussed in more details in Chapter I.4. Unless 
specified, the paramagnetic species described in this work will always refer to paramagnetic 
metal complexes.  
  
It is relevant to point out that the magnetic susceptibility of compounds characterized by the 
conservation of the magnetization without external field, such as ferromagnetic or 
antiferromagnetic compounds, is also positive, while a null susceptibility corresponds to 
vacuum. 
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I.2 Relaxation 
After the excitation by an RF pulse, the magnetization will not precess perpetually around the 
B0-field but will return to its equilibrium position along the z-axis. This phenomenon is 
known as relaxation. The motion of the magnetization during the relaxation (Figure I.3 A) 
can be described in three processes:  
 
- The precession of M around the z-axis  
- The evolution of the Mz component toward the thermal equilibrium position along z, 
known as longitudinal relaxation (Figure I.3 B) 
- The evolution of the Mxy component toward zero, defined as the transverse relaxation 
(Figure I.3 C). 
 
M
z
time  time
M
y
 
 
Figure I.3   –  The evolution of the magnetization M towards the equilibrium 
along the z-axis after a 90° RF pulse combining the three processes 
(A), the recovery of total Mz component (B) and the loss of signal 
in the xy-plane, seen from the y-axis (C).2 
 
The longitudinal relaxation represents the return of the populations toward the Boltzmann 
equilibrium, while the transverse relaxation corresponds to the loss of the spin coherence. The 
relaxation processes are described by the relaxation times T1 and T2 and the relaxation rates R1 
= 1 / T1 and R2 = 1 / T2 respectively.  
 
 
 
 
B C 
z 
x y 
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I.2.1. Autocorrelation and spectral density functions 
In order to describe the evolution of the magnetization and the causes of the relaxation, 
mathematics tools have to be introduced. The correlation function of a stochastic signal given 
by the time function f(t) is used to describe its time dependence. The most simple 
autocorrelation function G(τ) is defined by the mean value of the variable at time t multiplied 
by the variable at a time t + τ (equation I.21).  
 
( ) ( ) ( )G f t f t= +τ τ  I.21 
 
Where the average is written with brackets . For τ = 0, the function f(t) is multiplied by 
itself, resulting in the initial mean square value 2( )f t , while a long τ will make G(τ) average 
to zero. G(τ) describes the correlation of the function f(t), that is the rate of fluctuation of the 
stochastic variable. Fast fluctuating f(t) is characterized by a correlation function dropping 
rapidly to zero (Figure I.4 A) and slow fluctuations will lead to slowly decreasing G(τ) 
(Figure I.4 B).  
 
 
          
          
 
Figure I.4   –  The autocorrelation function G(τ) corresponding to the stochastic 
time function f(t) for fast (A) and slow (B) fluctuations. 
 
t t 
Chapter I 
16 
G(τ) is in general approximated by a simple negative exponential with the initial value 
2( )f t . The decay rate is characterized by the so-called correlation time τc, describing the 
“loss of memory” of the stochastic time function (equation I.22). 
 
2
c
( ) ( ) expG f t     
= −
τ
τ
τ
 I.22 
 
The Fourier Transform of this correlation function, leading to a Lorentzian function, allows 
the determination of the characteristic frequencies of the fluctuations described by the 
correlation function G(τ). The obtained function J(ω) is called the spectral density function, 
given by equation I.23 under its normalized form and illustrated by Figure I.5. 
 
 ( ) ( )12 2 2
0
( ) 2 ( )exp 2
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c
c
J f t G i d
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−
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J(ω
)
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Figure I.5   –  Positive part of the spectral density function J(ω) 
 
Applied to NMR, the stochastic variable is simply the intensity of the fluctuating magnetic 
field. The mean square value of the stochastic function 2( )f t  is therefore written 2B . 
 
I.2.2. Longitudinal relaxation 
The recovery of the magnetization along the z-axis represents the return of the spin 
populations to the Boltzmann equilibrium. This implies a transition from the high-energy state 
to the low-energy state, achieved either by spontaneous or stimulated emission. The 
probability of spontaneous emission, whose rate depends on the third power of the transition 
frequency, is however negligible at NMR frequencies.  
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The magnetic noise, i.e. the magnetic field fluctuations, is the source of the stimulations 
needed for these stimulated emissions. The fluctuations are created by the random motions of 
the molecules and can arise from several mechanisms generating time-dependent magnetic 
interactions, such as dipolar coupling, scalar coupling and electric quadrupole interaction to 
name a few (Chapter I.3). All these mechanisms contribute to the observable relaxation rate. 
The efficiency of the relaxation depends on the probability of finding an oscillation at the 
appropriate frequency. The relaxation rate for the ideal random field mechanism is described 
by equation I.24.4 2B  represents the mean square value of the local fluctuating field. 
 
( )2 2 2 20 2
1 0
1 γ γ
1 ( )
c
c
B J B
T
= =
+
τ
ω
ω τ
 I.24 
 
The NMR pulse sequence used to measure the longitudinal relaxation time T1 is called 
inversion recovery (IR). This sequence inverts the equilibrium magnetization along the z-axis 
M0 by a 180° pulse. The magnetization undergoes a longitudinal relaxation during a variable 
time τ, leading to the magnetization Mz(τ). Finally, Mz(τ) is laid down in the xy-plane by a 90° 
pulse in order to detect the free induction decay. 
 
 
τ
 
Figure I.6   –  The inversion recovery pulse sequence (A) and the evolution of 
the magnetization Mz(τ) with the variable delay τ (B). 
 
The exponential evolution of the magnetization with respect to the variable delays τ  allows 
the calculation of the longitudinal relaxation time T1, according to equation I.25. 
 
( ) 0
1
1 2expzM M T
        
−
= −
τ
τ  I.25 
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I.2.3. Transverse relaxation 
After a RF pulse, all the individual spins magnetic moments precess coherently around the z-
axis, creating a magnetization component in the xy-plane. The process called the transverse 
relaxation corresponds to the disappearance of this magnetization in the xy-plane and is 
characterized by the transverse relaxation time T2. This decay is due on one hand to the return 
of the magnetization along the z-axis, seen in case of the longitudinal relaxation, and on the 
other hand to the loss of coherence of the individual spin magnetic moments with each other. 
This spin phase dispersion, or spin dephasing, arises from the fluctuating magnetic field cause 
by molecular motions and B0-field inhomogeneities. 
 
As the magnetization recovery along the z-axis will inescapably lead to the decay of the Mxy-
component, the T2-relaxation can never be slower than the T1-relaxation. It can however be 
much faster. The transverse relaxation rate for the ideal random field mechanism is described 
by equation I.26.4 
 
( ) ( )2 2 2 2 2 2 2 20 2 2
2
1 1 1 1 1γ γ 0 γ γ
2 2 2 21
c
c
c
B J B J B B
T
= + = +
+
τ
ω τ
ω τ
 I.26 
 
The first term of this expression represents the T2-relaxation due to the longitudinal relaxation 
and is negligible in the slow motion limit (ω0τc  >> 1). In the extreme narrowing limit (ω0τc << 
1), the two parts of this expression become equal (J(ω0) ≈ J(0)), implying that the transverse 
relaxation rate is equal to the longitudinal relaxation rate. Figure I.7 presents the evolution of 
both relaxation times T1 and T2 with variable correlation time. 
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Figure I.7   –  Evolution of the longitudinal relaxation time T1 (solid) and the 
transverse relaxation time T2 (dash) with the correlation time τc, 
using 2 2γ B  = 4.5 · 109 s-2 and ω0/2π = 400 MHz.  
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Corresponding to the loss of the magnetization in the xy-plane, the FID decay represents in 
principle the transverse relaxation time T2. However, because of the inhomogeneities of the 
static field, it does not reflect the real T2, but the observed relaxation time T2* (equation I.27). 
 
( )* 2 2 02
1 1 1
T T BT
= +
Δ
 I.27 
 
To sidestep this difficulty, the chosen method to measure T2 consists in a series of spin echoes 
to refocus the spins and observe the real decay of the signal in the xy-plane. The so-called 
Carr-Purcell-Meiboom-Gill (CPMG) sequence is composed of one 90° pulse along the x-axis 
to lay down the magnetization in the xy-plane followed by a series of 180° pulses along the y-
axis that refocus the signal by spin echoes (Figure I.8 A). The exponential decrease of the 
echo amplitude is due to the effective T2 and is related to variable delay τ (equation I.28). The 
plot of the echo amplitude A(τ ) against τ (Figure I.8 B), obtained by repeated experiments 
with variable τ, allows  the determination of T2.  
 
 
 
 
 
 
 
 
Figure I.8   –  The CPMG pulse sequence (A) and the echo intensity as a function 
as the variable delay τ (B) used to determined the transverse 
relaxation time T2. 
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I.2.4. Bloch equations 
The rate of change of the global magnetization M due to the relaxation is expressed by three 
differential equations, proposed in 1946 by Felix Bloch and hence known as the Bloch 
equations (equations I.29) (with M0 the equilibrium magnetization along the z-axis). 
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The superposition of the relaxation processes with the precession motion describes the total 
rate of change of M. This is expressed by equation I.30, that combines the Bloch equations 
under their matrix notation with the precession equation I.17.  
 
( )0effddt = γ × − −
M M B R M M  I.30 
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I.3 Relaxation mechanisms 
This chapter presents the different mechanisms that can result in magnetic field fluctuations 
responsible for the relaxation. The contribution of each mechanism has to be taken into 
account to describe a global, or observed, relaxation. Because the relaxation rates constants, 
i.e. the reciprocal of the relaxation times, are additive magnitudes, the global relaxation rate is 
equal to the sum of the relaxation rates of each contribution (equation I.31, where 1/ miT  is the 
relaxation time of the mechanism m). The contribution of the various mechanisms differs 
drastically depending on the type of the nucleus, the chemical environment or the magnetic 
field strength. Though different mechanisms can interfere and induce a so-called cross-
correlation mechanism, the mechanisms will be considered as independent and no cross-
correlation will be treated.5-7 
 
i i
1 1
m
mT T
=  I.31 
 
I.3.1. Dipolar interaction 
Field fluctuations can arise from the interaction between two magnetic dipoles, known as the 
dipole-dipole or dipolar coupling. Due to the perpetual alignment of the spins along the 
magnetic field, the local dipolar field of a neighboring spin experienced by a nucleus depends 
on the orientation of the molecule (Figure I.9). This interaction can be heteronuclear or 
homonuclear, depending if the nuclei are different or the same sort respectively, and intra- or 
intermolecular. Moreover, in the case of a paramagnetic system, this interaction occurs with 
unpaired electrons (Chapter I.4). In 1/2 spin systems, the dipolar mechanism is the main 
contribution to the relaxation. This process is still important for higher spin systems. 
 
 
 
Figure I.9   –  Intramolecular orientation-dependent dipolar field experienced by 
a neighboring spin 
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The relaxation rate constants of spin I due to the dipolar interaction with spin S have been 
described by Solomon in 1955 (equations I.32 and I.33).8  
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Where γI and γS are the gyromagnetic ratios of spins I and S respectively, μ0 is the 
permeability of vacuum and rIS the inter-spin distance, CDD (I.34) is the dipolar coupling 
constant and J(ω,τd) the spectral density (equation I.23) with τd the specific correlation time.  
 
I.3.2. Scalar relaxation 
In addition to the strong dipole-dipole interaction between the nucleus and an electron, 
paramagnetic systems offer a new pathway for nuclear relaxation by considering as non-zero 
the probability of finding an electron at the nucleus. This interaction, known as the Fermi 
contact interaction, or scalar interaction, occurs when the nucleus-electron distance is about 
the nuclear radius (~ 10 fm) and where the particles can not be considered as point dipoles.  
 
The so-called delocalization contribution considers the probability of finding the unpaired 
electron on an interacting nucleus. This contribution is however not always important or even 
possible. Only nuclei bound directly to paramagnetic specie can undergo a scalar interaction. 
Moreover, the magnitude of this interaction depends on the shape of the Singly Occupied 
Molecular Orbital (SOMO). For instance, the accessible SOMOs of the transition metal 
induce an important effect, while the lanthanides, where the SOMOs are hidden, will not 
interact. As well as this spin delocalization contribution, such systems provide a spin 
polarization effect. In this contribution, the unpaired electrons draw the neighbor electrons of 
the same spin, which polarizes the orbital and changes their shapes. The probability of finding 
an electron on its own nucleus becomes then non-zero.9,10 The equation I.35 and I.36 
describes the relaxation rates of the scalar contribution. 
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Where A/   is the scalar coupling constant, S the spin of the nucleus S and τsc1 and τsc2 the 
effective correlation times related to the electronic relaxation rates 1/T1e and 1/T2e.  
 
I.3.3. Quadrupolar relaxation 
Besides their magnetic dipole moments, nuclei with spin quantum number I larger than 1/2 
possess an electric quadrupolar moment. The charge distribution in the nucleus, which can be 
visualized as elliptic with positive charge excess at the poles and charge depletion at the 
equator, induces a nuclear quadrupole moment Q.  
 
Quadrupoles, unlike dipoles, do not interact with uniform electric fields, but only with electric 
field gradients. In high symmetry systems (cubic, spherical, octahedral, tetrahedral), the 
electric field generated by surrounding charges cancel out, resulting in no quadrupolar 
interaction. In lower symmetry environments however, the nuclei experience an anisotropic 
electric field gradient, depending on the orientation of the molecule in the magnetic field. Due 
to this anisotropy, the random rotational reorientation of the molecule makes the local 
magnetic field fluctuate and induces consequently relaxation. Equation I.37 describes the 
longitudinal relaxation time due to the quadrupolar contribution. This mechanism prevails for 
diamagnetic I > ½ spin systems.  
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Where ( )2 21 / 3χ + η  is the quadrupolar coupling constant (equation I.38) with eqzz the electric 
field gradient along the arbitrary z axis (equation I.39), η the asymmetry parameter of the 
electric field gradient (equation I.40), and I is the nuclear spin. 
 
I.3.4. Chemical shift anisotropy 
Due to the interactions with the neighboring groups or magnetic moments induced by the 
external field, the chemical shift can be dependent on the orientation of the molecule in the 
field. Though it averages to zero in solution, this chemical shift anisotropy (CSA) can 
nevertheless provide a relaxation mechanism by modulating the magnetic field experienced 
by a nucleus. The CSA of an aromatic ring due to the magnetic field induced by the 
diamagnetic current is presented in Figure I.10. 
 
 
 
 
 
 
Figure I.10  –  Field fluctuations induced by the chemical shift anisotropy of an 
aromatic ring. 
 
The chemical shift anisotropy Δσ is presented in equation I.41 while the CSA longitudinal 
and transversal relaxation rates are given in equations I.42 and I.43 respectively.  
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Where σxx, σyy and σzz are the components of the CSA tensor, γI is the gyromagnetic ratio of 
nuclei I. The relaxation rates are field dependent, and are proportional to B02 under conditions 
of fast molecular motion (ωI2τc2 << 1). 
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I.3.5. Curie relaxation 
In paramagnetic systems, the differences in populations of the electron spins energy levels 
due to the Boltzmann distribution induce a magnetic moment. The relaxation arising from this 
perturbation is known as the Curie relaxation. The Curie relaxation rates and the induced 
magnetization zS  are given by equations I.44, I.45 and I.46 respectively, with CDD the 
dipolar coupling constant (equation I.34). 
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I.3.6. Spin-Rotation Relaxation 
This field fluctuation arises from magnetic moments created by the movement of the electrons 
in the molecule. The Spin-Rotation relaxation is particularly important for small molecules 
undergoing fast rotations in a non-viscous lattice. The longitudinal relaxation rate is given by 
equation I.47. 
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Where Ir is the molecular inertia moment and CSR is the spin-rotation constant, in Hz. This 
relationship is valid only for spherical molecules.  
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I.4 Paramagnetic Relaxation Enhancement 
As mentioned in previous chapters, the rates of both longitudinal and transverse nuclear 
relaxation are increased by the presence of paramagnetic species in solution, which offers new 
relaxation pathways. This phenomenon, known as the Paramagnetic Relaxation Enhancement 
(PRE), arises from the interaction of the nucleus with the magnetic moment of electron spins, 
called the hyperfine interaction. Because the gyromagnetic ratio of the electron is about 658 
times that of the proton, the hyperfine interaction is much stronger than the nucleus-nucleus 
interaction.5-7 
 
I.4.1. Relaxivity 
The observed relaxation rates 1/ obsiT  are the sums of the diamagnetic and paramagnetic 
contributions, 1/ diT  and 1/ piT  respectively (equation I.48). While the nucleus-nucleus dipole-
dipole, the quadrupolar, the CSA and the spin rotation mechanisms represent the diamagnetic 
contribution, the paramagnetic relaxation is caused by the nucleus-electron dipole-dipole, the 
scalar and the Curie interactions. 
 
1 1 1
  ;    1,2pobs d
ii i
i
TT T
= + =  I.48 
 
The paramagnetic relaxation rate is directly proportional to the concentration of the 
paramagnetic species. To refer their efficiency to enhance the relaxation rate, the notion of 
relaxivity ri, in units of mM-1 s-1, has been introduced. The observed relaxation rate in terms of 
relaxivity and concentration of the paramagnetic species [M] is given by equation I.49. 
 
1 1 M   ;    1,2iobs d
i i
r i
T T
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I.4.2. Paramagnetic metal complex 
Because of the rapid vanishing of the magnetic field with distance, a nucleus has to be in the 
immediate vicinity of the paramagnetic center in order to experience the PRE. The binding of 
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water molecules to a paramagnetic metal ion is a possible chemical interaction that allows this 
proximity. The inner coordination sphere water molecules and their protons exchange with 
bulk water molecules and protons, which propagates the paramagnetic effect to the bulk. The 
solvent molecules of the bulk however also experience the paramagnetic influence when 
diffusing nearby the metal ion. This contribution is defined as the outer sphere relaxation. The 
total paramagnetic relaxation rate enhancement 1/ piT  is therefore constituted by the inner-
sphere (IS) and the outer-sphere (OS) contributions (equations I.50 and I.51), that can 
contribute about the same extent.   
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I.4.3. Inner-sphere proton relaxivity 
The inner-sphere contribution arises from the chemical exchange of the coordinated water 
proton with the bulk. Equations I.52 and I.53 present the longitudinal and transverse inner-
sphere relaxation rates.11-13  
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Where [M] is the molality of the paramagnetic species M, q is the number of bound water 
molecules per paramagnetic center (hydration number), PM is the mole fraction of the bound 
water molecules, τM is the lifetime of a water proton in the inner sphere of the complex (the 
reciprocal of the water exchange rate kex), TiM  is the nuclear relaxation time in the 
paramagnetic environment and ΔωM the chemical shift difference between the bound and the 
bulk water. 
 
 
 
Chapter I 
28 
I.4.4. Solomon-Bloembergen-Morgan theory 
The contribution of the Curie mechanism to the paramagnetic relaxation enhancement is often 
very small, particularly for the longitudinal relaxation, and will therefore be neglected. The 
relaxation rate enhanced by the presence of a paramagnetic species is therefore assumed to be 
induced only by the dipole-dipole (DD) and scalar (SC) mechanisms contributions (equation 
I.32 to I.36). Considering the interaction between a proton and an electron, these equations 
can be simplified with the very good approximation that the Larmor frequency of the electron 
is much higher than that of the nuclei ωS >> ωI (equation I.6 : ω = γB, with γe ≈ 658 γH), and 
therefore ωS ± ωI ≈ ωS. The resulting equations are known as the modified Solomon-
Bloembergen equations (I.54 to I.59).  
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As discussed in Chapter I.3.1 and Figure I.9, the nucleus-electron dipolar interaction depends 
on the reorientation of the molecule. Moreover, this interaction is obviously affected by the 
orientation of the electron spin and the water proton exchange. The characteristic correlation 
time of the dipolar process τdi depends therefore on the rotational correlation time τR, the 
electronic relaxation time Tie (i = 1,2) and the lifetime of the nucleus in the inner sphere τM 
(equation I.60). 
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The scalar interaction is also dependent on the electron spin relaxation and the water proton 
exchange, but remains unsurprisingly unaffected by the orientation of the molecule. The 
effective correlation time of the scalar interaction is therefore given by the equation I.61.   
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A model of the electron spin relaxation rates was described by Bloembergen and Morgan 
(equations I.62 to I.64),14 based on the work of McLachlan15 and the Redfield theory.16,17 For 
systems with S > 1/2, the electron spin relaxations are interpreted in terms of a zero-field-
splitting (ZFS) interaction. The ZFS, i.e. the non-degeneration of the electron spin levels in 
the absence of the magnetic field, arises principally from the interaction of two neighboring 
electron spins and from the spin-orbit coupling combined with a ligand field. This model 
assumes the spherical symmetry of the complex and therefore no static ZFS. It considers 
however a transient ZFS, induced by the distortion of this symmetry.  
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Where τv is the correlation time for the modulation of the ZFS interaction, Δ is the amplitude 
of the transient ZFS and τS0 the electron spin relaxation time at zero field. Let’s note that the 
equations I.62 to I.64 are correct for the case S = 1 (exponential relaxation) but becomes an 
approximation for higher spin systems (S = 3/2 and S = 2 are biexponential, while S = 5/2 is 
characterized by three time constants).16  
 
The combination of equations I.54 to I.64 constitutes a complete theory describing the 
observed PRE. This model is referred as the Solomon-Bloembergen-Morgan (SBM) theory. 
The whole system is however rather complex and necessitates as previously mentioned 
several approximations and assumptions, which are listed below :16 
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- The Redfield limit18 is applied for the electron spin relaxation, i.e. the motion in the 
lattice occurs on a much faster time scale than the motions in the spin system.  
- The electron spin relaxation is uncorrelated with molecular reorientation. 
- The electron spin system is dominated by the electronic Zeeman interaction (single 
electron spin relaxation rate). 
- The electron spin is considered as a point-dipole centered at the metal ion. 
- The electron Landé g-tensor ge is assumed to be isotropic ( /e e Bg = γ μ ) 
- The reorientation of the electron spin is isotropic and characterized by a single 
correlation time. 
- The chemical exchange is not correlated with the motions of the lattice. 
 
The equations I.52 to I.64 introduce numerous parameters that influence the protons 
relaxivity. The metal-proton distance has a sixth-power dependence and influence 
significantly the dipolar relaxation rate (equations I.55, I.57 and I.59) (in particular, the Gd3+-
coordinated water proton distance has been determined precisely by Astashkin et al.19 at 3.1 ± 
0.1 Å and turned out to be rather constant in all complexes studied). The hydration number q, 
having a proportional effect (equation I.52), and the parameters determining the effective 
correlation time (i.e. the rotational correlation time, the electronic relaxation time and the 
proton exchange rate) are usually considered as the four parameters affecting the 
paramagnetic relaxation (Figure I.11).  
 
Figure I.11  –  Schematic representation of a paramagnetic chelate complex in 
water and the structural parameters affecting the proton relaxivity. 
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Two reactions are involved in the exchange of coordinated water protons : the exchange of the 
entire water molecule in the inner sphere of the complex and the exchange of the proton on 
the complexing water molecule. The latter case is accelerated by acid- and base-catalyzed 
processes (equation I.65). Between about pH 2 and pH 8 however, the proton exchange on a 
water molecule can be neglected, and the proton exchange rate equals the water exchange 
rate.   
 
2H O H + OH -H OHex ex ex exk k k k      = + +  I.65 
 
If the water exchange is the limiting contribution for the relaxivity (T1M << τM), the latter 
would be determined only by this exchange rate (equation I.52). On the contrary, if the 
exchange is fast (T1M >> τM), the observed relaxivity will be given by the relaxation rate of the 
coordinated proton T1m, which depends on the proton exchange rate, the rotational correlation 
time and the electronic relaxation rate. The three parameters τR, kex and Tie have therefore to 
be optimized at the same time to attain a maximum relaxivity.   
 
The water exchange rate constant kex is temperature-dependent, and is assumed to follow the 
Eyring equation (I.66), where ΔS‡ and ΔH‡ are the entropy and enthalpy of activation for the 
exchange process and 298exk  is the exchange rate constant at 25°C. 
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All other correlation times τc are also temperature-dependent. The related activation energy Ea 
described by the Arrhenius equation is often preferred to describe the system (equation I.67). 
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The activation enthalpies and energies are interchangeable quantities to describe an activation 
barrier. They can be related to each other by the equation I.68. 
 
‡
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I.4.5. Lipari-Szabo approach for internal rotation 
The global isotropic rotational correlation time describes perfectly the tumbling of small 
sphere-like chelate complexes in solution. It fails however in the case of larger molecules 
bearing several metal complexes, in which the motion of the chelate complex could be 
described by an overall rotation of the whole molecule and a local rotation around the arm 
connecting the chelate to the central core (anisotropic motion). The “model-free” Lipari-
Szabo approach introduces therefore two motions and hence two rotational correlation times 
to describe the spectral density function (equation I.69).20-22 
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With 1 1 1g l− − −= +τ τ τ  
 
The generalized order parameter S2 is a model-independent measure of the degree of spatial 
restriction of the local motion. The value of S2 is included between 0 and 1, indicating 
respectively a completely independent or a completely restricted local motion. In the latter 
case, the second part of the equation I.69 is equal to zero, reducing this expression to its 
original simple form (equation I.23). This parameter gives therefore indications on the rigidity 
of the molecule.  
 
I.4.6. Outer-sphere contribution 
The water molecules outside of the first coordination shell of the metal complex are actually 
constituted by two distinct types of molecules : the second-sphere water molecules, which 
remain in the proximity of the complex by interacting with the hydrophilic groups, and the 
bulk water molecules, whose random motions can bring them to the vicinity of the 
paramagnetic species. Though theoretical models considering a separate treatment for this two 
kinds of water exist,23,24 they will here be treated without distinction and referred as outer-
sphere water molecules. 
 
The interaction between the paramagnetic electron spin S and the water proton nuclear spin I 
is described by the only intermolecular dipolar interaction. The field fluctuations arise 
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exclusively from the random translational motion of the molecules and no interaction between 
the molecules is assumed. The resulting relaxation rate is given by equation I.70.25,26  
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Where NA is the Avogadro number, d is the closest distance of approach of spins I and S, D is 
the relative diffusion coefficient (D = DI + DS), [M] is the millimolar concentration of the 
paramagnetic metal and S is the electron spin. The spectral densities JOS(ω) depend on the 
conditional probability for the relative diffusion of spins I and S. 
 
I.4.7. NMRD profile 
As seen throughout the Chapter I.4, the PRE depends significantly on the magnetic field. The 
measurement of the relaxivities (equation I.49) over a wide range of magnetic field is called 
relaxometry and the plot presenting the relaxivities as a function of the Larmor frequency is 
called Nuclear Magnetic Relaxation Dispersion (NMRD) profiles. Because the different 
contributions to the relaxation will manifest themselves differently, the NMRD profiles can 
vary drastically depending on the metal center and the type of molecules and can therefore be 
used to characterize paramagnetic systems. 
 
The Figure I.12 shows the NMRD profiles of a Gd3+ complex, which presents different zones. 
In the low field region (from 0.01 MHz to about 1 MHz), the relaxation is governed by the 
electron spin relaxation rate, which is field independent and presents therefore a plateau. The 
relaxivity drop, or dispersion, from 1 MHz to 10 MHz is due to the dipolar contribution. The 
relaxivity in the high field region, i.e. from 20 to 200 MHz, is governed by the rotational 
correlation time. This region is probably the most interesting part of an NMRD profile, as it 
can change radically depending on the size of the molecule. It can be seen from equation I.52 
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that the contribution of the water exchange rate and the number of molecule in the inner 
sphere is present throughout the frequency range. 
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Figure I.12  –  Typical shape of NMRD profiles of a Gd3+ complex simulated for 
slowly rotating (τR = 1 ns) (solid) and fast rotating (τR = 0.1 ns) 
(dash) molecules. Other used parameters : τM = 100 ns;  τν = 10 ps; 
Δ2 = 0.5 · 1020 s-2; q = 1. 
 
The equations presented in this chapter (equations I.48 to I.70) represent a whole system 
describing the relaxation rates. They can therefore be used to fit the NMRD profiles, i.e. the 
relaxivity as a function of the Larmor frequency, and determine numerous parameters 
characterizing the paramagnetic entity. This is performed by computer methods minimizing 
errors on a fitted functions, such as the Levenberg-Marquardt algorithm.27,28 Though some 
common values can be used for similar systems, such as the distances, the diffusion 
coefficient or the quadropolar coupling constant for instance, this method does not allow the 
exact determination of all relaxation influencing parameters. The solution to this problem is to 
fit simultaneously the NMRD with completing data sharing some parameters with the water 
proton relaxation rates. The two techniques Electron Paramagnetic Relaxation (EPR) and 17O 
NMR have proved to be especially useful to complete the protons relaxivity experimental 
data. The linewidth of EPR spectra gives direct access to transverse electron spin relaxation 
rates, while 17O NMR relaxation rates and chemical shifts at variable temperature, pressure or 
magnetic field gives information on the water exchange rate, the number of water molecules 
in the inner sphere, the rotational correlation time or the longitudinal electronic relaxation 
rates. 
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I.4.8. 17O NMR measurements 
Because the water oxygen is bound to the metal center, variable temperature 17O NMR 
measurements allow the direct determination of the water exchange rate, through the reduced 
relaxation times Tir (equation I.71) and the reduced chemical shifts Δωr (I.72).  
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The external reference used to obtain the reduced values can be the diamagnetic analogue of 
the paramagnetic compound (Y(III) instead of Gd(III) for instance) but acid water (pH 3.5 
perchloric acid solution), that ensure a fast proton exchange regime, is often preferred for 
practical reasons. 
 
The transverse relaxation rate is related to the water molecule lifetime in the inner sphere of 
the complex τM through equation I.73. If we neglect the outer-sphere contribution to the 17O 
relaxation29 and the chemical shift of the bound oxygen (ΔωM << 1/T2M ; 1/τM), this equation 
simplifies to lead to the second part of equation I.73. Because the oxygen is directly bound to 
the metal center, the scalar mechanism is the most important contribution to the relaxation 
rate (equation I.74).11,12,30 
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The scalar coupling constant A/ħ determines the chemical shift of the coordinated water 
oxygen ΔωM (equation I.76), related to the reduced chemical shift Δωr (equation I.75). The 
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measurement of Δωr allows therefore the determination of A/ħ, used to determine the water 
exchange rate. The outer-sphere contribution to the 17O chemical shift ΔωOS is assumed to be 
proportional to ΔωM though the empirical proportionality constant COS (equation I.77).29-31  
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Where ge is the isotropic Landé g-factor of the electron, mB is the Bohr magneton, S is the 
electron spin and B is the magnetic field. 
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Figure I.13  –  Variable temperature 17O ln(1/T2r) (solid), ln(1/T1r) (dash) (A) and 
Δωr (straight) (B) and limiting cases (dot) for fast and slow 
exchange regions. Calculated with the following parameters :   
ΔH‡ = 50 kJ/mol; 298
ex
k  = 106 s-1; τR = 500 ps; τv = 6 ps; A/ħ = -
3.7·106 rad s-1; Δ2 = 0.5·1020 s-2; COS = 0.1 and B = 9.4 T. 
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I.4.9. Rast-Fries-Belorizky approach 
As mentioned in Chapter I.4.4, the SBM theory, and particularly its electronic relaxation 
treatment, is based on many assumptions and is therefore valid under very precise 
circumstances. Considering only a transient ZFS due to the distortion of the octahedral 
symmetry, this theory fails for systems with large static ZFS such as Ni2+, Fe2+, Co2+ and for 
systems whose electronic relaxation is not dominated by the ZFS, such as the lanthanides 
other than Gd3+. The electronic relaxation of the latter is however described by only one 
relaxation time, instead of the four required for a 7/2 electron-spin such as Gd3+ (mS =  ± 7/2 
↔ ± 5/2, mS =  ± 5/2 ↔ ± 3/2, mS =  ± 3/2 ↔ ± 1/2 and mS =  + 1/2 ↔ – 1/2). The resulting 
effect is a poor description of the relaxation rate, especially at low field where the relaxivity is 
governed by the electronic relaxation. 
 
Several theories have been developed in order to describe in a better way the electronic 
relaxation.32 Among them, the so-called Rast-Fries-Belorizky (RFB) or Grenoble approach, 
introduces a static ZFS and separates the electronic relaxation rate into a static and a transient 
ZFS contributions (equation I.78).33-35 The static ZFS is modulated by the rotational motion of 
the molecule, implying a τR-dependence of the electron spin relaxation rate. The theoretical 
description is elaborated up to the six order for the static ZFS part and to the second order for 
the transient part, leading to the introduction of up to four parameters describing the ZFS : a2, 
a4, a6 and a2T (equations I.79 and I.80).36  
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Though the RFB approach ameliorates considerably the description of the electronic 
relaxation rate, compared to the SBM theory, this model is not suitable to fit the relaxation of 
slowly tumbling molecules at low magnetic field. 
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I.4.10. Modified Florence approach 
The so-called modified Florence approach, based on a Liouville superoperator formalism, was 
developed to describe PRE for big and slowly rotating molecules.37-39 This model assumes a 
slow reorientation of the metal complex, which modulates both the hyperfine dipolar 
interaction and the static ZFS, and considers no correlation between molecular reorientation 
and the electronic relaxation.39 The latter assumption is known as the decomposition 
approximation and is valid only for slowly rotating systems.40 The electronic relaxation 
treatment assumes modulations of a transient ZFS, arising from the distortion due to the 
collisions with surrounding solvent molecules. These modulations are described by a 
pseudorotation model, which assumes a constant magnitude and a directional change 
following a rotational diffusion equation.31,41,36 The electronic relaxation treatment is 
described by a static and a transient ZFS, with amplitudes D and Δ, respectively, and the 
correlation time τv for the transient ZFS modulation. 
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I.5 Magnetic Resonance Imaging   
The Magnetic Resonance Imaging (MRI) is a widespread clinical technique for medical 
diagnostic. This not invasive and seemingly harmless method is based on the Nuclear 
Magnetic Resonance, and more exactly on the relaxation phenomenon. 
 
In 1971, the American scientist Raymond Vahan Damadian glimpsed a medical application to 
NMR and presented a method allowing tumor detection by NMR.42 Benefiting from the 
progress in the field of medical imaging by tomography, the American chemist Paul 
Lauterbur and the British physicist Sir Peter Mansfield developed in 1973 simultaneously but 
independently a NMR imaging based on the magnetic field gradient allowing the obtaining of 
a 2D section.43,44 They shared the Nobel Prize in Physiology or Medicine in 2003 “for their 
discoveries concerning magnetic resonance imaging”.45 
 
Thanks to the advances in the domains of informatics and electronics, the technique evolved 
rapidly. Richard Ernst used the Fourier transform to analyze the coding in frequency and 
phase of the NMR signal in 1975.46 The same year, Mansfield achieved the first imaging of 
human tissue and the imaging of a whole living human body is performed by Damadian in 
1977. 
 
This method is nowadays essential in the medical diagnostic and is in perpetual progress 
thanks to the development of new sequences and techniques, allowing for instance functional 
MRI (fMRI)47,48 or angiography.49 
 
I.5.1 MRI principle 
The opportunity of measuring spatial NMR experiment is possible through the method of 
pulsed field gradients, i.e. spatially inhomogeneous magnetic fields. The technique leads to 
position-dependent resonance frequencies and allows therefore the spatially selective 
excitation, and thus observation, by tuning the frequency of the RF pulse.  
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Equation I.10, presenting the relation between the magnetic field and the Larmor frequency, 
can be reformulated by equation I.81 in the case an inhomogeneous field. The field gradient G 
and the magnetic field at position r are therefore given by equations I.82 and I.83, 
respectively. 
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As seen in Chapter I.1.4, an applied RF pulse generates a magnetic field B1 along the x’ axis 
of the rotating frame. Considering a time constant gradient along the z-axis with strength Gz, 
the effective magnetic field Beff experienced at position Δz is given by the equation I.84 (from 
equation I.17). 
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= + + + ⋅ =γ
+ Δ − γ
ΩB B B G r
Ω
 I.84 
 
If the RF frequency Ω is tuned in order to be equal to γ(B0 + GzΔz), the z-component of the 
effective magnetic field would be zero and Beff would result in B1 along x’. The magnetization 
M’ rotating around Beff would therefore rotate around the x’-axis. On the contrary, if the z-
component of Beff is large compared to B1, M’ would be nearly unaffected by the RF pulse. 
This allows consequently the selective excitation of any slice along the z’-axis by adjusting 
the frequency Ω of the RF pulse. The thickness of the slice is controlled with the strength of 
either the B1 field or the gradient G. If applied to the three dimensions, the selective spatial 
element corresponds to a cube, known as the voxel ΔV(r), which represents the volume 
element of the NMR experiments.  
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Because this method does not apply to a specific pulse sequence, many different NMR 
experiments can be performed to obtain a specific spatial result and can be adapted to 
parameter of interest. Angiography for instance can be obtained by measuring the anisotropic 
diffusion of blood in veins through DOSY experiments,49 but the most common methods for 
body MR imaging are based on three parameters : the spin density ρ and the longitudinal and 
transverse relaxation times T1 and T2 of the water proton. The resulting images are classified 
according to the sensitivity of the principal parameters measured by the specific sequence. 
They are called proton-density-weighted (ρ-weighted), T1-weighted and T2-weighted images 
(Figure I.14). 
 
 
Figure I.14  –  Brain MRI measured by the most common methods for soft tissues 
imaging : (a) T1-weighted image, (b) ρ-weighted image and (c) T2-
wighted images.1 
 
I.5.2 MRI Contrast Agents 
Because it has a natural isotopic abundance of 99.99%, a very high gyromagnetic ratio and is 
a constituent of the water that represents about 70% w/w of a living body, the water proton is 
the perfect nucleus for such experiments. The MRI acquisition is however very long, typically 
a few tens of minutes, because of the main drawback of MRI, and that of NMR in general : its 
low sensitivity. This long examination, during which the patient cannot move, is tiresome and 
unprofitable. This acquisition time can be considerably reduced through the use of contrast 
agents (CAs). The contrast enhancement is obtained through the acceleration of relaxation via 
the use of paramagnetic or superparamagnetic substances, which can moreover permit the 
visualization of not very discernible tissues, such as brain lesions, in specific occasion (Figure 
I.15). The so-called T1 CAs decrease principally the longitudinal relaxation times and lead to 
a positive contrast, while the T2 CAs increase the transverse relaxation rate and are 
characterized by a negative contrast. Though T2 CAs are commonly used, principally under 
A B C A B 
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the form of nanoparticular superparamagnetic iron oxides (SPIO), this work will only refer to 
T1 contrast agents. 
 
 
Figure I.15  –  MRI T1-weighted image of a brain lesion before (A) and after (B) 
contrast agent uptake.1 
 
The most widely spread contrast agents for clinical use are gadolinium (III) complexes using 
cyclic or acyclic poly(aminocarboxylate) ligands. With its seven unpaired electrons and its 
slow electronic relaxation, the Gd3+ is the paramagnetic metal that provides the most effective 
PRE (Chapter I.4) and is therefore the best candidate for CAs.  The free metal ion is however 
highly toxic and can not be injected in living bodies. Free Gd3+ ions are rapidly sequestered 
within the bone and the liver, with biologic half-time of several weeks. This long-term 
retention of Gd3+ ions within the body favors interactions with physiologic systems and the 
inhibition of the activity of numerous endogenous enzymes, mainly through Ca2+ 
replacement. The calcium channel inhibition has severe consequences on processes that 
depend upon the Ca2+ influx, such as neural transmission and blood coagulation. Furthermore, 
the formation of insoluble complexes with phosphates or hydroxides at pH higher than 6.2, 
which can disrupt the immune system, and the crossing of the blood-brain-barrier figure also 
amongst the hazards of free Gd3+ ions. Finally, it has been proved that free gadolinium was 
closely related to the development of the serious syndrome nephrogenic systemic fibrosis 
(NSF).50,51 
 
The gadolinium has therefore to be injected under the stable form of chelate complexes. These 
inert forms prevent the metal ion to interact with endogenous compounds and ensure a rapid 
renal excretion.52 Chelate complexes including more than two water molecules in the inner 
sphere are not stable enough to permit any in vivo injection, but most of the commercial CAs 
encompass only one water molecules. Some example of the most widely used commercial 
Gd-based contrast agents are presented in Figure I.16. 
A B 
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Figure I.16  –  Structures, common names and commercial names of some 
gadolinium complexes commercially used as MRI contrast agents. 
 
For research, in vitro and animal experiment, the linear DTTA (H5DTTA = 
diethylenetriaminetetraacetic acid = 2,2’,2’’,2’’’-[iminobis(ethane-2,1-diylnitrilo)]tetraacetic 
acid) and the cyclic DO3A (H4DO3A = 1,4,7,10-tetraazacyclododecane-N,N’,N’’-triacetate) 
(Figure I.17), leading respectively to negative and neutral Gd3+ complexes, are widely 
employed chelating units. These two heptadentate chelators form stable complexes with Gd3+ 
including theoretically two water molecules in the inner sphere. The presence of the 
secondary amine, that can easily be functionalized to conjugate the complexes to other 
compounds, is moreover a very interesting property. 
 
 
Figure I.17  –  Structure of the common chelating units DTTA and DO3A. 
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Many studies using Gd3+ complexes have been achieved to graft several chelate complexes on 
a central structure aiming to increase the molecular relaxation enhancement, i.e. the relaxivity 
multiplied by the number of chelate complexes per particle. Macromolecular compounds have 
been particularly investigated to increase the relaxivity between 10 and 200 MHz. This had 
been performed with various materials such as linear polymers,22,53-56 dendrimers,57-61 
micelles62-66, proteins67-70, carbon nanotubes71,72 or gold nanoparticles73,74. The optimization 
of the relaxivity at frequencies higher than 200 MHz has also been investigated. These so-
called high field contrast agent should have rotational correlation times between 0.5 and 1 
ns75 and are formed with a few complexes around a small central core.76-79 
 
Conjugated Gd3+ complexes are also used for the development of smart, or responsive, 
contrast agents, which generate a signal depending on some variable in their immediate 
environment,80 such as temperature,81 pH,82,83 oxygen pressure84 or metal ion 
concentration85,86. Finally, the so-called targeted contrast agents are also developed from 
gadolinium complexes. This CA class aims to target specifically organs and tissues presenting 
particular properties through interaction with cell surface,87 antibodies88-90 or peptide 
receptors,91,92 to name a few.  
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I.6 Scope of this work 
This thesis deals with the development of new potential MRI contrast agents. These new 
compounds present different properties and were designed to induce different effects on the 
relaxivity. The synthesis, the analytical characterizations, the relaxivity measurements and the 
theoretical treatments of each compound will be presented in the upcoming chapters. 
 
Chapter II presents the tricephalous complex {Mes[Gd(DO3A)(H2O)2]-3} (Figure I.18), 
composed by three Gd-DO3A complexes bound to a central benzene ring, and designed as a 
potential high field CAs. The difficulty to insert three Gd3+ ions has constrained us to develop 
an alternative complexation method, based on a Mg2+ complexation and transmetallation.  
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Figure I.18  –  The trinuclear complex {Mes[Gd(DO3A)(H2O)2]-3} (Chapter II). 
 
Chapter III presents another trinuclear complex around an aromatic central core, the 
{Ph4[Gd(DTTA)(H2O)2]-3} (Figure I.19). The central core of this compound is constituted by 
a system of four benzene rings and was designed to form aggregates. As expected, this 
compound presents exceptionally high relaxivities for such a mid-size compound. The 
dynamic aggregation is investigated and characterized.  
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Figure I.19  –  The trinuclear complex {Ph4[Gd(DTTA)(H2O)2]-3} (Chapter III). 
 
Chapter IV deals with the controlled coupling of the complex [Gd(DTTA-N’but)(H2O)2]- on 
the linear polysaccharide chitosan (Figure I.20). This compound, obtained from chitin, has 
remarkable chemical and biomedical properties. A particular kind of nanoparticles, called 
nanogels, is produced from the linear chain. The structural and relaxometric characterization 
of the linear polysaccharide and the nanogels will be presented and discussed. 
 
 
 
Figure I.20  –  Structure of the modified chitosan linear chain 
{Chi[Gd(DTTA)(H2O)2]-} (Chapter IV). 
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Chapter V presents a family of potential targeting CAs composed by a Gd-DOTA complex on 
which the peptide bombesin is conjugated. The latter is a peptide neurotransmitter, whose 
receptors are overexpressed by numerous malignant tumor cells, including prostate, breast 
and small cell lung cancers. The particular affinity of the peptide towards these cells is a 
promising route to develop specific MRI CAs. To optimize this affinity, these compounds 
have been synthesized with two bombesin analogues : the Lys3-bombesin and the Ahx-
bombesin(4-14). The relaxivities of compounds presenting one and two bombesin peptide 
grafted on the chelating units DOTA (Figure I.19) are measured and characterized. 
 
 
Figure I.21  –  The potential specific CAs {BN[Gd(DOTA)(H2O)]-} and 
{BN2[Gd(DOTA)(H2O)]-} (Chapter V). 
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II.1. Introduction 
Currently all approved gadolinium based contrast agents (CA) for magnetic resonance 
Imaging (MRI) are based on complexes with chelating poly(amino carboxylate) ligands.1 
These octa-dentate ligands, which are either acyclic like DTPA or DTPA-BMA or 
macrocyclic like DOTA or HP-DO3A (see chapter I.5.2), form extremely stable complexes 
with lanthanides offering space for the coordination of one water molecule.2 Tremendous 
efforts have been spent in the last decade to develop new compounds with increased 
efficiency required for targeted CA and molecular imaging. The enhancement of longitudinal 
nuclear spin relaxation, commonly expressed as relaxivity (r1) if normalized to 1 mM solution 
of gadolinium ions, could be increased by more than an order of magnitude, mainly by 
slowing down the rotational diffusion of the molecules.3 This increase in relaxivity has been 
achieved at magnetic fields common to MRI instruments actually used in clinical application. 
 
However, most highly efficient CA lose nearly all of the gain in relaxivity at high magnetic 
fields above 3 T. MRI instruments working at 7 T or even above are now successively 
installed in research institutions, creating a need for contrast agents designed for application at 
these conditions.4 Theoretical calculations using the simple Solomon-Bloembergen-Morgan 
approach5-8 show that the relaxivity which can be reached at magnetic fields above 3 T is well 
below the performance which can be achieved between 1 and 1.5 T.8,9 Staying with chelate 
complexes of gadolinium, the only way to boost the efficiency of CA is to increase the 
number (q) of water molecules directly bound to Gd3+ and the assembly of many chelating 
units in larger molecules. The theoretical calculations have also shown that the compounds 
should have a reasonable size leading to rotational correlation times between 0.5 and 1 ns. 
  
Several mid-size molecules assembled around a benzene ring have been synthesized and 
tested for their relaxation enhancement capabilities (Figure II.1).10-12 The chelating groups 
used are either the acyclic DTTA (H4DTTA = diethylenetriaminetetraacetic acid = 
2,2’,2’’,2’’’-[iminobis(ethane-2,1-dinitrilo)tetraacetic acid) or the macrocyclic DO3A 
(1,4,7,10-tetraazacyclododecane-N,N’,N’’-triacetate). Both can form Gd3+ complexes with 
two water molecules (q = 2) in the first coordination sphere. Surprisingly it had been found 
that the compounds with DO3A11 had q = 1 and formed aggregates in aqueous solution. 
Chapter II 
 
56 
 
 
 
Figure II.1  –  Structures of benzene based mid-size molecules which can 
complex 2 Gd3+ ions (pX(DTTA)2, mX(DTTA)2 (A),10 
pX(DO3A)2 (L1) and mX(DO3A)2 (L2) (B)11) or three Gd3+ ions  
(L) (C)12. 
 
To further investigate the behavior of gadolinium-DO3A complexes bound to a benzene ring 
we decided to synthesize and to determine the relaxivity of {Mes[Gd(DO3A)(H2O)2]3}, a tris-
gadolinium complex formed by mesitylene substituted with three DO3A units on the three 
methyl positions (Figure II.2). It would be interesting to see if these compounds form 
aggregates in aqueous solution. The aromatic part sits in the center of the molecule and 
aggregation by π-stacking of the benzene rings would be strongly disfavored. A second 
question we intended to answer concerns the number of inner sphere water molecules. Will 
we also find q = 1 as for the xylene-cored dinuclear Gd chelates11 and for other DO3A based 
dimeric Gd complexes13,14 or will we find q ≅ 2 as for the DO3A monomer15 ? 
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Figure II.2  –  The trinuclear complex {Mes[Gd(DO3A)(H2O)2]3} 
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II.2. Experimental Section 
II.2.1. Ligand synthesis and characterization 
 
 
Figure II.3  –  Mes(DO3A)3 synthesis scheme 
 
This synthesis was performed by Felipe Reviriego and Raphaël Tripier, from UMR CNRS 
6521, Université de Bretagne Occidentale in Brest, France. 
 
1 2 
3 4 
6 5 
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Reagents were purchased from ACROS Organics and from ALDRICH Chemical Co. NMR 
and mass spectrometry were investigated at the “services communs” of the University of 
Brest. Elemental analyses were performed at the Service de Microanalyse, CNRS, Gif sur 
Yvette, France. 
  
Synthesis of decahydro-2a,4a,6a,8a-tetraazacyclopenta[fg]acenaphthylene (2)  
This compound, referred as cyclen-glyoxal, was synthesized by direct condensation of 
glyoxal with cyclen 1 as previously reported.16-19  
 
Synthesis of 2a,2a’,2a’’-(benzene-1,3,5-triyltrimethanediyl)tris(decahydro-4a,6a,8a-
triaza-2a-azoniacyclopenta[fg]acenaphthylene (3) 
To a solution of cyclen-glyoxal (2) (0.97 g, 5 mmol, 3.3 eq.) in anhydrous acetonitrile (5 mL) 
vigorously stirred at room temperature was slowly added 1,3,5-tris(bromomethyl)benzene 
(0.54 g, 1.5 mmol) in anhydrous acetonitrile (10 mL). When the addition was complete the 
reaction was allowed to proceed for 2 weeks. The solid was filtered off and dried in vacuum 
to give compound 3 (90 %). 13C NMR (100 MHz, D2O, 298 K): δ = 141.23 (CAr), 133.13 
(CHAr), 86.38 (CH), 74.32 (CHaminal), 64.39 (αCH2-Ar), 62.87, 60.02, 54.12, 51.03, 50.87, 
50.33 (2), 46.35 (αCH2) ppm. Anal. calcd. for C39H63Br3N12 (939.72): C 49.85, H 6.76, N 
17.89; found: C 49.72, H 6.51, N 17.33. 
 
Synthesis of 1,1’,1’’-(benzene-1,3,5-triyltrimethanediyl)tris(1,4,7,10-
tetraazacyclodidecane) (4) 
Compound 3 was refluxed in 10 mL of hydrazine hydrate for 2 hours. After cooling, the 
solvent was removed to dryness to yield 4 (quantitative yield).13C NMR (100 MHz, CDCl3, 
298 K): δ = 138.9 (CAr), 129.4 (CHAr), 59.0 (αCH2Ar), 51.0, 47.2, 46.6, 45.1(αCH2). Anal. 
calcd. for C33H66N12 (630.97): C 62.82, H 10.54, N 26.64; found: C 62.71, H 10.66, N 26.32. 
MS (FAB) : m/z (%) 631.1 (100) [M+H]+. 
 
Synthesis of 1,1’,1’’-(benzene-1,3,5-triyltrimethanediyl)tris[triethyl 2,2’,2’’-(1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate] (5) 
1.57 g (9.3 eq) of ethyl bromoacetate in acetonitrile (mL) was slowly added to a solution of 
compound 4 (0.63 g, 1 mol) with K2CO3 in acetonitrile. The reaction was allowed to proceed 
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to reflux for 24 hours and the solution was filtered. After solvent evaporation, the residue was 
dissolved in water (20 mL) and extracted with chloroform (3 x 20 mL). The organic phase 
was dried with MgSO4 and evaporated to dryness to yield 5 as a solid (93%). 13C NMR (100 
MHz, CDCl3, 298 K): δ = 171.40 (CO), 138.71 (br s, CAr), 128.25 (br s, CHAr), 61.32 
(CH2CAr), 60.09 (CH2CH3), 55.24, 51.74, 51.59 (αCH2), 14.03 (CH3) ppm. Anal. calcd. for 
C69H120N12O18 (1405.78): C 58.95, H 8.60, N 11.96; found: C 59.01, H 8.72, N 11.59. MS 
(FAB) : m/z (%) 1406.1 (100) [M+H]+. 
 
Synthesis of 2,2’,2’’,2’’’,2’’’’,2’’’’’,2’’’’’’,2’’’’’’’,2’’’’’’’’-[benzene-1,3,5-
triyltris(methanediyl-1,4,7,10-tetraazacyclododecane-10,1,4,7-tetrayl)]nonacetic acid (6)  
This compound will be referred as Mes(DO3A)3. Compound 5 was dissolved in a 
hydrochloric acid solution (6N) and stirred at 80 ºC during 12 h. After evaporation to dryness 
the compound was dissolved in water and evaporated (3 times). The product was dissolved in 
a small amount of water (5 mL) and eluted first through a column packed with a Dowex 
50WX8 (H+ form) cation exchange resin with ammonium hydroxide and after eluted through 
a column with a Dowex 1X2-200 (OH- form) anion exchange resin with hydrochloric acid. 
The compound was obtained in 93% of yield like a maroon solid as an adduct with 
hydrochloric acid. 13C NMR (100 MHz, D2O, 298 K): δ = 176.54, 170.84 (vbr s, CO), 138.03 
(vbr s, CAr-CH2), 132.10 (vbr s, CAr), 58.93 (br s, CH2-CAr), 55.83, 54.52, 51.53 (vbr s, 
CH2) ppm. Anal. calcd. for C51H84N12O18 · 12 HCl · 2.5 H2O (1635.86) : C 37.45, H 6.22, N 
10.27, Cl 26.01; found: C 37.20, H 6.52, N 10.00 Cl 25.98. MS (ESI) : m/z (%) : 577.79 (50) 
[M+2H]2+, 385.36 (100) [M+3H] 3+. 
 
II.2.2. Sample preparation 
The purity of the ligand molecule was checked with gas chromatography (HP 6890 with a 
20m FFAP column specific for carboxylic acids). One single and pure compound was 
detected at 10.55 min. 
 
A 29.5 mM Gd3+ solution in water was prepared from GdCl3 (79.0 mg of GdCl3 (0.3 mmol) in 
10.0 mL H2O). The exact concentration of the metal ion was measured by complexometric 
titration with Na2H2EDTA 5 mM in urotropine/HCl buffer and xylenol orange as metal 
indicator. 97.3 mg of the solid ligand 6 (C51H84N12O18 · 12 HCl · 2.5 H2O, M = 1635.86          
g mol-1, 59.48 μmol) were dissolved in 1.00 mL of water in order to obtain a theoretical 59.5 
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mM solution. The exact concentration of 6, determined by complexometric back titration of a 
Gd3+ excess with Na2H2EDTA 5 mM in urotropine buffer and xylenol orange as metal 
indicator, was determined at 58.8 mM based on the formation of the complex 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}-. 
 
All attempts to prepare the tris-Gd complex by mixing a ligand solution with an adequate 
amount of Gd3+ solution failed. In all cases the bis-Gd complex 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- with an excess of free Gd3+ was obtained. Finally 
solutions {Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- without free gadolinium ions were prepared 
by mixing a ligand solution with a GdCl3 stock solution in a 1:2 stoichiometric ratio. The pH, 
which drops spontaneously after mixing to 1.2, was corrected to 5.8 by adding NaOH (0.01 
M) (measured with combined glass electrode on a Metrohm 713 pH Meter, calibrated with 
Metrohm buffers). The solution was stirred overnight and finally heated to 60°C under argon 
bubbling in order to remove carbon dioxide. The absence of free Gd3+ was verified with the 
xylenol orange test. 
 
The tris-Gd complex {Mes[Gd(DO3A)(H2O)2]3} was prepared by complexing 6 in a first step 
with Mg2+ followed by transmetallation with Gd3+. 11.8 mg of MgCl2 · 2H2O (58 μmol, 3 eq.) 
in 100 μL H2O were added to the ligand solution (31.5 mg, 19.3 μmol, 1 eq.). The pH was set 
to 8.9 with NaOH (2 M) and the solution was stirred overnight. The following day, the pH 
was adjusted to 5.8 with HCl and the solution was added to 3 mL of a 29.50 mM Gd3+ (88.5 
μmol, 4.59 eq.) solution, previously adjusted to pH 5.9 with NaOH (0.1 M) and degassed with 
argon for 15 min. The transmetallation reaction was followed by relaxometry. The excess of 
Gd3+ and the released Mg2+ were removed by size exclusion chromatography (Sephadex G-25 
resin, eluted with water). The fractions containing the complex were identified by its yellow 
color and confirmed by UV (254 nm) on a TLC silica plate. The xylenol orange test was 
performed to indicate the absence of free ions. The collected fractions were dried and the 
solid complex was recovered. 
 
Gadolinium and carbon mass contents were measured by ICP-MS (Perkin-Elmer) and by 
elemental analysis, respectively. Gd/ligand ratios were calculated from Gd/C ratios assuming 
that carbons are only from the ligand (51 C atoms per ligand). The exact concentrations of the 
paramagnetic Gd3+ were determined by bulk magnetic susceptibility (BMS)20 at 25°C on a 
Bruker DRX-400 NMR spectrometer. 
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II.2.3. Transmetallation  
The transmetallation from Mg2+ to Gd3+ was followed by NMR relaxometry at 25 °C and 30 
MHz using a Bruker Minispec mq40. In a first step the longitudinal relaxation rate of the 
GdCl3 solution has been measured. In a second step the GdCl3 and 
{Mes[Mg(DO3A)(H2O)x]3}3- solutions were mixed (8% excess of Gd3+ with respect to the 
DO3A binding sites) at 25 °C and the solution degassed for 5 min with argon. The relaxation 
rates were measured at 10 minutes intervals during 800 minutes after mixing. 
 
II.2.4. 1H relaxometry 
Longitudinal relaxation times T1 for a full NMRD profile were measured at 1H Larmor 
frequencies from 0.01 to 400 MHz using the following equipment: Stellar Spinmaster FFC 
relaxometer (0.01 to 20 MHz),21 Bruker Minispec mq40 (30 and 40 MHz) and mq60 (60 
MHz), and Bruker NMR spectrometers working at 100, 200 and 400 MHz. The measurements 
were made at 25.0 °C and 37.0 °C using Gd3+ concentrations of 5.53 and 20.15 mM for 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- and 12.79 mM for {Mes[Gd(DO3A)(H2O)2]3}. 
 
II.2.5. 17O NMR spectroscopy 
Two 17O enriched solutions (2% in 17O obtained by diluting 20% 17O enriched normalized 
water, Isotec) were prepared with final concentrations of Gd3+ 20.15 mM 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- and 20.61 mM {Mes[Gd(DO3A)(H2O)2]3}. Relaxation 
measurements (R1 = 1/T1 by the inversion-recovery method22,23 and R2 = 1/T2 by the Carr-
Purcell-Meiboom-Gill method23,24) and chemical shifts (using spherical samples to avoid 
susceptibility corrections25) were performed on a Bruker ARX-400 spectrometer (9.4 T, 54.2 
MHz). Acidified water (HClO4, pH = 3.0) was used as external reference. In all 
measurements, the temperature was maintained by a Bruker B-VT 3000 temperature control 
unit, and was measured by a substitution technique.26  
 
II.2.6. Data treatment 
Solomon-Bloembergen-Morgan (SBM) theory6,7 has been used for data analysis (for 
equations see ref. 7). 1H NMRD profiles, 17O relaxation and chemical shifts were fitted in a 
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simultaneous fit using the Visualiseur/Optimiseur 3.5.0 program27,28 running on a Matlab® 
6.5 platform. 
 
II.2.7. Molecular mechanics 
All calculations were performed using Scigress Explorer Ultra Version 7.70.47 (Fujitsu Ltd) 
and the classical MM3 force field. Gd3+ ions have been replaced by Y3+ having the same ionic 
radius. The [Mes{DO3A}{Y(DO3A)(H2O)}2]3- complex was embedded into a drop of water 
consisting of 393 H2O molecules. Convergence was supposed to be attaint for an energy 
gradient < 10-5 kcal/mol. 
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II.3. Results and discussion 
II.3.1. Ligand synthesis 
Poly-tetraazacycloalkane ligands are very attractive compounds for coordination chemistry 
since they are now easily obtained by selective N-alkylation of the starting macrocycle.16-19 
As shown in Figure II.3, the studied ligand 6 consists in three DO3A moieties linked with a 
mesitylenyl center and is obtained following an easy route involving the bisaminal 
methodology of tetraazacycloalkanes.29-32 In a first step, the macrocyclic bis-aminal 2 has 
been obtained by condensation of glyoxal with cyclen 1 as previously described.33 Reaction of 
one equivalent of the tris-electrophile 1,3,5-tris(bromomethyl)benzene with 2 leads to the tris-
salt 3, easily deprotected by hydrazine monohydrate to obtain the tris-cyclen 4 in quantitative 
yield. This step is followed by the alkylation of the three secondary amine functions of each 
cyclen moities with ethyl bromoacetate. Finally, the nine-fold ester derivative is hydrolyzed in 
HCl (6N) with 78 % overall yield. 
 
II.3.2. Complexation 
The classical complexation method consists in mixing a ligand solution with stoichiometric 
quantities of Gd3+ calculated for {Mes[Gd(DO3A)(H2O)2]3} (see Experimental Section, 
chapter II.2.2.). In the case of our ligand 6 this leads to a surprising result. From the back 
titration of free Gd3+ is has been found that only 1.98 Gd3+ are bound to the ligand instead of 
the 3 expected. The calculation of this Gd/L ratio has been based on the molar mass 
established from the elementary analysis (C51H84N12O18 · 12HCl · 2.5H2O). This surprising 
result is confirmed by the Gd/L ratio of 2.17 which is obtained from gadolinium to carbon 
mass ratios determined by ICP-MS and elementary analysis for Gd and C, respectively. 
 
The observed difficulties to complex a third Gd3+ ion by the ligand 6 could arise subsequently 
from the important pH drop during the complexation reaction (pH ~ 1.2 after mixing). This 
pH drop implies a protonation of the amines of the third DO3A ring, which prevents the 
chelation of the third Gd3+. After restoring the pH to 5.8, the two acetates of the uncomplexed 
DO3A, instead of staying deprotonated and free, are suspected to bind immediately to the two 
chelated Gd3+ ions by replacing one water molecule from the first coordination sphere of each 
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of the two paramagnetic centers (Figure II.4).34,35 We therefore conclude that we synthesized 
the compound {Mes(H2DO3A)[Gd(DO3A)(H2O)]2}-, which we named bis-Gd (Figure II.4 B) 
as opposed to {Mes[Gd(DO3A)(H2O)2]3} which we named tris-Gd (Figure II.4 A). 
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Figure II.4  –  Proposed structures of the tris-Gd complex 
{Mes[Gd(DO3A)(H2O)2]3} (A) and the bis-Gd complex 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- (B). 
 
A preparation of the tris-Gd complex by starting the reaction at much higher pH is not 
possible due to the formation of gadolinium hydroxide at pH > 5.9. We therefore decided to 
prepare {Mes[Gd(DO3A)(H2O)2]3} in two steps. In a first step we complex the ligand 
Mes(DO3A)3 with a metal ion forming much weaker complexes than Gd3+. A condition is that 
this metal should not form precipitating hydroxides at a pH at which only one or two amines 
of the DO3A are protonated (pH ~ 9).35,36 In a second step this first complex is transformed to 
the final gadolinium compound by transmetallation at pH 5.8. We have chosen the Mg2+ ion 
to perform the first complexation step of 6. Besides the much lower stability of DO3A 
complexes with 2+ ions36 we selected the smallest alkali earth ion to disfavor binding of 
acetate groups from another DO3A chelate of 6 due to steric crowding around the cation. 
After adjusting the pH of the solution to 5.8 by adding NaOH a solution containing an excess 
of GdCl3 was added. The advancement of the reaction has been followed by measuring the 
water proton relaxation rate R1 = 1/T1 at 30 MHz (Figure II.5). The relaxation rate drops after 
mixing and reaches a stable value after ~800 min. The pH of the mixture did not change 
during the transmetallation reaction. After eliminating the excess of Gd3+ and free Mg2+ ions 
by size exclusion chromatography a Gd3+/ligand ratio of 2.96 has been determined by ICP-
MS / elemental analysis. 
A B 
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Figure II.5  –  Transmetallation reaction from {Mes[Mg(DO3A)(H2O)x]3}3- to 
{Mes[Gd(DO3A)(H2O)2]3} followed by 1H NMR relaxation of 
water at 30 MHz and 25.0°C.  
 
II.3.3. Structural transition induced by pH 
In a simple experiment we tried to confirm the binding of two acetate groups of the 
uncomplexed DO3A to the two Gd3+ ions bound to the other two chelating groups. By 
replacing the paramagnetic lanthanide Gd3+ by the diamagnetic Y3+, which has the same 
charge and a very similar ionic radius, we are able to measure the 1H NMR spectrum of the 
bis-Y complex in D2O solution. The 1H NMR spectra are rather complex due to the presence 
of different geometrical isomers in slow exchange. At about neutral pH there are two 
relatively broad signals in the aromatic region at 7.09 ppm and 7.52 ppm corresponding to 
two main isomers of the bis-Gd complex, called isomer A and isomer B. Varying the pH of 
the solution by adding 2 M NaOD in D2O shows an isomer transition, occurring between pH 
3 and 5.6 and shifting the equilibrium from isomer B to A (Figure II.6). We attribute the 
isomer A to the closed, or capped, form of the bis-Y complex, i.e. with acetate groups bound 
to the Y3+-ions as presented in Figure II.4 (B). Isomer B would correspond to the open form 
of the bis-Y complex with protonated and unbound acetate groups. The isomer transition 
would prove the formation of a closed conformation, unable to bind a third metal center at 
working pH. (4 to 5.8).  
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Figure II.6  –  Normalized peak area of the aromatic 1H NMR signals at 7.09 
ppm (isomer A, ●) and 7.52 ppm (isomer B, ○) vs. pH for 
{Mes(H2DO3A)[Y(DO3A)(H2O)]2}-. 
  
II.3.4. 1H NMRD profiles  
To characterize the relaxivity of the bis-Gd and tris-Gd complexes nuclear magnetic 
relaxation dispersion (NMRD) profiles of water protons have been measured at 25.0 °C and 
37.0 °C (Figure II.7). Comparison of the relaxation enhancement at low Larmor frequencies 
(ν < 1 MHz) induced by 1 mM Gd3+ (relaxivity, r1) shows that the relaxivity of the bis-Gd 
compound (Figure II.7 empty symbols) is about half of that of the tris-Gd compound (Figure 
II.7 filled symbols). Assuming similar relaxation rates of the Gd3+ electron spin for both 
compounds the only explanation for this difference in relaxivity is a change in the number q 
of coordinated water molecules. 
 
It has been shown that [Gd(DO3A)(H2O)q] shows an equilibrium between 8 and 9 
coordination and q = 1.8 and 1.9 has been determined by UV-Vis spectroscopy and 
luminescence lifetime of [Eu(DO3A)(H2O)q]15 and [Tb(DO3A)(H2O)q]37, respectively. We 
can therefore conclude that in the tris-Gd complex two water molecules are directly bound to 
the cation (q = 2). For the bis-Gd complex two structures with two first coordinations sphere 
water molecules per compound are conceivable: the first one having one Gd3+ with q = 2 and 
one with q = 0 and the second one having two Gd3+ ions with q = 1. For the first compound 
the coordination sphere of the Gd3+ with q = 0 is completed by two acetate groups from the 
metal free DO3A. For the second compound each Gd3+ ion binds one acetate group of the free 
DO3A (Figure II.4 (B)). Molecular mechanics calculations (Chapter II.3.6) show that the first 
structure leads to high intramolecular strain if compared to the second structure. This 
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reinforces our assumption of the structure proposed in Figure II.4 (B) with coordination of 
acetate groups of the uncomplexed DO3A to each of the two gadolinium ions in 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}-. 
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Figure II.7  –  NMRD Profiles of the tris-Gd complex (filled symbols) and of the 
bis-Gd complex (empty symbols) at 25 ° C (○,●) and at 37°C 
(□,■). Lines calculated from a simultaneous fit of 1H NMRD and 
17O NMR data using the parameters presented in Table II.1. 
 
II.3.5. 17O NMR spectroscopy 
The longitudinal and transverse 17O NMR relaxation enhancements as well as the 17O NMR 
chemical shift differences, all with respect to acidified water, have been measured as a 
function of temperature. The reduced relaxation rates 1/T1r, 1/T2r, and the reduced chemical 
shift differences, Δωr, are calculated by equations I.71 and I.72 and the results shown in 
Figure II.8. The mole fraction of bound water, PM, has been calculated for the bis-Gd and the 
tris-Gd complexes using q = 1 and q = 2, respectively.  
 
The 17O paramagnetic chemical shift experienced by water molecules directly bound to 
gadolinium ions is governed by the scalar or Fermi contact term.38 At high temperatures (T > 
322 K, 1000/T < 3.1 K-1) in the fast exchange regime the reduced chemical shift Δωr is 
directly given by the chemical shift of the bound water molecules, ΔωM.2 Because ΔωM, which 
is proportional to the scalar coupling constant A/ħ, is very similar for complexes with the 
same chelating unit,11,15 it can be used to estimate the number of coordinated water molecules. 
From the chemical shift results in Figure II.8 it can be seen that the reduced shifts for bis-Gd 
and tris-Gd complexes are essentially the same. Because their values have been calculated 
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using q = 1 for bis-Gd and q = 2 for tris-Gd this confirms that the number of water molecules 
bound to the Gd3+ ions is different for the bis-Gd and tris-Gd complexes. 
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Figure II.8  –  Reduced 17O NMR relaxation rates 1/T2r (■,□) and 1/T1r (●, ○) and 
reduced chemical shifts, Δωr (,), for the tris-Gd (filled symbols) 
and for the bis-Gd complex (open symbols). Lines calculated from 
the fitted parameters presented in Table II.1. 
 
Like the chemical shift differences, the reduced enhancement of transverse (1/T2r) and 
longitudinal (1/T1r) relaxation are very similar for bis-Gd and tris-Gd (Figure II.8). The 
continuous decrease of 1/T2r with increasing temperature is a clear indication that the water 
exchange is in the fast exchange regime.39 The reduced 17O NMR transverse relaxation rates, 
1/T2r, are determined by the water exchange rate constant kex, the scalar relaxation of bound 
oxygen atoms and the chemical shift difference ΔωM.39 Because the 1/T2r values of bis-Gd and 
tris-Gd complexes are so similar we can conclude that the water exchange rates are the same 
over the temperature range of the study. 
 
The quantitative analysis of the NMR data has been performed in two steps using the standard 
Solomon-Bloembergen-Morgan approach.6 If we are not interested in detailed information 
Synthesis, complexation and NMR relaxation properties of Gd3+ complexes of Mes(DO3A)3 
 
69 
 
about the electron spin relaxation and if we restrict the data analysis to medium to high 
magnetic fields the SBM approach gives reliable information on dynamic processes like water 
exchange rate constants and rotational correlation times for small to mid-size complexes.40 In 
a first step we fitted the 17O relaxation rates and chemical shift data of both compounds 
together. We fixed the distance between Gd3+ and the water oxygen, rGdO, to 2.5 Å. The 
nuclear quadrupole coupling constant, χ(1+η2/3)1/2, has been fixed to the value of neat water, 
7.58 MHz. From the fit we obtained for the exchange rate constant kex298 = 3.2×107 s-1 and 
ΔH‡ = 25.8 kJ mol-1. A mean rotational correlation time τR298 = 212 ps (ER = 19.7 kJ mol-1) 
has been calculated from the longitudinal 17O spin relaxation. 
 
In a second step we fitted the 17O NMR data together with the high frequency 1H relaxivity 
(ν(1H) > 6 MHz) in separate fits for bis-Gd and tris-Gd. In these separate fits we fixed the 
exchange rate constant and activation enthalpy to the values obtained from the 17O NMR data 
analysis. The water proton-Gd distance, rGdH, and parameters defining the outer sphere 
contribution to the 1H relaxivity have been fixed to common values (Table II.1). Rotational 
correlation times and parameters defining the electron spin relaxation (Δ2, the amplitude of 
the transient zero-field splitting, and τv, the correlation time for the transient zero-field 
splitting) are obtained from the two fits (Table II.1). The reasonable quality of the fits 
(calculated curves in Figure II.7 and Figure II.8) confirms once again the difference in water 
coordination numbers q of the two compounds. 
 
The water exchange rate constant is surprising in two aspects. First of all it is unexpected that 
the water exchange rates in the bis-Gd and the tris-Gd compounds are so similar. If we accept 
the coordination of one of the acetate to the Gd3+ ion as proposed above the coordination 
number of gadolinium is nine at all coordination sites in the two compounds. The local 
electric charge is however different since an acetate oxygen is more negatively charged than a 
water oxygen. This should lead to a marked difference.2,41,42 As a general trend it has been 
found that a higher negative overall charge favors the departure of the water molecule in a 
dissociative process.42 We expected therefore a faster exchange on the negatively charged 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- with respect to the neutral {Mes[Gd(DO3A)(H2O)2]3}. 
This is clearly not observed. The second unexpected result is the fast water exchange due to 
the low activation enthalpy (ΔH‡ = 25.8 kJ mol-1). The water exchange rate constant on 
[Gd(DO3A)(H2O)2] has been measured to 11×106 s-1 which is about three times slower.15 
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Terreno et al43 concluded from two DO3A derivatives that the water exchange rate is 
modulated by the basicity of the macrocylic nitrogen atom bearing the pendant group: a lower 
basicity results in a slower water exchange rate. The fastest exchange rate constant measured 
(kex298 = 17.6×106 s-1 on [Gd(NH2PhDO3A)(H2O)2]) is about 1.8 times slower than our 
exchange rate. Botta et al44 measured a 1.7 times faster water exchange on a substituted 
DO3A complex (Figure II.4 (B)) which has also q = 2. The activation entropy is negative (ΔS‡ 
= -14.7 J K-1 mol-1) suggesting a change in mechanism from dissociative activation to 
associative activation. This would mean that for both compounds an incoming water molecule 
helps the bound water molecule to leave the first coordination sphere. 
 
Parameters / complex bis-Gd tris-Gd 
q  1 2 
RE / kJ mol
-1
 18 ± 1 20.9 ± 0.5 
298
Rτ / ps 193 ± 4 201 ± 2 
298
vτ / ps 18.5 ± 4 10.9 ± 1 
2Δ  / 1020 s-2 0.38 ± 0.04 0.19 ± 0.01 
298
exk  / 10
6
 s-1 32 ± 3 
HΔ ‡ / kJ mol-1 25.8 ± 1.2 
SΔ ‡ / kJ mol-1 -14.7 ± 4 
/A   / 106 rad-1 -3.1 ± 0.2 
GdOr  / Å 2.5 
GdHr  / Å 3.1 
2 1/ 2(1 / 3)χ + η  / MHz 7.58 
GdHd  / Å 3.6 
298
GdHD / 10
-5
 cm2 s-1 2.5 
GdHE / kJ mol
-1
 20 
vE  / kJ mol
-1
 1 
 
Table II.1   –  Parameters obtained from the simultaneous fits of the 17O NMR 
and the 1H NMRD data, using the Solomon-Bloembergen-Morgan 
approach. Underlined values obtained from the preliminary 17O 
NMR fit. Bold values fixed. 
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II.3.6. Molecular modeling 
Simple molecular mechanics studies have been performed to evaluate different theoretical 
structures for [Mes{H2DO3A}{Gd(DO3A)(H2O)}2]-. The first structure minimized is shown 
in Figure II.9 (A). The structure corresponds to that proposed in Figure II.4 (B) : two 
carboxylates from the uncomplexed DO3A-unit bind to two different Y3+ ions on the two 
other DO3A. Each Y3+ ion has one water molecule in the first coordination sphere. This 
structure corresponds to the lowest energy of all minimized structures (-2363 kcal / mol). 
 
The second structure (Figure II.9 (B)) was obtained by starting with a configuration with two 
carboxylates bound to the same Y3+. The second Y3+ has two water molecules in the first 
coordination sphere. This structure could only be minimized by introducing a hydrogen bond 
between the ion and a carboxylate oxygen. The energy of this conformation is 481 kcal / mol 
higher than that of Figure II.9 (A). 
  
The conformation shown in Figure II.9 (C) is obtained by deleting the weak Y3+-O bond 
introduced in Figure II.9 (B) followed by energy minimization. One of the two acetates leaves 
the first coordination sphere of the Y3+. The energy of conformation (C) is 288 kcal / mol 
higher than that of conformation (A). If the second weak bond is also deleted the carboxylate 
stays in the first coordination sphere but the energy decreases again and the difference to (A) 
is now +98 kcal / mol. 
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Figure II.9  –  Structures of {Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- from 
molecular mechanics using MM3 force field. All structures have 
been minimized in a drop of 393 water molecules. 
 
A 
B 
C 
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II.4. Conclusion 
In order to develop new high field MRI contrast agents based on small molecules bearing 
multiple Gd3+ complexes, we synthesized the novel ligand Mes(DO3A)3. Its trinuclear 
complex with Gd3+ was characterized and a relaxivity of 10.2 mM-1 s-1 (13.7 mM-1 s-1) has 
been determined at 20 MHz and 37°C (25°C). This relaxivity is slightly higher than that 
measured for similar trimeric compounds (see, for example, Table 21 in Caravan et al.41). The 
complexation of the ligand was however not straightforward since the classical method lead 
to the undesired binuclear chelate complex {Mes(H2DO3A)[Gd(DO3A)(H2O)]2}-. This has 
been seen through the 1H NMR relaxivities r1 and the reduced 17O NMR chemical shifts Δωr. 
Surprisingly, water exchange rate on both complexes, the negatively charged 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- with q = 1 and the neutral {Mes[Gd(DO3A)(H2O)2]3} 
with q = 2, is very similar. The measured rate constant is among the highest found so far on 
DO3A-type Gd-complexes (Table II.2). 
 
To achieve the complete complexation, we had to develop a new alternative method, using 
pre-complexation with Mg2+ and transmetallation. This complexation method turned out to be 
very efficient to sidestep the coordination of neighboring chelating units preventing the 
complete complexation. The vicinity of the chelators in this mide-size molecule and the use of 
cyclic chelating unit, whose complexation kinetics are slow, have probably favored the 
coordination of neighboring carboxylate groups. 
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Compound q kex
298 
106 s-1 
ΔH‡  
kJ mol-1 
ΔS‡  
kJ mol-1 Ref 
Mononuclear      
[Gd(DO3A)(H2O)q] 1.9 11 33.6 +2 15 
[Gd(NO2PhDO3A)(H2O)q] 1 7.4 33.8 (0) a 43 
[Gd(NH2PhDO3A)(H2O)q] 1 17.6 36.2 (+15.2) a 43 
[Gd(B-DO3A)(H2O)q] b 2 55 40.8 (+40.1) a 44 
Dinuclear      
{pip[Gd(DO3A)(H2O)q]2} 2 1.5 34.2 -12 14 
{bisoxa[Gd(DO3A)(H2O)q]2} 2 1.4 38.5 +2 14 
{pX[Gd(DO3A)(H2O)q]2} 1 7.5 45.9 +41 11 
{mX[Gd(DO3A) (H2O)q]2} 1 11 41.0 +28 11 
{mX(COOH)[Gd(DO3A)(H2O)q]2} 1 12 32.7 +0.3 11 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}-  1 32 25.8 -14.7  
Trinuclear      
{Mes[Gd(DO3A)(H2O)q]3} 2 32 25.8 -14.7  
 
a
 Calculated from kex298 and ΔH‡. b Ligand 5 in ref. 44. 
 
Table II.2   –  Hydration numbers q, water exchange rates kex298, activation 
enthalpies ΔH‡ and activation entropies ΔS‡ for a selection of 
DO3A-type Gd chelates.  
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III.1 Introduction 
The two last decades have witnessed tremendous effort and successful progress in the 
optimization of the efficiency of magnetic resonance imaging (MRI) T1 contrast agents (CA). 
The latter are constituted by paramagnetic metal chelate complexes, mainly gadolinium (III) 
chelated with cyclic or acyclic poly(amino caboxylate) ligands, that increase the relaxation 
rate of the water protons. The efficiency of a contrast agent, called the relaxivity r1, depends 
on the electronic relaxation of the metal center, on the number of water molecules in the inner 
sphere of the complex and their exchange rate, and finally on the rotational correlation time 
τR, linked to the size of the molecule. 
 
The rotational correlation time is the predominant parameter of the relaxivity from about 10 to 
200 MHz, as illustrated in Figure III.1. This range, typically 64 MHz (1.5 T), corresponded 
until a few years ago to the working frequencies of most medical MRI magnets.1 The 
optimization of the efficiency of MRI CA had then to go through big and slowly tumbling 
molecules and many developments had been achieved with the intention of augmenting the 
molecular size. 
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Figure III.1 –  Simulated effect of the rotational correlation time on the relaxivity 
as a function of the Larmor frequency, calculated by SBM for τR = 
0.1 ns (dash), 0.5 ns (dot), 1 ns (straight), 5 ns (dash dot) and 10 ns 
(short dot). Other parameters : τM = 100 ns;  τν = 10 ps; Δ2 = 0.5 · 
1020 s-2; q = 1. 
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With the technological progress of the magnets however, developed to counteract the relative 
low sensitivity of NMR and MRI, these big CA became less and less effective with the 
increasing of the MRI magnetic field (Figure III.1). MRI high-field magnets (3T, 127 MHz) 
for human medical use became commercially available since approximately 1998,1,2 the first 
results performed on human using a 9.4 T magnet (400 MHz) were published in 2006,3 and 
the upcoming French brain imaging center NeuroSpin announce a 17 T (724 MHz) research 
murine magnet and a 11.7 T (500 MHz) human medical magnet.4 In order to optimize their 
efficiency towards current technological march, contrast agents whose rotational correlation 
times ranges from 0.5 to 1 ns are nowadays developed (Figure III.1). 
 
Though the efficiency of CA is characterized by the relaxivity, defined as the relaxation rate 
enhancement induced by 1 mM of the paramagnetic species, the density of metal complexes 
plays also an important role on the effect on the relaxation time. The term “density of 
relaxivity” is used to describe the efficiency of CA per unit of mass. From this perspective, 
many studies have been carried out on the purpose to develop mid-size compounds bearing 
several coordination sites, with central benzene5-8 or metal9-12 core. 
 
Within this framework, Costa et al. described unusual systems, constituted by two DO3A3- 
chelating units linked in meta and para to a central xylene core, presenting exceptionally high 
relaxivities for mid-size molecules (Figure III.2) (DO3A3- = 1,4,7,10-tetraazacyclododecane-
1,4,7-triacetate).6 Self-aggregations, constituted of about ten “monomers”, were proved to be 
accountable for these unexpected relaxivities. As such aggregates have not been observed in 
non-aromatic dimeric Gd3+ complexes,13,14 the intermolecular interactions result most 
probably from π-stacking of the aromatic core, though other hydrophobic interactions or 
hydrogen bonding can not be excluded. 
 
 
 
Figure III.2  – Costa et al. aggregating systems, with R = H (DO3A in meta and 
para positions) and R = COOH (DO3A in 3,5-meta position) 
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In line with this project, this chapter presents the molecule Ph4DTTA3 (1,3,5-tris-{4-[(bis{2-
[bis(carboxymethyl)amino]ethyl}amino)methyl]phenyl}benzene), composed by three 
heptadentate DTTA chelating moieties around a central core constituted by four benzene 
rings. The aromatic central core has been designed specially to favor formation of aggregates, 
thought to be induced by strong π-stacking intermolecular interactions. We report here the 
synthesis of the ligand and the relaxometric characterization of its Gd3+ complexes of this 
compound designed as a potential MRI contrast agent (Figure III.3).  
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Figure III.3  – The gadolinium (III) complex {Ph4[Gd(DTTA)(H2O)2]-3} 
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III.2 Experimental Section 
III.2.1 Ligand synthesis and characterization 
 
 
 
Figure III.4  – Ph4DTTA3 synthesis scheme 
 
All chemicals were purchased from high quality grade chemical sources (Sigma-Adrich, 
Acros) and were used as received without purification. 
1 
2 3 
4 5 
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All 1H and 13C NMR spectra were recorded on a Bruker DRX-400 spectrometer (9.4 T). Mass 
Spectrometry analyses were performed on a Thermo Fischer TSQ7000 spectrometer using 
ESI ion source. HPLC purifications were performed on a Dionex system made up of a UVD 
170U detector and a P580 Pump, using a SunfireTM Prep C18 OBDTM 5 μm column (19 x 150 
mM). Elemental analysis was performed by Dr. Euro Solari at the Elemental Analysis Service 
at ISIC, EPFL.  
 
Synthesis of tert-butyl 2,2’,2’’,2’’’-[iminobis(ethane-2,1-diylnitrilo)]tetraacetate (1)  
This compound, referred as or DTTA+, was synthesized according to literature.15,7 
 
Synthesis of 1,3,5-tris-(4-methylphenyl)benzene (2) and 1,3,5-tris-(4-
bromomethylphenyl)benzene (3) 
These compounds, referred as Ph4Me3 and Ph4Br3 respectively, were synthesized according to 
literature.16-19 
 
Synthesis of 1,3,5-tris-{4-[(bis{2-[bis(tert-butyl acetate)amino]ethyl}amino)methyl] 
phenyl}benzene (4) 
This compound will be referred as Ph4DTTA+3. 1.83 g (3.27 mmol) of DTTA+ (1) was 
dissolved in 90 ml of dry DMF. 608.7 mg (1.040 mmol) of 1,3,5-tris-(4-
bromomethylphenyl)benzene (3), dissolved in 10 mL of dry DMF, were added dropwise 
under argon atmosphere. The reaction mixture was stirred overnight at 55°C and evaporated 
to dryness. The residue was dissolved in 200 ml of DCM and washed three times with 100 ml 
of water. The organic phase was dried over sodium sulfate and evaporated to dryness. The 
crude product was purified by silica gel chromatography (DCM/MeOH 95:5) (Rf = 0.19). 212 
mg (yield 10%) of pure compound (4) were obtained. 1H-NMR (CDCl3, 400 MHz) δ in ppm : 
1.43 (s, 108 H), 2.67 (t, J undetermined, 12 H), 2.87 (t, J undetermined, 12 H), 3.43 (s, 24 H), 
3.70 (s, 6H), 7.41 (d, J = 7.0 Hz, 6 H), 7.61 (d, J = 7.0 Hz, 6 H), 7.74 (s, 3 H). MS (ESI) m/z 
(%) : 675.1 (100) [M+3H]3+, 1011.3 (5) [M+2H]2+. 
 
Synthesis of 1,3,5-tris-{4-[(bis{2-[bis(carboxymethyl)amino]ethyl}amino)methyl] 
phenyl}benzene (5) 
This compound will be referred as Ph4DTTA3. 200 mg (99 μmol) of Ph4DTTA+3 (4) were 
dissolved in 5 ml of a 5% water in TFA solution and stirred for 3 h. The solvents were 
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removed by evaporation and the residue was washed with 10 ml of water and evaporated to 
dryness five times. The resulting solid was dissolved in 12 ml of a 0.1 M triethylammonium 
acetate buffer and purified on a C18 preparative HPLC column, using 0.1 M 
triethylammonium acetate buffer and a 0 to 60% in 30 minutes acetonitrile gradient as elution 
system. The pure fractions, eluted after 15.0 minutes, were collected, evaporated and washed 
until no triethylammonium acetate remained. 52 mg (39 μmol) of the pure product (5) were 
obtained (yield 39%). 1H-NMR (D2O, 400 MHz) δ in ppm : 2.99 (t, J undetermined, 12 H), 
3.51 (t, J undetermined, 12 H), 3.69 (s, 24 H), 3.82 (s, 6 H), 7.54 (d, J = 6.7 Hz, 6 H), 7.80 (d, 
J = 6.4 Hz, 6H), 7.96 (s, 3 H). 13C-NMR (D2O, 54.3 MHz) δ in ppm : 47.38 (CH2-N), 52.12 
(CH2-N), 56.73 (CH2-CO), 57.64 (Ar-CH2-N), 124.89 (CHAr), 127.69 (CH-CHAr), 130.51 
(CH-CHAr), 135.91 (CAr), 139.96 (CAr), 141.55 (CAr), 170.34 (CO). MS (ESI) m/z (%) : 
675.3 (100) [M+2H]2+, 1349.5 (96) [M+H]+. Elemental analysis calculated (%) for 
[H15Ph4DTTA3]3+[Cl]-3 (C63H84Cl3N9O24) + 0.67 [HNEt3+Cl-] (C6H15ClN ; integration of 1H 
NMR peak) (C67.03H94.09Cl3.67N9.67O24 ; 1549.64 g mol-1) : C 51.96, H 6.12, N 8.74 ; found : C 
52.15, H 6.05, N 8.64. 
 
III.2.2 Sample preparation 
The solid salt GdCl3·x H2O (x ≈ 6.7) was dissolved in H2O to prepare the Gd3+ stock solution. 
The exact ion concentration was measured by complexometric titration using Na2H2EDTA 5 
mM. Ph4DTTA3 solution was prepared in H2O and the chelator concentration was determined 
by back titration of a Gd3+ excess with Na2H2EDTA 5 mM. The titrations were performed on 
a Metrohm 665 Dosimat, using xylenol orange as complexometric indicator and buffered at 
pH 5.8 with a 5% (w/v) urotropine solution in water. The complex {Ph4[Gd(DTTA)(H2O)2]-3} 
was prepared by adding a slight deficit of Gd3+ (2%) to the ligand solution. The pH was 
brought back to 5.8 with 0.1 M NaOH and the absence of free gadolinium was checked by the 
xylenol orange test. Finally, the exact final Gd3+ concentration was measured by bulk 
magnetic susceptibility (BMS)20 at 23.3°C on a Bruker DRX-400 (9.4 T, 400 MHz) 
spectrometer. This was performed by measuring the shift of the tert-butanol alkyl protons in 
the paramagnetic environment compared to the diamagnetic reference contained in a coaxial 
NMR tube. 
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III.2.3 1H relaxivities 
T1 were determined by the inversion-recovery method21 using the following equipment : 
Stelar Spinmaster Fast Field Cycling (FFC) NMR relaxometer22 (2.35 · 10-4 to 0.47 T; 1H 
Larmor frequencies : 0.01 to 20 MHz) equipped with a VTC90 temperature control unit, 
Bruker Minispec mq20 0.47 T (20 MHz), mq40 0.70 T (30 MHz), mq40 0.94 T (40 MHz) and 
mq60 1.41 T (60 MHz), Bruker Avance-200 console connected to a 2.35 T (100 MHz) and a 
4.7 T (200 MHz) cryomagnets, Bruker Avance-II 9.4 T (400 MHz) and Bruker Avance-II 
18.8 T (800 MHz). The spectrometers were equipped with Bruker BVT3000 temperature 
control units and Bruker BCU05 cooling units. All temperatures were measured by 
substitution techniques.23 The relaxation rates 1/T1 were corrected by diamagnetic 
contributions of 0.366 s-1 and 0.326 s-1 for 25°C and 37°C respectively. 
 
The 1/T1 NMRD profiles of {Ph4[Gd(DTTA)(H2O)2]-3} were measured at 25.0°C (Gd3+ 
concentrations of 18.18 mM, 1.838 mM and 0.1010 mM) and 37.0°C (Gd3+ concentrations of 
18.18 mM and 1.838 mM). Samples in 7.5 mm tubes were used on Bruker mq40s and mq60 
while samples sealed in glass spheres adapted for 10 mm NMR tubes were used for all other 
instruments. 
 
Relaxivities of {Ph4[Gd(DTTA)(H2O)2]-3} ~ 0.77 mM solutions at six different pH between 4 
and 7 were measured at 25°C and 30 MHz. 
 
Relaxivities of {Ph4[Gd(DTTA)(H2O)2]-3} ~ 2.25 mM solutions containing 0, 11, 21, 51, 116, 
222 and 507 mM of phosphate buffer were measured at 25°C and 30 MHz 10 minutes after 
phosphate addition and then every 24h. The phosphate buffer was prepared from mono and 
dibasic sodium phosphate in order to obtain a final pH 5.8 solution. At the same time, the 
relaxivity of the 2.25 mM complex in human serum (32% w/w) (Human serum from human 
male AB plasma, Sigma-Aldrich) was measured in the same conditions. 
 
III.2.4 17O NMR spectroscopy 
Variable temperature 17O NMR measurements were performed on a Bruker Avance-II 9.4 T 
(54.3 MHz) spectrometer, equipped with a Bruker BVT3000 temperature control unit and a 
Bruker BCU05 cooling unit. 10.5% 17O-enriched water (Irakli Gverdtsiteli Research and 
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Technology Center on High Technologies and Super Pure Material LTD) was added to the 
sample to obtain a final 2% 17O enrichment and a 15.37 mM Gd3+ concentration. The sample 
was sealed in a glass sphere adapted for 10 mm NMR tubes to avoid susceptibility corrections 
to the chemical shifts. Transverse and longitudinal relaxation rates, using the inversion-
recovery21 and the Carr-Purcell-Meiboom-Gill24 pulse sequences respectively, and the 
chemical shift differences in comparison to the pH 3.5 water reference (1% 17O enrichment) 
were measured at 11 different temperatures spread from -2°C to 89.9°C. 
 
III.2.5 Data treatment 
Simultaneous fit on the 1H NMRD and 17O NMR data using a Solomon-Bloembergen based 
theory25-27 supplemented with the Lipari-Szabo free-model approach for the internal 
rotation28,29 and the Rast-Fries-Belorizky model for electronic spin relaxation,30 were 
performed on Visualiseur/Optimiseur31,32 running on a MATLAB© 7.3.0 (R2006b) platform. 
This approach will be referred as SB-LS-RFB. 
 
The fittings of the NMRD profiles using the “modified Florence approach”33-35 calculations 
were performed with the “modified Florence program”36 adapted to run on a MATLAB© 
7.3.0 (R2006b) platform. 
 
III.2.6 Molecular modeling 
The molecular simulation was performed by molecular mechanics using the MM3 force 
field37-39 with Scigress Explorer ™ Ultra 7.7.0.47. 
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III.3 Results and discussion 
III.3.1. Ligand synthesis 
The use of the chelator DTTA presents many advantages. First, this acyclic poly(amino 
carboxylate) is heptadentate, which allows two water molecules in the inner sphere of the 
Gd3+ complex (Figure III.5), and hence doubles its relaxivity. Then, the two water molecules 
in the complex are not adjacent which prevents complexation with bidentate salts, such as 
carbonate typically, and allows skipping of degassing steps. Finally, its synthesis using a 
succession of protection and deprotection is straightforward (four steps, Figure III.4), 
inexpensive, and leads to acceptable global yield (40%).7 Though its stability would not allow 
human applications, this chelating unit is stable enough for in vitro or in vivo animal studies.40 
 
 
 
Figure III.5  – The Gd3+ chelating complex [Gd(DTTA)(H2O)2]-  
 
The overall synthesis route of the ligand Ph4DTTA3, presented on Figure III.4, consists in 
three major steps : the synthesis of the chelating unit DTTA (1), the synthesis of the central 
core Ph4Br3 (3) and their conjugation.  
 
1,3,5-tris-(4-methylphenyl)benzene (2) is formed with good yield through the triple 
condensation of the 1-(4-methylphenyl)ethanone. The next step, the bromination of the 
methyl groups, using N-bromosuccinimide (NBS) and benzoyl peroxide (BPO) is more 
delicate. The exact quantity of NBS has to be added dropwise in order to brominate every 
methyl position and to avoid the massive formation of dibrominated methyl. The presence of 
side products, consisting of the compound 3 with unsubstituted, disubstituted or hydrolized (-
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OH instead of -Br) methyl makes the separation arduous throughout the synthesis until the 
preparative HPLC purification. 
 
The next step consists in the conjugation of the protected chelating moieties DTTA+ on the 
three alkyl halides of the core Ph4Br3 (3) in the presence of K2CO3. It gives the desired 
compound Ph4DTTA+3 (4), but its purification by chromatography, using a dichloromethane / 
methanol system and turned out to be laborious due to the presence of side products in the 
majority of the fractions. These impurities were essentially the compound 4 with one 
unsubsituted methyl, arising from its unbromination, or with hydroxymethyl, coming from 
hydrolyzation of unreacted bromide. This difficult separation, besides the three SN2 reactions 
on the same molecule, explains the unexpected low yield (10%). 
 
Finally, the tert-butyl protecting groups were removed by TFA to obtain the free acid 
Ph4DTTA3 (5). Due to the behavior of this compound, which precipitates in aqueous solutions 
with pH lower than 3, the purification of this step was here again fastidious. The cationic 
exchange resin, commonly used to purify poly(amino carboxylates), was not possible, while 
the anionic exchange resin as well as the size exclusion resin SephadexTM LH-20 turned out to 
be inefficient. The purification has finally been possible by preparative HPLC, using water 
with 0.1 M triethylammonium acetate as buffer and ion pairing agent in a water/acetonitrile 
system. ESI-MS analyses were performed with pure methanol without formic acid to prevent 
any precipitation in the capillary. Eventually, ligand 5 was isolated in 8 steps with an overall 
yield of 2 %.
 
 
III.3.2. Concentration effect 
Early relaxivity measurements revealed exceptionally high values for a mid-size molecule. 
Moreover, the relaxivity turned out to be dependent on the concentration. As the electronic 
relaxation rate, the water exchange rate and the number of molecules in the inner sphere of the 
complex are supposed to be unaffected by the concentration, this concentration dependence 
has to be induced by the rotational correlation time τR, directly related to the size. The 
formation of dynamic intermolecular structures, such as aggregation by π-stacking, is 
probably the only way to explain the high relaxivities and their concentration dependence by 
increasing the rotational correlation time. 
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Figure III.6 shows the reproducible concentration-dependent relaxivities of two 
{Ph4[Gd(DTTA)(H2O)2]-3} systems issued from two different synthesis and complexations. 
To get a better idea of this effect, the results are presented in both linear and log scales. The 
evolution of the relaxivities with the Gd3+ concentration presents a sigmoid shape that can be 
described in three phases :  
 
- A relaxivity stationary plateau around r1 = 27 mM-1s-1 for Gd3+ concentrations up to 
0.1 mM. This plateau indicates that the size of the entities does not significantly 
change for this concentration range. This could correspond to the monomeric species. 
- A marked increase for Gd3+ concentrations between 0.1 and 1 mM. The formation of 
aggregates is favored in this concentration rate, and their size increase with the 
concentration. 
- A flattening of the relaxivity enhancement for concentrations higher than 1 mM. The 
formation of bigger aggregates still occurs but their size increase less when 
augmenting the concentration. 
 
 
 
 
 
 
 
 
 
 
 
Figure III.6  – Concentration-dependent relaxivities r1, in linear and log scales, of 
two different {Ph4[Gd(DTTA)(H2O)2]-3} systems (●) and (○) at 30 
MHz, 25.0°C. 
 
Calculations of the propagation of uncertainty (only shown on the log scale of Figure III.6) 
has been performed by considering a relative error of 3% on both the observed and the 
diamagnetic reference relaxation times and by assuming the Gd3+ concentration as being 
exact. The equation III.1 has been used to determine the relative error on the relaxivity r1. 
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III.3.3. 1H NMRD profiles 
The concentration dependence of the size of the entities, and hence their relaxivities, leads to 
typical NMRD profiles for each concentration. This is exemplified by Figure III.7 showing 
the NMRD profiles at 25°C of the system for Gd3+ concentrations of 0.101 mM, 1.84 mM and 
18.2 mM. The shape of the profiles, particularly the relaxivity humps between 10 and 100 
MHz, flat for the diluted and steep for the concentrated samples, the increasing hump 
amplitude with the concentration and the shift of the hump maximum are strong evidences for 
a change of the size of the particles with the concentration (see Figure III.1). The complete 
NMRD profiles at 25°C and 37°C are independently presented in Figure III.8. Due to the very 
short relaxation times (about 1 ms), T1 measurements on the 18.2 mM sample were not 
achievable on the FFC relaxometer, i.e. from 0.01 to 16 MHz. The NMRD profiles of this 
sample were therefore measured only from 20 to 800 MHz. 
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Figure III.7  – NMRD profiles of {Ph4[Gd(DTTA)(H2O)2]-3} at 25°C for 0.101  
mM (○), 1.84 mM (○) and 18.2 mM (●) samples. 
 
III.3.4. 17O NMR spectroscopy 
This experiment was achieved to allow a simultaneous fit of 17O NMR data with 1H NMRD 
data of the concentrated samples. This allows the determination of several parameters 
common to all systems, whatever the concentration. The variable temperature 17O NMR 
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measurements, performed on a 15.4 mM sample, are presented on Figure III.9. The reduced 
relaxation rates T1r and T2r and the reduced chemical shift differences Δωr are calculated using 
equations I.71 and I.72. All values were calculated with respect to acidic water, interpolated 
reference chemical shifts were used for the calculation of Δωr. The number of water 
molecules in the inner sphere of the complex q was fixed to 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.8  –  NMRD profiles of {Ph4[Gd(DTTA)(H2O)2]-3} at (A) 0.101 mM 
25°C (●), (B)  1.84 mM 25°C and 37°C (○) (●) and (C) 18.2 mM 
25°C (●) and 37°C (○). 
 
 
A 
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III.3.5. 17O and 1H NMR data fittings with SB-LS-RFB 
The simultaneous fit (Figure III.9) and 17O NMR and NMRD data allows most of the 
parameters common to each samples to be determined.  
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Figure III.9  – SB-LS-RFB simultaneous best fittings of (A) the 17O NMR data 
(ln 1/T1r (●), ln 1/T2r (○) and Δωr (■)) and (B) the NMRD profile of 
high concentrated {Ph4[Gd(DTTA)(H2O)2]-3} samples at 25°C (●) 
and 37°C (○). 
 
 
A 
B 
2.6 2.8 3.0 3.2 3.4 3.6 3.8
-0.8
-0.6
-0.4
-0.2
 
 
Δω
r 
/ 1
06
 
ra
d 
s-
1
1000/T / K-1
Dynamic aggregation of the mid-size gadolinium complex {Ph4[Gd(DTTA)(H2O)2]-3} 
 
95 
As the concentration dependence of the relaxivity is supposed to arise exclusively from the 
size of the aggregates, only global rotational correlation time τR and possibly the rigidity of 
the particle, characterized by the Lipari-Szabo factor S2, should be affected by the 
concentration. All other fitted parameters, including the water exchange rate constant 298exk , the 
scalar coupling constant /A   or the electronic relaxation parameters for instance, are 
expected to remain unchanged whatever the size of the agglomerates. 
 
The approach of the calculation is to fit simultaneously the 1H NMRD and the 17O NMR 
measurements of high concentration samples. All parameters, except the global rotational 
correlation time τR and the Lipari-Szabo factor S2, will then be fixed and used as it is to fit the 
NMRD profiles of the samples at 0.1 and 1.8 mM. Though the sample concentration of the 1H 
NMRD and the 17O measurements are slightly different ([Gd3+] = 18.2 mM and 15.4 mM for 
the 1H NMRD and the 17O measurements respectively), they are assumed to be compatible 
(Figure III.6). By considering potentially too high 1H relaxivities, the only affected parameter 
would be the HW OWR R/τ τ  ratio, caused by the internal rotation of the water molecule in the inner 
sphere, which will appear slightly higher. With a fitted value for HW OWR R/τ τ  of 0.88 instead of 
the theoretical 0.7 or 0.8, this artifact is actually observed. The simultaneous fit of the highly 
concentrated sample experimental points (17O 1/T1r, 1/T2r, Δωr and high field 1H NMRD) are 
shown on Figure III.9 and the best fitted parameters are reported on Table III.1. 
 
The fit on experimental data of the concentrated samples was first performed by fitting the 
17O NMR data, leading to a fit very close to experimental points. The high field 1H NMRD 
profiles data has been incorporated subsequently to the fitted data. Very few parameters, 
including the various constants and distances, are kept fixed in the final fit. A possible 
outersphere contribution to the chemical shifts has been neglected and the higher order static 
ZFS terms 4a  and 6a , very close to zero when fitted, are decided to be fixed to zero. 
 
Let’s note that the temperature of the sample probably affects also the size of the aggregates, 
generating smaller particles at higher temperature. As a wide temperature range is used, this 
can have an influence on the 17O NMR experimental points, particularly on the values of T1, 
dependent to the rotational correlation time 298Rτ .41 This phenomenon can also have a slight 
effect on the NMRD profiles, where the entities are supposed to be bigger at 25°C than at 
37°C. The relaxivities of the latter case will be a bit lower than expected in the hump region 
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(20 to 100 MHz, corresponding to the fitted region), leading to a bigger gap between the two 
temperature profiles at this frequencies. The expected effect on the fitted parameters would 
result in unusually high rotation activation energy RE , which is exactly what has been 
observed (26.8 kJ mol-1) (Table III.1). 
 
Parameters / [Gd3+] 18 mM 1.8 mM 0.10 mM 
HΔ ‡  / kJ mol-1 39.9 ± 7.9 39.9 39.9 
298
exk  / 106 s-1 17.0 ± 5.1 17.0 17.0 
RE  / kJ mol
-1
 26.8 ± 5.7 26.8 26.8 
298
Rτ  / ps 2770 ± 628 1987 ± 99 817 ± 100 
lE  / kJ mol
-1
 18.0 ± 4.9 18.0 18.0 
298
lτ  / ps 197 ± 331 197 197 
vE  / kJ mol
-1
 1 1 1 
298
vτ  / ps 0.756 ± 0.191 0.756 0.756 
/A   / 106 rad s-1 3.70 ± 0.68 -3.70 -3.70 
osC  0 0 0 
g  2 2 2 
298
GdHD  / 10
-10
 m2 s-1 25 25 25 
DGdHE  / kJ mol
-1
 22 22 22 
GdOr  / Å 2.5 2.5 2.5 
HW OW
R R/τ τ  0.88 ± 1.43 0.88 0.88 
2a  / 10
10
 s-1 0.88 ± 0.71  0.88 0.88 
4a  / 10
10
 s-1 0 0 0 
6a  / 10
10
 s-1 0 0 0 
2Ta  / 10
10
 s-1 0.52 ± 0.16 0.52 0.52 
2S  0.61 ± 0.02 0.54 ± 0.02 0.47 ± 0.05 
( )21 / 3χ +η  / MHz 7.58 7.58 7.58 
WATq  2 2 2 
stGdH 1r  / Å 3.1 3.1 3.1 
ndGdH 2r  / Å 3.2 3.5 3.5 
 
Table III.1  –  Best fitted parameters by SB-LS-RFB theory of 17O NMR and 1H 
NMRD data for {Ph4[Gd(DTTA)(H2O)2]-3} at various 
concentrations. Fixed values underlined. 
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Most of the fitted parameters obtained for the highly concentrated samples are then used to fit 
the 1H NMRD profiles of the lower concentration samples (Figure III.10). Only the rotational 
correlation time 298Rτ  and the Lipari-Szabo factor S2 are released for the fittings. The best fitted 
parameters are also presented on Table III.1. 
 
The approach SB-LS-RFB however is not suitable for slow tumbling molecules at low 
magnetic fields.42 A fitting performed on the whole profile would inexorably induce 
erroneous 298Rτ . For this reasons, the NMRD profiles of the compound at 1.8 mM and 0.1 mM 
are fitted only from 16 MHz to 800 MHz. 
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Figure III.10– NMRD profile of {Ph4[Gd(DTTA)(H2O)2]-3} at (A) 1.8 mM at 
25°C (●) and 37°C (○) and (B) 0.10 mM at 25°C (●), fitted with 
SB-LS-RFB. 
 
When comparing the fitted parameters for the three different concentrations, we see that the 
rotational correlation time changes significantly with the concentration, reinforcing the 
hypothesis that the size of the molecule is dependent on the concentration.  
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It can be noticed that the Lipari-Szabo factor S2 is notably lower in the case of the diluted 
sample, indicating a more flexible structure. The chelating units of molecules wedged in an 
aggregate are supposed to have less degree of freedom for internal rotation than the 
monomers or molecules on the edge. With more “stacked” molecules, the bigger aggregates 
induce therefore more rigid structures, and hence bigger S2. 
 
Furthermore, it cannot be excluded that aggregation influences the relaxivity contribution of 
the outer sphere. The water environment of “stacked” and “edge” complexes may be different. 
Though outer sphere does nearly not affect the relaxation of oxygen relaxation, it has a non-
negligible effect on the proton T1 and therefore on the NMRD profile and the fitting.  
 
III.3.6. 1H NMRD data fittings with the modified Florence approach 
As mentioned, the SB-LS-RFB model is not valid for slowly rotating compounds. The fitting 
of the whole NMRD profiles has to be performed with a method appropriated for slowly 
rotating molecules, as the modified Florence approach. This model considers also a static and 
a transient ZFS, but assumes slow reorientation of the complex and no correlation between 
the rotation and translation of the complex and the electronic spin dynamics.34,43 
 
The approach we have chosen in our calculation is to use a few fixed parameters calculated 
with the SB-LS-RFB model (see chapter III.3.5) to implement it in the “modified Florence 
program”. The water exchange parameters kex (= 1/τM) and HΔ ‡ , fitted from experimental 17O 
NMR data, as well as the internal rotation parameters τl, El and S2 obtained by SB-LS-RFB 
are kept unchanged. 
 
At first, the 1.8 mM NMRD profiles, because full NMRD profiles at two temperatures were 
available (Figure III.11), were fitted with free electronic relaxation parameters Eν, τν, Δ and D, 
and global rotation parameters ER and τR. 
 
The obtained electronic relaxation parameters were then fixed and used to fit the NMRD 
profiles of the 18.2 and 0.10 mM samples, considering the only parameters ER and τR as 
variable. The best fitting parameters and the fitted NMRD profiles at other concentrations are 
presented on Table III.2 and Figure III.12, respectively. 
 
Dynamic aggregation of the mid-size gadolinium complex {Ph4[Gd(DTTA)(H2O)2]-3} 
 
99 
0.01 0.1 1 10 100 1000
0
10
20
30
40
50
 
r 1
 
/ m
M
-
1 s
-
1
ν 
1H / MHz
 
Figure III.11 – NMRD profile of {Ph4[Gd(DTTA)(H2O)2]-3} at 1.8 mM at 25°C 
(●) and 37°C (○) fitted with  the Florence approach. 
 
Parameters / [Gd3+] 18 mM 1.8 mM 0.10 mM 
RE  / kJ mol
-1
 14.71 22.29 - 
298
Rτ / ps 1586 1344 612.7 
vE / kJ mol
-1
 12.53 12.53 - 
298
vτ  / ps 51.73 51.73 51.73 
Δ  / cm-1 0.02224 0.02224 0.02224 
D  / cm-1 0.04234 0.04234 0.04234 
2S  0.61 0.544 0.47 
lE  / kJ mol
-1
 18.0 18.0 18.0 
298
lτ  / ps 197 197 197 
ME / kJ mol
-1
 39.9 39.9 - 
Μτ / 10
-6
 s 0.05882 0.05882 0.05882 
DGdHE / kJ mol
-1
 22 22 - 
298
GdHD  / 10
-5
 cm2 s-1 2.5 2.5 2.5 
WATq  2 2 2 
stGdH 1r  / Å 3.1 3.1 3.1 
ndGdH 2r  / Å 3.5 3.5 3.5 
 
Table III.2   –  Best fitted parameters using the Florence approach and 1H NMRD 
data for {Ph4[Gd(DTTA)(H2O)2]-3} 18.2 mM, 1.84 mM and 0.101 
mM. Fixed values underlined. 
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Figure III.12 – NMRD profile of {Ph4[Gd(DTTA)(H2O)2]-3} at (A) 18.2 mM at 
25°C (●) and 37°C (○) and (B) 0.10 mM at 25°C (●) fitted with  
the Florence approach using the parameters of the 1.8 mM sample. 
 
As the NMRD profile of the 0.1 mM sample was measured only at 25°C, the activation 
energies can not be calculated, and hence do not appear in the table. The unit conversion to 
compare with the SB-LS-RFB fitted values of the transient ZFS term Δ (using equation III.2, 
with c the speed of light = 3 · 1010 cm s-1), corresponding to 2Ta , and the static ZFS term D, 
equivalent to 2a , led to the consistent values of 0.419 · 10
10
 s-1 and 0.798 · 1010 s-1 
respectively.  
 
( )2 2-2 -1[s ] [cm ] 2 cΔ = Δ ⋅ π  (III.2) 
 
Though the rotational correlation times τR calculated with the two fitting methods do not 
correspond perfectly, they indicate in both cases a clear dependence on the concentration. 
Moreover, the modification of this only parameter and the LS factor S2 allows remarkably 
good fitting of the profiles for the different concentrations. Finally, the three profiles have 
been fitted particularly well with the Florence approach by keeping the water exchange 
 
B 
A 
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parameters and the local rotation parameters obtained by the SB-LS-RFB theory, which 
points out the coherence of the fitted values for the system. 
 
III.3.7. Aggregate size estimation 
The equation of Stokes-Einstein-Debye (SED), using l = 2 spherical harmonics,44 (equation 
III.3) allows the mean radii of the aggregates to be estimated from the rotational correlation 
time. The calculated radii for the two fitting methods are presented in the Table III.3. 
 
3
R
4πr
3 Bk T
=
η
τ  (III.3) 
    
Where τR is the correlation time, r the radius of the corresponding sphere, η the viscosity 
coefficient (η = 0.891 cP at 25°C)45, kB the Boltzmann constant and T the temperature. 
 
Fitting method / [Gd3+] 18 mM 1.8 mM 0.10 mM 
SB-LS-RFB 1.5 1.3 1.0 
r / nm 
Florence 1.2 1.1 0.9 
 
Table III.3   –  Estimated mean radii (in nm) of the {Ph4[Gd(DTTA)(H2O)2]-3} 
agglomerates at various concentration and 25°C, using the SED 
equation. 
 
To compare, a simple molecular modeling (Figure III.13) was performed to determine the 
radius and the thickness of the monomer, estimated at 1.3 nm and 0.8 nm respectively. The 
calculated dimension of the most diluted sample is astonishingly close to the ones determined 
by molecular modeling. Moreover, the relaxivities do not decrease with decreasing 
concentration below 0.1 mM (Figure III.6). Those two elements let us presume that no 
aggregations are formed at Gd3+ concentrations smaller than 0.1 mM (corresponding to 
{Ph4[Gd(DTTA)(H2O)2]-3} concentration of 33 μM). 
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Figure III.13 – Molecular modeling of the {Ph4[Gd(DTTA)(H2O)2]-3} complex. 
 
Another evidence is observed when comparing the NMRD profiles and the fitted rotational 
correlations times of {Ph4[Gd(DTTA)(H2O)2]-3} 0.1 mM to other DTTA systems with 
comparable size (Figure III.14 and Table III.4).  
 
 
298
Rτ
 / ps 
Compound / Fit method SB-LS-RFB SBM Florence 
{Ph4[Gd(DTTA)(H2O)2]-3} 0.1 mM 817 ± 100 - 613 
[Gd3L(H2O)6]3-    7 - 540 ± 100 - 
[Fe(tpy-DTTA)2Gd2(H2O)4]    9 - 410 ± 10 - 
{Ru[Gd2bpy-DTTA2(H2O)4]3}4-    12 - 1120 833 
 
Table III.4  –  Obtained fitted 298Rτ  of systems comparable to 
{Ph4[Gd(DTTA)(H2O)2]-3} 0.1 mM. 
 
The {Ph4[Gd(DTTA)(H2O)2]-3} monomeric system is expected to be a bit bigger than the 
xylene core trinuclear complex described by Livramento et al.7 and the iron terpyridine 
dimeric complex,9 while it is significantly smaller than the ruthenium-based metallostar 
described by Moriggi et al.12 The observed relaxivities correspond fully to these expectations, 
reinforcing the idea of the presence of the only monomeric specie at Gd3+ concentrations 
lower than 0.1 mM. 
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Figure III.14 – NMRD profiles at 25°C of {Ph4[Gd(DTTA)(H2O)2]-3} 0.1 mM 
(●), [Gd3L(H2O)6]3- (○)7 , [Fe(tpy-DTTA)2Gd2(H2O)4] (□)9 and  
{Ru[Gd2bpy-DTTA2(H2O)4]3}4- (◊)12 
 
III.3.8. 1H relaxivity as a function of pH 
The relaxivity was proved to be unaffected by the pH throughout the working pH range 
(Figure III.15). 
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Figure III.15 – Relaxivity of {Ph4[Gd(DTTA)(H2O)2]-3} 0.8 mM as a function of 
pH 
 
III.3.9. 1H relaxivity in presence of phosphate buffer 
This experiment was designed to break the aggregates, ideally until the total disaggregation of 
the system to leave the only monomer in solution. That was tried by adding from 5 to 250 
equivalents of phosphate buffer, which proved to be an efficient disaggregating agent for π-
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stacking systems,46,47 to a 2.25 mM solution of {Ph4[Gd(DTTA)(H2O)2]-3}. This relative high 
concentration was necessary in order to induce aggregates. The evolution of the relaxivities 
with time for the different phosphate concentrations is presented on Figure III.16. 
 
Though a clear relaxivity drop is observed, this experiment turned out to be not quantitative, 
as the phosphate makes the compound precipitate, even in the most phosphate diluted sample. 
The relaxivity decrease is therefore not only due to a disaggregation.  
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Figure III.16 – Relaxivity evolution in time of 2.3 mM samples containing various 
concentrations of phosphate buffer 
 
III.3.10. 1H relaxivity in presence of human serum 
An experiment to test if the aggregates can exist in human serum was also performed. A slight 
relaxivity decrease is observed (Figure III.17). Because of the turbidity of the serum however, 
precipitation of the compound is not clearly distinguishable but cannot be excluded. The 
inorganic phosphate concentration in adult serum ranges to 0.8 to 1.45 mM,48 which implies a 
concentration between 0.26 and 0.46 mM with the dilution. In addition to phosphate ions that 
precipitate the molecule, the concentrations of other salts in the serum have to be taken into 
account to explain the minor relaxivity drop. The sodium chloride can indeed play a role in 
disaggregation,46 while lactates and carbonates can complex, monodentately in the case of the 
DTTA for the two free positions are not adjacent, the gadolinium. The higher initial 
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relaxivities in serum compared to water are certainly due to the higher viscosity of the 
solution. 
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Figure III.17 – Relaxivity evolution in time of a 2.3 mM sample in human serum  
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III.4 Conclusion 
In the framework of the development of potential MRI CAs, composed by several Gd3+ 
chelate complexes around a small or mid-size central core, we describe the synthesis of the 
compound 1,3,5-tris-{4-[(bis{2-[bis(tert-butyl acetate)amino]ethyl}amino)methyl] 
phenyl}benzene, referred as Ph4DTTA3.  
 
This synthesis was carried out through the coupling of the central core Ph4Br3 with the 
protected chelating agent DTTA+. Though the purification of the protected compound 
Ph4DTTA+3 was not trivial, mainly due to the presence of disubstituted compound, this 
synthesis has been achieved with no major difficulty. After the deprotection however, the 
purification and the characterization of the compound Ph4DTTA3 turned out to be fussy, for 
this molecule precipitates at pH lower than 3. The purification has finally been possible by 
preparative HPLC using the volatile buffer triethylammonium acetate (Et3NH+ COO-) as ion 
pairing agent. 
 
After the complexation with Gd3+ and the first relaxivities measurements, the exceptionally 
high relaxivities for such a mid-size molecule and the difficulties to obtain reproducible 
values indicated an unusual system. This was confirmed with the concentration-dependence 
of the relaxivities of the complex {Ph4[Gd(DTTA)(H2O)2]-3}. The size is the only parameter 
that acts on the relaxivities and that can change by the only dilution. A dynamic aggregation 
of the molecules was therefore the only possible reason for this atypical behavior. 
 
The size variation has been proved by the measurements of the NMRD profiles at three 
different concentrations and the 17O NMR measurements of the more concentrated sample. 
Simultaneous fits using the Solomon-Bloembergen theory together with the Lipari-Szabo 
free-model approach for the internal rotation and an electronic treatment according to Rast-
Fries-Belorizky allowed the setting of all the parameters of this system, excepted the 
rotational correlation time τR and the Lipari-Szabo rigidity factor S2 which remain the only 
parameters specific for each concentration. Furthermore, the entire NMRD profiles have been 
precisely fitted with the modified Florence approach, suitable for big slowly rotating 
molecules, using the internal rotation and the water exchange parameters fitted with SB-LS-
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RFB. With this method also it was possible to fit the different concentration NMRD by 
varying S2 and releasing τR. 
  
The fitted rotational correlations times were used to estimate the number of molecules in the 
aggregates. It turned out that only the monomer might exist at Gd3+ concentration lower than 
0.1 mM (compound concentration of 33 μM). The mean number of molecules in aggregates at 
higher concentrations was estimated to a few units. Compared to other described aggregating 
systems, the number of aggregating molecules is relatively low for a compound specially 
designed to induce aggregation. This is probably due to the steric hindrance of the three 
massive chelating units. A system composed by the same aromatic core with only two 
chelating units (Figure III.18), or a system composed by a mix of bis and tris substituted 
aromatic core might significantly increase the relaxivity, thought it would decrease the 
density of relaxivity.  
 
 
 
Figure III.18 – The complex {Ph4[Gd(DTTA)(H2O)2]-2} potentially interesting to 
form bigger aggregates.  
 
Though the size of the aggregates has been characterized by fittings methods of the 
relaxometric data, many questions remain on this system. Direct size measurement methods 
such as MALDI-TOF mass spectrometry or Dynamic Light Scattering (DLS) turned out to be 
unsuccessful. Other size characterization methods such as Analytical Ultracentrifugation 
(AUC) might be successful. Furthermore, the type of interaction inducing aggregations has 
not been proved yet, though the π-stacking seems to be the most probable option. 
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IV.1. Introduction 
The chitosan (Chi) is a linear polysaccharide made up of randomly-distributed β-(1,4)-D-
glucosamine and β-(1,4)-N-acetyl-D-glucosamine (Figure IV.1). This compound is found in 
some microorganisms, yeasts and fungi,1-3 but is more widely available through the partial 
deacetylation of chitin, the most common natural polymer apart from cellulose, constituting 
for instance the main component of the exoskeleton of crustaceans and insects.4 
 
In addition to its non-toxic, biocompatible and biodegradable properties, this bioadhesive 
compound demonstrates film and gel forming ability. Due to these interesting and particular 
characteristics, the chitosan has been the subject of many researches over the last decades, 
mainly used as pharmaceutical excipient.5 Drug transport enhancement and antimicrobial 
properties figure also among its most relevant applications in the pharmaceutical and 
biomedical fields.1,5-7  
 
 
Figure IV.1  –  Randomly-distributed glucosamine unit types in the linear 
polysaccharide chitosan. 
 
Many properties of this compound depend strongly on the fraction of deacetylated units, 
referred as the degree of deacetylation or DD (and its one’s complement, the degree of 
acetylation DA). For instance, the solubility of the compound is closely related to the degree 
of ionization of the free amines. As a result, chitosan with a DD of 0.5 is water-soluble at 
neutral pH, while high DD (0.85) requires a pH lower than 4.5-5 to allow solubilization.4 
However, the solubility depends also on the ionic concentration, the pKa of the acid used for 
the protonation or the distribution of acetyl groups along the chain.4 The number of positive 
charges on the free amines, and therefore the DD, affects also the electrostatic interactions of 
the chitosan with negatively charged materials, such as cell surface or mucus.1 
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The possibilities offered by coupling the chitosan to a chelating unit have been noticed a few 
years ago, for metal adsorption8,9 or neutron-capture therapy (NCT)10-12 for instance. More 
recently, the chitosan has been investigated as a support for gadolinium complexes to design 
potential MRI T1 contrast agent (CA). The coupling of the Gd3+ chelate complex on the 
polyglucosamine chain has been achieved either by ionic interactions13-15 or covalently 
through amide bond formation between the primary deacetylated amine of the chitosan and 
one carboxylate of the chelating unit.16-18 Some of these works presented coupling reactions 
with complexing (Figure IV.2 A)16 or unprotected (Figure IV.2 B)17 acetates of the chelating 
units. Both methods can however not exclude the possibility of two coupling with the same 
chelator. Two conjugations with the same chelating unit would induce intra- or intermolecular 
cross-links, destabilizing the metal complex and preventing the complete characterization of 
the system.  
 
 
 
Figure IV.2  –  Chitosan coupling reaction with complexed (A) or unprotected (B) 
acetates of the chelating unit, that can induce cross-links, and 
controlled coupling of the Gd-DTTA using an uncoordinated 
carboxylate pending arm (C). 
 
This work reports here a new strategy for a highly controlled coupling of a Gd3+ complex to 
the free of the chitosan. This has been executed by functionalizing the central amine of the 
chelating agent DTTA (2,2’,2’’,2’’’-[iminobis(ethane-2,1-diylnitrilo)]tetraacetic acid) with a 
non complexing carboxylate arm (Figure IV.2 C). This chapter presents the synthesis, the 
structural characterization and the relaxometric properties of the modified linear chitosan. 
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In addition to the linear polysaccharide, this chapter also presents the formation, the 
characterization and the relaxometric properties of nanogels (Ng), i.e. nano-size hydrogels, 
formed from the chitosan. These particles, denser and more rigid than the linear material, are 
constituted almost exclusively by water, surrounding a hydrophilic polymeric framework, 
which allows the free diffusion of water molecules within the particles. The ionotropic 
gelation method (Figure IV.3 A) allows the chitosan nanogels to be obtained through 
electrostatic interactions of the positively charged primary amine of the chitosan with the 
polyanionic group triphosphate, or TPP (Figure IV.1 B).19,20 In order to stabilize the 
nanoparticles at physiological pH, the hydrogels were coated with the negatively charged 
polysaccharide alginate through ionic interactions.21,22 This linear copolymer (Figure IV.3 C) 
is constituted by randomly distributed (1-4)-linked β-D-mannuronate and α-L-guluronate, 
abbreviated M and G respectively. 
 
 
 
 
 
 
 
Figure IV.3  –  Formation of the modified chitosan nanogels (A), with    the Gd3+ 
complexes,    the TPP and      the alginate. Chemical structure of 
the involved compounds : triphosphate (TPP) used for the core 
folding (B) and the alginate for the coating (C). 
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IV.2. Experimental Section 
IV.2.1. Ligand synthesis and characterization 
 
 
Figure IV.4  –  Synthesis scheme of the Gd(III) complexe 
{Chi[Gd(DTTA)(H2O)2] -} 
 
All chemicals were purchased from high quality grade chemical sources (Sigma-Adrich, 
Acros) and were used as received without purification. Unless specified, H2O is ultrapure 
filtered water (resistivity 18.2 MΩ/cm). 
 
All 1H and 13C NMR spectra were recorded on a Bruker DRX-400 spectrometer (9.4 T). Mass 
Spectrometry analyses were performed on a Thermo Fischer TSQ7000 spectrometer using 
ESI ion source. Elemental analysis was performed at the Elemental Analysis Service at ISIC, 
EPFL (Dr. Euro Solari).  
3 1 2 
4 chitosan 
5 
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Synthesis of tert-butyl 2,2’,2’’,2’’’-[iminobis(ethane-2,1-diylnitrilo)]tetraacetate (1)  
This compound, referred as DTTA+, was synthesized according to literature.23,24 
 
Synthesis of ethyl 4-(bis{2-[bis(tert-butyl acetate)amino]ethyl}amino) butanoate (2) 
2.52 g (12.94 mmol) of ethyl 4-bromobutanoate were added dropwise under argon 
atmosphere to a solution of DTTA+ (1) (3.62 g, 6.47 mmol) in 120 mL DMF in presence of 
potassium carbonate (1.25 g, 9.06 mmol). The reaction mixture was stirred overnight at 70°C 
and evaporated to dryness. The residue was dissolved in 200 mL DCM and wash three times 
with 100 mL of water. The organic phase was dried over sodium sulfate and evaporated to 
dryness. The crude product was purified by silica gel chromatography (MeOH/DCM 7:93) (Rf 
= 0.10). 2.189 g (3.25 mmol, yield 50%) of pure compound 2 were obtained. 1H-NMR 
(CDCl3, 400 MHz) δ in ppm : 1.24 (t, J = 6.9 Hz, 3 H), 1.45 (s, 36 H), 1.73 (tt, J = 6.6 Hz, 2 
H), 2.28 (t, J = 6.9 Hz, 2 H), 2.47 (t, J = 6.4, 2 H), 2.59 (t, J = 6.6 Hz, 4 H), 2.77 (t, J = 6.6 Hz, 
4 H), 3.44 (s, 8 H), 4.11 (q, J = 6.9 Hz, 2 H). MS (ESI) m/z (%) : 674.6 (100) [M+H]+. 
 
Synthesis of 4-(bis{2-[bis(tert-butyl acetate)amino]ethyl}amino) butanoic acid (3) 
This compound will be referred as DTTA-N’but. 35 mL of a 0.4 M NaOH aqueous solution 
were added to a solution of 2 (1.65 g, 2.45 mmol) dissolved in 50 mL EtOH. The reaction 
mixture was stirred 60 hrs at room temperature, and evaporated to dryness. The solid residue 
was dissolved in 50 mL of a 5% water solution in TFA and stirred for 3.5 hrs at room 
temperature. The resulting water soluble oil was dissolved in 25 mL H2O and evaporated five 
times to remove the residual TFA, and purified by anionic exchange resin (BIO-RAD™ AG 
50W-X4) using a 1 to 5 M HCl gradient as elution system. 756 mg (1.79 mmol, yield 65%) of 
pure compound 3 were obtained. 1H-NMR (D2O, 400 MHz) δ in ppm : 2.00 (tt, J 
undetermined, 2 H), 2.49 (t, J = 6.4 Hz, 2 H), 3.30 (t, J = 7.7 Hz, 2 H), 3.37 (t, J = 5.1 Hz, 4 
H), 3.49 (t, J = 5.2 Hz, 4 H), 3.79 (s, 8 H). 13C-NMR (D2O, 54.3 MHz) δ in ppm : 17.90 (N’-
CH2-CH2-CH2-COOH), 29.89 (CH2-CH2-COOH), 49.74 (N’-CH2-CH2-N), 50.31 (N’-CH2-
CH2-N), 52.60 (N’-CH2-CH2-CH2-COOH), 55.36 (N-CH2-COOH), 171.84 (N-CH2-COOH), 
176.31 (CH2-CH2-COOH). MS (ESI) m/z (%) : 422.7 (100) [M+H]+, 444.7 (35) [M+Na]+, 
466.6 (20) [M+2Na-H]+. Elemental analysis calculated (%) for [H8DTTA-N’but]3+[Cl]-3· 
2H2O (C16H34Cl3N3O12) : C 33.90, H 6.05, N 7.41 ; found : C 33.96, H 5.84, N 7.42. 
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Synthesis of [Gd(DTTA-N’but)(H2O)2]2- (4) 
The solid salt GdCl3·xH2O (x ≈ 6.7) was dissolved in H2O to prepare the Gd3+ stock solution. 
The exact ion concentration was measured by complexometric titration using Na2H2EDTA 5 
mM. DTTA-N’but was dissolved in H2O and its concentration in the stock solution was 
determined by back titration of a Gd3+ excess with Na2H2EDTA 5 mM. The titrations were 
performed on a Metrohm 665 Dosimat, using xylenol orange as complexometric indicator and 
buffered at pH 5.8 with a 5% (w/v) urotropine solution in water. The complex [Gd(DTTA-
N’but)(H2O)]2- was prepared by adding a slight deficit of Gd3+ (2%) to the ligand solution. 
The pH was brought back to 5.8 with 0.1 M NaOH and the absence of free gadolinium was 
checked by the xylenol orange test.  
 
Synthesis of {Chi[Gd(DTTA-N’but)(H2O)2]-} (5) 
A 0.5% (w/v) chitosan DD ~ 0.85 was prepared by dissolving 100 mg chitosan (596 μmol of 
glucosamine unit) in 20 mL H2O. The pH was stabilized at 4 by addition of HCl 1M. 4.12 mL 
of a 8.19 mM [Gd(DTTA-N’but)(H2O)2]2- aqueous solution (33.8 μmol) were added to the 
chitosan solution, followed by 29.3 mg (135.2 μmol) of sodium 1-hydroxy-2,5-dioxo-3-
pyrrolidinesulfonate (N-hydoxysulfosuccinimide ; Sulfo-NHS). 19.4 mg (101.4 μmol) of N-
[3-(dimethylamino) propyl]-N’-ethylcarbodiimide hydrochloride (EDC) were added in three 
times with 45 minutes between each addition, whilst stirring at room temperature. The 
reaction was continued for 2 hours after the last addition. The sample was purified three times 
by size exclusion chromatography using Sephadex™ LH20 resin in a 25 x 4.5 cm column. 
The absence of uncoupled Gd3+ complex was controlled by the stable relaxivity at 20 MHz, 
25°C before and after the final size exclusion columns. See sections IV.2.2 and IV.3.2 for 
characterization. 
 
Formation of the nanogels Ng{Chi[Gd(DTTA-N’but)(H2O)2]-}  
The nanogels were prepared by Catherine Schütz, group of Dr. MER Christine Wandrey, 
LMRP, EPFL. A 0.1% w/v {Chi[Gd(DTTA-N’but)(H2O)2]-} solution was prepared by 
dissolving 5 mg of modified chitosan in 5 mL H2O adding HCl 1M dropwise until the pH was 
stabilized at 2.8. The solution was left overnight at 4°C to allow complete solubilization. The 
pH of the chitosan solution was raised to 4.8 with NaOH 0.1 M to ensure total complexation. 
The solution was sterile filtered prior to nanogel formation (0.2μm filter Minisart hydrophilic 
cellulose acetate, Sartorius). Under sterile condition, the nanogels were prepared by a slow 
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dropwise addition of one volume equivalent of a 0.1% w/v sodium triphosphate (TPP) 
solution to the nine volume equivalents of chitosan solution under strong agitation. The pH 
was controlled during addition and maintained around 4.75 with HCl 0.1 M. The solution was 
stirred for 1h before surface coating. For the nanogel surface coating, the chitosan-TPP 
dispersion was diluted twice with sterile H2O. An equal volume of the diluted nanogel 
dispersion was added dropwise to a 0.1% w/v sterile filtered aqueous sodium alginate (G / M 
~ 0.4 : 0.6) solution under strong agitation. The pH was constantly maintained between 7.1 
and 7.5 by addition of 0.02M NaOH, leading to a final pH of 7.35. The dispersion was filtered 
through a 1.2μm hydrophilic filter (Minisart, Sartorius) and stored at 4°C. The sample was 
concentrated ten times under a nitrogen flux before undergoing relaxivity measurements.21 
 
IV.2.2. Structural characterization of the modified chitosan 
The degree of deacetylation (DD) of the starting chitosan was determined by 1H-NMR by 
integrating the acetyl peak (3 H) over the methylene region (6 H). The H1, very close to the 
HOD peak is not included in the integral region.25,26  
  
The carbon mass fractions were determined by elemental analysis performed at the Elemental 
Analysis Service at ISIC, EPFL (Dr. Euro Solari). 
 
The gadolinium mass fractions of linear {Chi[Gd(DTTA-N’but)(H2O)2]-} and nanogels 
Ng{Chi[Gd(DTTA-N’but)(H2O)2]-} were determined by inductively coupled plasma mass 
spectrometry (ICP-MS) performed on a quadrupole spectrometer Elan 6100 DRC (Perkin 
Elmer™, Waltham, Massachusetts, USA) at the Institut de Minéralogie et Géochimie, 
University de Lausanne (Dr. Alexey Ulianov). All solutions (blank, standards and samples) 
were prepared with a final 1.5% (w/w) HCl and 300 ppb (w/v) europium as the internal 
reference concentration. The measurements were performed on isotope 155Gd, 157Gd and 
151Eu. The Gd3+ concentration was determined with respect to two standards, whose 
concentrations surround the target concentration (1 ppm and 300 ppb). The exact 
concentration of the Eu3+ reference and the Gd3+ standards stock solutions were measured by 
complexometric titration (see synthesis of 4). 
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IV.2.3. Ng{Chi[Gd(DTTA-N’but)(H2O)2]-} characterization 
The nanogels were characterized by Catherine Schütz, group of Dr. MER Christine Wandrey, 
LMRP, EPFL The size distribution was measured by dynamic light scattering (DLS) using a 
Malvern ZetaSizer (ZEN3600 Nano-ZS, Malvern Instruments, Worcestershire, UK). The 
surface charge of the nanogel formulations was analyzed by measuring the electrophoretic 
mobility and expressed as zeta potential. Both measurements were performed simultaneously 
in a DTS 1060 cell. With regard to the day of the production, the size distribution of the 
nanongels was measured at days 0, 5, 9 and 29 to control the particles stability. 
 
For transmission electron microscopy (TEM), a drop (10 μL) of nanogel suspension was 
deposed on a 200-mesh carbon/formvar coated copper grid (Electron Microscopy Sciences, 
Hatfield, PA, USA) and air-dried. Sample was stained with a 2% w/v phosphotunstic acid 
solution by deposing one drop (10 μL) of solution on the grid, waiting 30-40 s and blotting 
the excess liquid off. Imaging was performed on a CM-10 (Philips/FEI).  
 
IV.2.4. Bulk Magnetic Susceptibility 
Unless specified, the Gd3+ concentrations used to calculate the relaxivities were measured by 
bulk magnetic susceptibility (BMS)27 on a Bruker DRX-400 (9.4 T, 400 MHz) spectrometer. 
This was performed by measuring the shift of the tert-butanol protons in the paramagnetic 
environment compared to the diamagnetic reference contained in a coaxial NMR tube. 
 
IV.2.5. 1H relaxivities 
T1 were determined by the inversion-recovery method28 using the following equipment : Fast 
Field Cycling (FFC) NMR relaxometer29 2.35 · 10-4 to 0.47 T (1H Larmor frequencies : 0.01 
to 20 MHz) equipped with a VTC90 temperature control unit (Stelar Spinmaster, Mede, 
Italy), Bruker Minispec mq20 0.47 T (20 MHz), mq40 0.70 T (30 MHz), mq40 0.94 T (40 
MHz) and mq60 1.41 T (60 MHz), Bruker Avance-200 console connected to a 2.35 T (100 
MHz) and a 4.7 T (200 MHz) cryomagnets, Bruker Avance-II 9.4 T (400 MHz). The 
spectrometers were equipped with Bruker BVT3000 temperature control units and Bruker 
BCU05 cooling units. All temperatures were measured by substitution techniques.30 The 
relaxation rates 1/T1 were corrected by diamagnetic contributions of 0.366 s-1 and 0.326 s-1 for 
25°C and 37°C respectively. 
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The 1H NMRD profiles of [Gd(DTTA-Me)(H2O)2]- (2.55 mM and 3.50 mM),        
[Gd(DTTA-N’but)(H2O)2]2- (3.30 mM and 2.97 mM), {Chi[Gd(DTTA-N’but)(H2O)2]-} 
(0.972 mM and 0.649 mM) were measured at 25.0°C and 37.0°C. The NMRD profile of 
Ng{Chi[Gd(DTTA-N’but)(H2O)2]-} (0.127 mM) has been measured at 25.0°C. Samples in 
7.5 mm tubes were used on Bruker mq40’s and mq60 while samples sealed in glass spheres 
adapted for 10 mm NMR tubes were used for all other instruments. 
 
The variable-concentration {Chi[Gd(DTTA-N’but)(H2O)2]-} relaxivities were measured at 20 
MHz, 25°C. The time evolution of {Chi[Gd(DTTA-N’but)(H2O)2]-} relaxivity was performed 
by measuring T1 at 20 MHz, 25°C, after 1, 2, 3, 4, 7, 14 and 31 days. The solution was kept at 
4°C between each measurement. 
 
IV.2.6. Data treatment 
The fitting of the 1H NMRD profiles using the Solomon-Bloembergen-Morgan theory 
(SBM)31-34 for [Gd(DTTA-Me)(H2O)2]-  and [Gd(DTTA-N’but)(H2O)2]2-, and the SBM theory 
together with the Lipari-Szabo (LS) free-model approach for the internal rotation35,36 for 
{Chi[Gd(DTTA-N’but)(H2O)2]-} and {Chi[Gd(DTTA-N’but)(H2O)2]-} nanogels were 
performed on Visualiseur/Optimiseur37,38 running on a MATLAB© 7.3.0 (R2006b) platform. 
 
The fitting of the 1H NMRD profiles using the “modified Florence approach”39-41 were 
performed with a version of the “modified Florence program”42 including  Lipari-Szabo 
treatment of the internal rotation adapted to run on a MATLAB© 7.3.0 (R2006b) platform. 
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IV.3. Results and discussion 
IV.3.1. Ligand synthesis 
The coupling of two acetates of a single chelator to chitosan primary amines would prevent 
these groups to conjugate the metal and consequently have severe consequences on the 
stability of the complex, which is not suitable for a potential CA. As a result, the 
undetermined hydration number, water exchange rate, affected by the geometry of the 
complex, and size of the molecule in the case of an intermolecular cross-link, would moreover 
not allow the characterization of the system. The non-complexation of the fifth arm is 
therefore essential for this coupling strategy with the chitosan. 
 
The first attempt to couple the chelating unit DTTA to the chitosan was performed through 
the partially protected derivative of DTTA-N’prop 6.43,44 This compound, presenting 
protected acids except the only N’-propionic acid, was obtained through the coupling of 
DTTA+ (1) with 3-bromopropanoic acid (Figure IV.5). The deprotection of the acetate groups 
however turned out to be unfeasible, as the use of TFA led to an insoluble product while 
highly concentrated HCl can damage and depolymerize the polysaccharide chain.45 
 
 
Figure IV.5  –  Synthesis of chitosan- N’prop-DTTA+. 
 
The second strategy to couple of DTTA on the chitosan is therefore to employ a complexed 
form of DTTA, using the metal centre as the “protecting group” of the acetates to avoid inter- 
and intramolecular cross-links. This can not be achieved with the complexe [Gd(DTTA-
N’prop)(H2O)]2- (chelator presented in Figure IV.6 A), whose all five carboxylates complex 
the metal centre.43 Alternatively, based on the chelating agent H6TTAHA46 (Figure IV.6 B) 
whose six-membered pending arm was proved not to complex Gd3+ by X-ray crystal 
structure,47 the chelator H5DTTA-N’but was synthesized (Figure IV.6 C). This synthesis 
1 6 7 
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could not be achieved directly with the bromobutyric acid, which undergoes a cyclization 
leading to the formation of the inert lactone. It was therefore accomplished with an ester 
derivative (the ethyl 4-bromobutanoate (Figure IV.4) was used for a matter of commercial 
availability). The compound had to undergo two different deprotection reactions. NaOH 
removes the ethyl group, but it not very efficient on tert-butyl because of the accessibility, 
while TFA is ideal for tert-butyl, whose tertiary carbon stabilizes the formation of a 
carbocation.  
 
 
 
Figure IV.6  –  The chelating units H6DTTA-N’prop (A), H6TTAHA (B), 
H5DTTA-N’but (C) and H4DTTA-Me (D). 
 
The next step, consisting in coupling the complex with chitosan, had to be performed in water 
to allow the solubilization of the chitosan. Amongst the few coupling agents allowing an 
aqueous environment, the couple EDC/Sulfo-NHS (Figure IV.7) was the most promising.48,49  
 
 
Figure IV.7  –  Mechanism of the couple EDC/Sulfo-NHS as coupling agent in 
water.50 
 
The coupling reaction was set up in order to modify statistically one in fifteen deacetylated 
units. From the perspective of forming nanogels by using the free amines, this was important 
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to keep the largest part of the free amines unconjugated. The number of moles of primary 
amines was determined by the mean molar mass of a glucosamine unit (161.16 g/mol and 
203.19 g/mol for the deacetylated and the acetylated unit respectively). One equivalent of 
Gd3+ complex, four equivalents of Sulfo-NHS and three times one equivalent of EDC were 
used. The reagent excesses were discarded with successive Sephadex size exclusion column 
purification. The constant relaxivity before and after the last purification column allowed to 
control the absence of the unconjugated [Gd(DTTA-N’but)(H2O)2]- complex. 
 
IV.3.2. Structural characterization of the chitosan chain 
The initial fraction of deacetylated units, called the degree of deacetylation or DD, was 
calculated by integration of the acetyl peak in the 1H NMR spectrum compared to six 
methylene protons (the H1, close to HOD, is difficult to isolate and therefore not taken into 
account). The initial degree of acetylation DA was determined at 0.156. The initial DD is 
therefore 0.844. 
 
The fraction of units modified by addition of Gd3+ chelates with respect to all units, written 
DM for degree of modification, was determined with the gadolinium and carbon mass 
fractions, assuming that all carbons came from the modified chitosan. This ratio had to be 
used in order to take the effective mass, including counterions and inorganic salts, into 
account. The mass ratio of gadolinium was determined by ICP-MS, measuring its 
concentration with respect to the internal reference Eu3+. The ratio of the concentrations is 
proportional to the ratio of the measured intensities (in counts per second) corrected by the 
ratio of the intensities in the blank (equation IV.1). The slope a, or proportionality constant, 
was determined by fitting the experimental values of two Gd3+ standards above and below the 
target concentration, plus the origin (0;0). The Gd3+ concentration is averaged from the 
experimental results for the two isotopes 155Gd and 157Gd. 
 
3+ blank
Gd Gd
blank3+
Eu Eu
Gd I I
  
I IEu
a
           
= −    (IV.1) 
 
The mean elemental composition of the glucosamine units is dependent on the DM. The mass 
fractions of carbon wC and gadolinium wGd can be expressed by equations IV.2 and IV.3, 
respectively. 
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A M D
C C C C
C A M D
  
  
(DA n + DM n + DD n ) M
 = 
DA M + DM M + DD M
w
⋅ ⋅ ⋅ ⋅
⋅ ⋅ ⋅
 (IV.2) 
 
Gd
Gd A M D
  
DM M
 = 
DA M + DM M + DD M
w
⋅
⋅ ⋅ ⋅
 (IV.3) 
 
Where ACn , MCn  and DCn  express the number of carbon atoms in acetylated, modified and 
deacetylated unit respectively, MC and MGd the atomic mass of carbon and gadolinium and 
MA, MM and MD the molecular mass of acetylated, modified and deacetylated glucosamine 
respectively.  
 
The conjugation is performed on deacetylated amines, the DM affects therefore the DD, 
which can be written DD = 1 – DA – DM. The molar mass ratio wGd / wC is therefore given by 
equation IV.4, which is developed and rearranged to give equation IV.5. 
 
Gd Gd
A M D
C C C C C
DM M
 = (DA n  + DM n  + (1 DA DM) n ) M
w
w
⋅
⋅ ⋅ − − ⋅ ⋅
 (IV.4) 
 
( )( )A D DC C C CGd
D M
C C C CGd Gd
M DA n n n
DM = 
M M (n n )
w
w w
⋅ − +
⋅ + ⋅ −
 (IV.5) 
 
The carbon mass ratio wC measured by elemental analysis is equal to 23.4%, the gadolinium 
mass ration determined at 1.53 % by ICP-MS, and the number of number of carbon atoms in 
acetylated, modified and deacetylated unit is 8, 22 and 6 respectively. From this calculation, 
the fraction of modified units in the modified chitosan, whose final composition is presented 
in Table IV.1, is determined at 3.4%. With respect to the deacetylated units, this degree of 
modification corresponds to 4.1%. The reaction was set up in order to conjugate statistically 
one over fifteen deacetylated units, i.e. 6.7%. This ratio allows the determination of the 
reaction yield, which is 60%.  
 
 DA DD DM 
Glucosamide unit fraction  0.156 0.810 0.034 
 
Table IV.1   –  Ratio of the different unit type in the final composition of the 
modified chitosan, expressed in degrees of acetylation (DA), 
deacetylation (DD) and modification (DM).  
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IV.3.3. 1H relaxivities of [Gd(DTTA-N’but)(H2O)2]2- 
The relaxivities of Gd(DTTA-N’but)(H2O)2]2- were measured to ensure the non-complexation 
of the N’-butanoate. This element is essential in order to couple the complex covalently using 
the free carboxylic acid, while the metal centre acts as a protecting group on the four acetates 
to prevent any reaction of these groups, and therefore cross-links. The evidence of two water 
molecules in the inner sphere of the complex, proved by relaxivity, would therefore certify the 
non-coordination of the pending arm and its accessibility for the coupling reaction. Let’s 
mention that even a fluxonial butanoate group, characterized by an equilibrium between the 
coordinating and the non-coordinating forms, would allow the complete conjugation, as the 
coupling shifts the equilibrium towards the uncomplexing form. 
 
The 1H NMRD profiles of [Gd(DTTA-N’but)(H2O)2]2- and [Gd(DTTA-Me)(H2O)2]- are 
measured at 25°C and 37°C (Figure IV.8). The complex [Gd(DTTA-Me)(H2O)2]- has two 
water molecules in its inner sphere (chelator presented in Figure IV.6).51 Considering the few 
differences between the two complex structures, it becomes clear that [Gd(DTTA-
N’but)(H2O)2]2- can not have a smaller hydration number, relaxivity being directly 
proportional to it. The modest relaxivities enhancement observed is most probably due to the 
more voluminous N’-substituent of the [Gd(DTTA-N’but)(H2O)2]2-  complex. 
 
 
 
 
 
 
 
 
 
 
Figure IV.8  –  1H NMRD profiles (A) [Gd(DTTA-N’but)(H2O)2]2- at 25°C (●) 
and 37°C (○) ; (B) [Gd(DTTA-Me)(H2O)2]- at 25°C (●) and 37°C 
(○). Lines obtained by SBM fit with parameters presented in Table 
IV.2. 
 
 
A B 
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The NMRD profiles are fitted with the Solomon-Bloembergen-Morgan theory to corroborate 
this assumption. The best fitting parameters for both fits are presented in Table IV.2. As 
expected, the rotational correlation time 298Rτ  of [Gd(DTTA-N’but)(H2O)2]2- is slightly higher. 
The correlation time for the transient zero-field-splitting fluctuation 298ντ  and the mean square 
zero-field-splitting energy Δ2 change significantly for the two fits. It should however be kept 
in mind that only the product of these two terms is considered in the electronic relaxation 
treatment (equation I.59). Though it is not constant, this product is consistent (Δ2 298ντ  = 7.48 · 
108 and 8.6 · 108 for [Gd(DTTA-N’but)(H2O)2]2- and [Gd(DTTA-Me)(H2O)2]-, respectively).  
 
In the absence of 17O NMR data, the activation enthalpy HΔ ‡  and the water exchange rate 
298
exk  cannot be reasonably fitted. Fitted values for the water exchange rate constant of the well 
described DTTA system [Gd2(pX(DTTA)2)(H2O)4]2- were therefore used to fix these 
parameters.52 
 
Parameters / Complex [Gd(DTTA-N’but)(H2O)2]2- [Gd(DTTA-Me)(H2O)2]- 
HΔ ‡  / kJ mol-1 45.4 45.4 
298
exk  / 106 s-1 9 9 
RE  / kJ mol-1 26.0 ± 0.8 16.2 ± 0.6 
298
Rτ  / ps 136 ± 2 91 ± 1 
vE  / kJ mol-1 1 1 
298
vτ  / ps 34 ± 2 20 ± 1 
298
GdHD  / 10
-10 m2 s-1 25 25 
DGdHE  / kJ mol
-1
 22 22 
2Δ / 1020 s-1 0.22 ± 0.01 0.43 ± 0.03 
WATq  2 2 
stGdH 1r  / Å 3.1 3.1 
ndGdH 2r  / Å 3.5 3.5 
 
Table IV.2   –  SBM fitted parameters of the NMRD profiles of [Gd(DTTA-
N’but)(H2O)2]2- and [Gd(DTTA-Me)(H2O)2]-. Fixed values 
underlined. 
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IV.3.4. 1H relaxivities of {Chi[Gd(DTTA-N’but)(H2O)2]-} 
The NMRD profile of the linear chitosan compound were measured at 25°C and 37°C to 
characterize the 1H relaxivity of this potential contrast agent (Figure IV.4). The relaxivities at 
low magnetic field are more than twice as high as that of the uncoupled complex. The profiles 
present a relaxivity hump between 10 and 200 MHz, characteristic for slowly rotating 
molecules. 
 
The profiles were fitted first with the SBM-LS theory. The LS approach for internal rotation 
has been introduced, in comparison to the previous fittings, because the modified chitosan is a 
linear and most probably very flexible chain. The degree of freedom for the internal rotation 
is therefore expected to be high, characterized by a low LS factor S2. Once again, the absence 
of 17O NMR data has constrained us to fix the activation enthalpy HΔ ‡  and the water 
exchange rate constant 298exk  using the fitted values of a well characterized DTTA system. 
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Figure IV.9  –  NMRD profile of {Chi[Gd(DTTA-N’but)(H2O)2]-} at 25°C (●) 
and 37°C (○) fitted with SBM-LS theory (straight line) and the 
Florence approach (dashed line) using parameters presented in 
Table IV.3. 
 
Because of its very simple description of the electron spin relaxation,40 the SBM theory fails 
at low magnetic field, particularly for slowly tumbling molecules.53 A reasonable fit on the 
whole frequency range was consequently not achievable. For this reason, the fitting has been 
performed only above 6 MHz. The fit of this region, using the SBM-LS parameters presented 
in Table IV.3, is remarkably good. As expected, S2 is particularly low, indicating a great 
freedom for the internal rotation. 
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The profile was subsequently fitted with the “modified Florence approach”,39-41 which was 
proved to be appropriate to fit slowly rotating molecules (Chapter I.4.11). Here again, the 
activation energy aE  and water exchange rate 298exk  were fixed, using literature values.52 The 
activation energy was calculated with the equation (I.65), obtained by comparison of the 
Arrhenius and the Eyring equations. The transient ZFS amplitude Δ  and static ZFS amplitude 
D , given in cm-1, have been converted into s-1 in order to use the same units than the SBM-LS 
fitted parameters (equation III.3). The Lipari-Szabo factor S2 was fixed, using the values 
obtained with SBM-LS model. 
 
Parameters / Fitting Method SBM-LS  Florence 
HΔ ‡  / kJ mol-1 45.4 - 
aE  / kJ mol
-1
 
- 47.9 
298
exk  (1/ Μτ ) / 106 s-1 9 9 
RE  / kJ mol
-1
 28.3 ± 4.2 34.5 
298
Rτ  / ps 2700 ± 320 2170 
lE  / kJ mol
-1
 31 ± 3 25 
298
lτ  / ps 367 ± 16 351 
Eν  / kJ mol
-1
 1 1 
298
ντ  / ps 11.0 ± 0.9 81.0 
298
GdHD  / 10
-10
 m2 s-1 25 25 
DGdHE  / kJ mol
-1 22 22 
Δ  / 1010 s-1 0.34 ± 0.02 0.52 
D  / 1010 s-1 - 0.87 
2S  0.21 ± 0.02 0.21 
q  2 2 
stGdH 1r  / Å 3.1 3.1 
ndGdH 2r  / Å 3.5 3.5 
 
Table IV.3   –  Best fitting parameters of the NMRD profiles of the modified 
chitosan {Chi[Gd(DTTA-N’but)(H2O)2]-} using the SBM-LS 
theory and the Florence approach. Fixed values underlined. 
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The two fitting methods lead to astonishingly coherent values for the global and local 
rotational correlation times 298Rτ  and 298lτ  respectively, which suggests a particularly good 
characterization of the system.  
 
IV.3.5. Effect of concentration on the relaxivity 
The chitosan solution becomes very viscous when its concentration is higher than 0.1 % (w/v) 
(1 mg/mL). In order to determine the effect of the solution viscosity to allow working at 
higher concentrations, the relaxation times were measured at variable concentrations within 
the working range (Figure IV.10). The relationship between Gd3+ and chitosan concentrations 
is set with the ratio of modified unit DM and the mean molar mass of a glucosamine unit 
(Mchi = 187.01 g / mol), determined with the experimental chitosan composition (equation 
IV.6). 
 
( ) 2 IIIChi chi chi chi Gd chi3 m M n M n M10% w/v 0.1 0.1 0.1 GdV V DM V DM10   = = = =  (IV.6) 
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Figure IV.10 – Influence of the viscosity, due to the chitosan concentration, on the 
relaxivity of {Chi[Gd(DTTA-N’but)(H2O)2]-} ; 20 MHz, 25°C. 
 
The Figure IV.10 shows that the high viscosity of the concentrated chitosan solution (more 
than 0.2%) has no significant influence on the relaxivity within the working concentration 
range. Calculations of the propagation of uncertainty has been performed by considering a 
relative error of 3% on both the observed and the diamagnetic reference relaxation times and 
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by assuming the Gd3+ concentration as being exact. The equation III.2 has been used to 
determine the relative error on the relaxivity r1. 
 
IV.3.6. Time stability of the relaxivity 
As a carbohydrate, the chitosan solution is a perfect media for bacterial growth. The stability 
of the relaxivity was controlled during one month to ensure metabolization or internalization 
of the Gd3+ complex in invisible microorganisms could not induce undesirable effect on the 
measurements (Figure IV.11). The relaxivity of the clear solution turned out to be very stable 
in a time period of one month when the solution was kept at 4°C. When the white cottony 
bacterial colony is visible, the solution has to be discarded. 
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Figure IV.11 – Evolution of the relaxivity of {Chi[Gd(DTTA-N’but)(H2O)2]-} 
with time ; 20 MHz, 25°C.   
 
IV.3.7. Formation of the nanogels Ng{Chi[Gd(DTTA-N’but)(H2O)2]-}  
The formation of nanogels with the modified chitosan has potentially very interesting contrast 
agent properties. Contrary to other nanoparticles implying gadolinium complexes,54,55 
constituted by a rigid core with chelate complexes on the surface, this nanogel is formed by a 
folded linear chain, with randomly distributed Gd3+ complexes. This leads to a flexible and 
porous material, constituted mainly by water, which can freely diffuse within the particle. A 
potential CA formed by such a hydrogel would therefore present the benefits of nanoparticle 
based CA, i.e. the size and the Gd3+ complex density, with a biocompatible and biodegradable 
core. 
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The principle of the ionotropic, or ionic, gelation (Figure IV.3 A) forming such structures is to 
use the anion triphosphate (TPP) to form linkage between the positively charged primary 
amines by electrostatic interaction, inducing a dynamic intra- and intermolecular folding. The 
nanogels are subsequently electrostatically coated with sodium alginate, to stabilize the 
particles at physiological pH and to obtain negatively charged surfaces.21 The method has 
been chosen amongst the several methods allowing the preparation of nanoparticles from the 
chitosan for its simplicity and its mild and aqueous conditions.56 The formation of the 
nanogels was not trivial and hardly reproducible, because of the easy precipitation of the 
material in presence of TPP and difficulty of complete solubilisation of the modified chitosan. 
It had however been possible to form the nanogels, which was confirmed by dynamic light 
scattering (DLS), and transmission electron microscopy (TEM), two methods commonly used 
to characterize the physicochemical properties of nanoparticles, including their size, 
morphology, surface charge and stability. 
 
IV.3.8. Ng{Chi[Gd(DTTA-N’but)(H2O)2]-} characterization 
Dynamic Light Scattering 
 
The DLS measures time dependent fluctuations in scattering intensity produced by particles in 
Brownian motion.57 The velocity of the Brownian motion of particles, defined as the 
translational diffusion coefficient D, is related to their size by the Stokes-Einstein relation 
(equation IV.7), where kB is the Boltzmann constant, T the temperature and η the viscosity 
coefficient of the solvent. The reported diameter corresponds to that of a sphere having the 
same diffusion coefficient, implying the necessary assumption of the sphericity of the 
nanogels. Moreover, this diameter does not correspond to the “hard core” of the particles, but 
encompasses the solvent layer diffusing with the particle. This diameter is known as the 
hydrodynamic diameter dH and the boundary demarcating the hydrodynamic entity from the 
bulk is called the slipping plane.  
 
Hd  = 3π
Bk T
Dη  (IV.7) 
 
The most common parameters for nanoparticle size DLS characterization are the Z-average 
and the polydispersity index PdI (Table IV.4). The Z-average arises from a single exponential 
fitting of the correlation function and corresponds to the intensity average hydrodynamic size. 
The size distribution is characterized by the PdI, related to the standard deviation of the single 
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exponential fit. The complete size distribution (Figure IV.12), obtained by fitting the 
correlation function with multi-exponential algorithms, is another way of presenting the result 
of particle size measurements.  
 
standard chi-Ng (average on 6 batches) 
Parameters modified chi-Ng 
in H2O in PBS 
Z-average / nm 374 ± 4 535 ± 74 403 ± 36 
PdI  0.20 ± 0.02 0.465 ± 0.050 0.252 ± 0.018 
Zeta potential / mV -56.8 ± 1.0 -63.3 ± 0.7 - 
 
Table IV.4   –  Z-average, PdI and zeta potential of Ng{Chi[Gd(DTTA-
N’but)(H2O)2]-} at day 0 compared to unmodified chitosan 
nanogels in water and in PBS. 
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Figure IV.12 – Size distribution of the modified nanogels Ng{Chi[Gd(DTTA-
N’but)(H2O)2]-} (black) and an example of unmodified chitosan 
nanogels (grey) determined by Dynamic Light Scattering. 
 
The temporal stability of the formed nanogels was confirmed by the tallying results of the 
DLS experiments performed on the day of the particles production and after 5, 9 and 29 days. 
 
The colloidal stability of the particles was demonstrated with the same instrumentation by 
measuring the zeta potential. The latter is a function of the surface charge density and 
corresponds to the electrostatic potential at the slipping plane, i.e. the boundary inside which 
ions and nanoparticles form a stable entity. This parameter is determined from the mobility of 
the particles and the ions within the slipping plane when performing an electrophoretic light 
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scattering (ELS) experiment. During this experiment, an electric field is applied through the 
dispersion, which induces a migration of the entities with velocities proportional to their zeta 
potential. This potential can be considered as the force preventing the particles aggregating or 
flocculating, and gives therefore indications on their colloidal stability. Entities with zeta 
potential higher than ± 30 mV are generally considered as stable.58,59  
        
When compared to unmodified chitosan nanogels, one can notice that the Ng{Chi[Gd(DTTA-
N’but)(H2O)2]-} are significantly smaller (ΔZ-average ≈ 160 nm, Table IV.4). The 
inaccessible substituted amines and the resulting steric hindrance, preventing more ionic 
interactions, might explain this difference. The PdI is also smaller than the unmodified 
nanogels, indicating a narrower distribution, which could arise from the absence of bigger 
particles. The Z-average and the PdI of the formed Ng are comparable to that of unmodified 
Ng in a high ionic force medium, such as PBS (Table IV.4). 
 
Transmission Electron Microscopy 
 
The TEM is another widely used technique to observe the particles size and their morphology. 
It should however be kept in mind that the sample has to be dried, which might alter the size 
and the morphology of the particles, particularly for the water-soaked hydrogels. Moreover, 
the reconcentration of the dispersion induced by the droplet evaporation can generate bigger 
aggregates. Evidence of the formation of modified chitosan nanogels is nevertheless visible 
(Figure IV.13). The observed light grey streaks arise probably from salts residues (NaCl) and 
alginate excess, inherent to this dynamic coating method. 
 
   
Figure IV.13 – Transmission Electron Microscopy of the formed nanogels.  
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IV.3.9. 1H relaxivities of Ng{Chi[Gd(DTTA-N’but)(H2O)2]-} 
The relaxivity of the nanogel was characterized by the measuring of its 1/T1 NMRD profile 
(Figure IV.14). Despite the reconcentration, the final Gd3+ concentration was rather low (~ 
0.13 mM) and had to be determined by ICP-MS. The long relaxation times (~ 500 ms) 
induced by so low concentrations imply a substantial uncertainty on the relaxivities, 
particularly on the FFC relaxometer, which had some difficulties measuring coherent 
relaxation times.  
 
It is relevant to notice that the relaxivities are lower than those of the linear chitosan chains. 
Moreover, the small hump from 10 to 200 MHz suggests that the formed particles are smaller 
than the starting linear chitosan, while the opposite was expected because a nanogel is formed 
by several chitosan strains. The experimental data were fitted the same way than as in section 
IV.3.4, i.e. using the SBM-LS approach from mid-field to high-field and the modified 
Florence approach to fit the whole profile. The fitted parameters are presented in Table IV.5.  
0.01 0.1 1 10 100 1000
5
10
15
20
25
 
 
r 1
 
/ m
M
-
1 s
-
1
ν 
1H / MHz
 
Figure IV.14 – NMRD profile and SBM-LS (straight) and Florence approach 
(dash) fittings of the Ng{Chi[Gd(DTTA-N’but)(H2O)2]-} at 25°C. 
 
While the nanogels formed were expected to be bigger than the linear chitosan chain, the two 
methods led to surprisingly low rotational correlation times 298Rτ  and 298lτ . The fixation of 
certain fitting parameters might induce such incongruous values. First, the number of water 
molecules in the inner sphere has a proportional effect on the relaxivities. A partial Gd3+ 
complexation by the triphosphate oxygen would induce a q lower than 2, and would have 
repercussions on the fitted parameters ( 298Rτ  ≈ 2000 ps when q is fixed to 1). Secondly, the 
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water exchange rate 298exk  has been fixed to a rapid exchange value, taken from a well 
characterized system.52 A slower exchange, caused by a limited diffusion of the water 
molecules inside the nanogels for instance, would considerably influence the fitted parameters 
( 298Rτ  ≈ 2700 ps when 298exk  is fixed to 1· 106 s-1). Finally, the LS factor S2, expected to be 
higher in the case of the more rigid nanogels, reaches the unreasonable value of 0.1 when 
fitted, indicating a higher degree of freedom for internal rotation. It was therefore fixed to the 
value fitted for the linear chitosan, resulting in a drop of the global rotation correlation time 
( 298Rτ  ≈ 2600 ps when S2 is fitted to 0.1).  
 
Parameters / Fitting Method SBM-LS Florence 
298
exk  (1/ Μτ ) / 106 s-1 9 9 
298
Rτ  / ps 1080 ± 150 1050 
298
lτ  / ps 98 ± 21 107 
298
ντ  / ps 87 ± 25000 25 
298
GdHD  / 10
-10
 m2 s-1 25 25 
DGdHE  / kJ mol
-1 22 22 
Δ  / 1010 s-1 0.7 ± 200 0.33 
D  / s-1 - 0.39 
2S  0.21 0.21 
q  2 2 
stGdH 1r  / Å 3.1 3.1 
ndGdH 2r  / Å 3.5 3.5 
 
Table IV.5   –  Best fitting parameters of the NMRD profiles of {Chi[Gd(DTTA-
N’but)(H2O)2]-} nanogels using the SBM-LS theory and the 
Florence approach. Fixed values underlined. 
 
17O NMR measurement would be an indispensable tool to investigate further this system by 
determining the water exchange rate and the number of water molecules in the inner sphere. 
These experiments require however a solution about 100 more concentrated, and therefore 
much larger amount of modified chitosan nanogels. Moreover, highly concentrated solutions 
would probably induce undesirable effects such as precipitation, aggregation of the nanogels 
or really important viscosity.   
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IV.4. Conclusion 
This work described the synthesis, the structural characterization and the relaxivity 
measurements of potential contrast agents based on the polysaccharide chitosan. The idea 
developed to create such a compound was to bind covalently a Gd3+ chelate complex to the 
deacetylated amine of the chitosan. Experimental limitations have constrained us to use an 
alternative method for the conjugation of the CA on the polymer, by complexing the chelator 
first and then grafting the complex. This has been performed though an uncomplexing arm of 
a modified DTTA chelating agent. The non-complexation and availability of this arm was 
proved by comparing the 1/T1 NMRD profiles of the synthesized complex to that of the well 
known system [Gd(DTTA-Me)(H2O)2]-. 
 
The coupling of the uncomplexing butanoate arm with the primary amine of the chitosan has 
been performed successfully using the coupling agents EDC / Sulfo-NHS in water. The 
structural characterization of the modified chitosan has been performed by 1H NMR to 
determine the degree of acetylation DA and by elemental analysis and ICP-MS to determine 
the degree of modification DM. The final chitosan linear chain was composed by 81% of 
deacetylated, 15.6% of acetylated and 3.4% of modified units. The NMRD profile of the 
linear modified chain {Chi[Gd(DTTA-N’but)(H2O)2]-}, characterizing its relaxivity, have 
been measured and fitted with the Solomon-Bloembergen-Morgan theory with the Lipari-
Szabo model for internal rotation (SBM-LS) and with the modified Florence approach.  
 
In the absence of relaxometric characterization for comparable chitosan conjugates, the 
relaxivity of the modified linear chitosan are compared with other linear systems. The 
relaxivity of {Chi[Gd(DTTA-N’but)(H2O)2]-} turned out to be comparable to other linear 
polymers (Table IV.6). The relaxivities of less flexible and more compact highly branched 
macromolecular contrast agents, such as the dendritic PAMAM-G4-[Gd(DOTA pBn)(H2O)]–, 
are however about twice as high.60 
 
To make this material more rigid and more compact, nanogels have been formed from the 
modified linear chitosan. This was done by means of the anion triphosphate, which induced a 
folding through ionic interaction with the positively charged amines of the chitosan. The 
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formed particles were subsequently coated, always via ionic interactions, with the negatively 
charged polysaccharide alginate. The nanogels were characterized with DLS and TEM, 
determining their hydrodynamic size and size distribution. Finally the NMRD profiles of the 
hydrogels measured and fitted with the SBM-LS and the Florence approaches. This system 
presented unfortunately disappointing relaxivities. Some fixed parameters used for the fits, 
such as the water exchange rate 298exk  and the number of water molecules in the inner sphere of 
the complex q, might have been erroneous. Moreover, the fitted parameters, including the LS 
factor S2 and the global and local rotational correlation times 298Rτ  and 298lτ , presented some 
unreasonable values. The impossibility of performing 17O NMR measurements on this system 
did unfortunately not allow further investigations on this interesting and promising 
compound. 
 
Linear compound r1 
mM-1s-1 q 
ν 1H 
MHz 
T 
°C Ref 
{Chi[Gd(DTTA-N’but)(H2O)2]-} 33.6 2 40 25  
[Gd(EGTA-BA)(H2O)-(CH2)12]nn+ 15.5 1 40 20 61 
P(Gd-DTPA-PETO-EG-PM) 15.2 1 80 25 62 
Gd(DTPA-CHD) 8.8 1 40 37 63 
Gd(DTPA-BA)-PEG 5.5 1 40 25 64 
Table IV.6   –  Comparative table for the relaxivities of linear polymeric 
compounds designed as potential CA.  
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V.1. Introduction 
The overexpression of various peptide receptors on the surface of many malignant tumor cells 
has been investigated intensively over the last decades as a target for MRI and radionuclide 
therapy.1-3 Somatostatin, which has been successfully exploited for imaging and therapy, but 
also cholecystokinin, neurotensin and bombesin receptors showed the most interesting and 
promising potential.4-9 The bombesin receptors, and more precisely the subtype gastrin-
releasing peptide (GRP) receptors, present a particular interest, as they are overexpressed by 
many prevalent malignant tumor cells, such as prostate, breast or lung cancer.10-12 The 
development of MRI contrast agents (CAs) coupled to the neurotransmitter bombesin (BN) 
analogues represents therefore a promising route to target GRP receptor-expressing tumors as 
a MRI diagnostic tool (Figure V.1). 
 
 
Figure V.1   –  Strategy to target BN receptor overexpressing tumor cell with a 
MRI CA (   ) through the interaction bombesin-bombesin receptor. 
 
A strong and specific interaction between the peptide vector and its receptor is an essential 
factor for an effective targeting and imaging of the targeted cell. The optimization of the 
affinity and the specificity of this interaction through the development of different peptides 
analogues is therefore an important contribution to this targeting strategy. Moreover, the use 
of multivalent peptide compounds has been proved to increase markedly the binding affinity 
between of the labeled peptide and its receptor.13,14 
 
 
Tumor cell 
bombesin receptor 
bombesin-        
Gd3+ complex 
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Within this framework, four compounds presenting bombesin peptide coupled to the chelating 
unit DOTA and developed as potential targeted CAs have been synthesized by Dr. Abiraj 
Keelara.4 These potential CAs were prepared as mono-peptide and bis-peptide conjugates, 
involving two different bombesin analogues, the Ahx-Bombesin(4-14) and the Lys3-
Bombesin (Figure V.2). The tumor cell uptake and the cellular retention of these four 
compounds have been measured and compared.4 
 
This chapter presents the synthesis, the relaxometric measurements and the theoretical fit 
characterization of the two mono-bombesin Gd3+ complexes {Lys3-BN[Gd(DOTA)(H2O)]} 
and  {Ahx-BN(4-14)[Gd(DOTA)(H2O)]} and their dimeric analogues {Ahx-BN(4-
14)2[Gd(DOTA)(H2O)]} and {(Lys3-BN)2[Gd(DOTA)(H2O)]}. 
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Figure V.2   –  The four studied Gd-DOTA complexes composed by the two 
mono-peptide conjugates and their dimeric analogues. 
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V.2. Experimental Section 
V.2.1 Synthesis and characterization 
 
Figure V.3   –   General synthesis scheme for the mono-peptide compounds.4,15 
 
 
 
Figure V.4   –  General synthesis scheme for bis-peptide compounds.4  
1 
2 
1 6 7 
3 - 4 
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Monomeric and dimeric peptide compounds have been synthesized with two bombesin 
analogues : the Ahx-Bombesin(4-14) and the Lys3-Bombesin (Figure V.5).  
 
 
Figure V.5   –  The bombesin analogues Lys3-Bombesin and Ahx-Bombesin(4-14).  
 
All the synthesis have been performed by Dr. Abiraj Keelara in the laboratory of Prof. Helmut 
R. Maecke, Division of Radiological Chemistry, University Hospital Basel, Switzerland. 
 
Materials and Methods 
All chemicals were obtained from commercial sources and used without further purification. 
Rink amide 4-methylbenzhydrylalanine (MBHA) resin (0.34 mmole/g; 100-200 mesh) and all 
the Fmoc-protected amino acids are commercially available from NovaBiochem 
(Laeufelfingen, Switzerland). 1,4,7,10-Tetraazacyclododecane and 1,4,7,10-
Tetraazacyclododecane-1,7-bis(t-butyl acetate) (5) was purchased from Macrocyclics, Dallas, 
Texas, USA. Electrospray ionisation (ESI) mass spectroscopy was carried out with a Finnigan 
SSQ7000 (Bremen, Germany) and MALDI-MS measurements on a Voyager sSTR equipped 
with an Nd:YAG laser (Applied Biosystems, Framingham, USA). Analytical high-
performance liquid chromatography (HPLC) was performed on a Hewlett Packard 1050 
HPLC system with a multiwavelength detector and a flow-through Berthold LB 506 Cl γ-
detector using a Macherey-Nagel Nucleosil 120 C18 column. Preparative HPLC was 
performed on a Metrohm HPLC system LC-CaDI 22–14 with a Macherey-Nagel VP 250/21 
Nucleosil 100–5 C18 column. Both analytical and preparative columns were eluted with a 
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gradient system of mixtures of H2O with 0.1% TFA (solvent A) and acetonitrile (solvent B). 
The NMR spectra were recorded on a Bruker DRX 500 spectrometer using a triple inverse 
probe. 1H shifts were referenced to DMSO-d6 at 2.49 ppm. The 1D-1H, 1H-1H-COSY, 1D-13C 
and 1H-13C-COSY (HSQC) experiments were conducted. 
 
Peptide Synthesis 
The SPPS was performed on a semiautomatic peptide synthesizer (RinkCombichem, 
Bubendorf, Switzerland) employing standard Fmoc strategy.16 The required peptides were 
assembled on Rink amide MBHA resin. The Trt was used as protecting group for Gln, Asn 
and His, ivDde for Lys and Boc for Trp. The coupling reactions were achieved with 3 fold 
excess of Fmoc-amino acids, using DIC/HOBt as activating agents in NMP. After a coupling 
time of 2 h, the completeness of the reaction was monitored by standard ninhydrin test. Fmoc 
removal was achieved with 20% piperidine in DMF in three successive 10 min treatments. 
After assembling the desired amino acids, cleavage from the resin and simultaneous sidechain 
deprotection of the peptides was accomplished by incubating for 3.5 h in a cleavage cocktail 
comprising TFA / thioanisole / H2O / triisopropylsilane 95 : 3 : 1 : 1. The resin was then 
filtered and washed with the above mixture, evaporation of the filtrate followed by trituration 
with diethyl ether yielded the crude peptide. The yields of the crude peptides ranged from 70-
80% and were further purified by semi-preparative HPLC. 
 
Synthesis of (R/S) α-bromoglutaric acid 1-tert-butyl ester 5-benzyl ester (1) 
This compound was synthesized starting from the commercially available L-glutamic acid 5-
benzyl ester in two steps as described before.15 
 
Synthesis of 1,4,7,10- tetraazacyclododecane-1,4,7-tris(tert-butyl acetate)-10- (glutaric 
acid 1-tert-butyl ester) (2) 
This prochelator was synthesized from 1,4,7,10-tetraazacyclododecane in three steps using 
the reported procedure.15 
 
General procedure for monovalent conjugation (3 and 4) 
After assembling the desired amino acids on the resin, the final Fmoc group was removed. 
The prochelator 2 (3 equivalents) was coupled to the N-terminal of the peptides using HATU 
(3.3 equivalents) and DIPEA (7 equivalents) for 4h. The monovalent peptide-chelator 
conjugates were then cleaved from the resin as described above. The conjugates were further 
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subjected to deprotection for 3h using the same cleavage cocktail, triturated with diethyl 
ether, filtered and dried. This deprotection and trituration steps were repeated until the 
complete removal of t-Bu was observed (by analytical HPLC). The monovalent peptide-
chelator conjugates were further purified by semi-preparative HPLC (0 min, 80% A, 20 min 
40% A) and characterized by ESI-MS. 
 
 
Molecular 
Formula M 
Yielda 
(%) 
Rt 
(min) MS-ESI: m/z (%) 
Lys3-BN-DOTA (4) C90H140N26O27S 2050.30 38 20.85 2089.4 [M+K]
+
 (22) 
1044.9 [M+K]++ (100) 
Ahx-Bn(4-14)-DOTA (5) C80H126N22O23S 1796.06 44 22.14 1835.1 [M+K]
+
 (100) 
918.0 [M+K]++ (74) 
 
Table V.1   –  Analytical data for the monovalent peptide conjugates Lys3-
bombesin-DOTA (4) and Ahx-bombesin(4-14)-DOTA (5). aYields 
were based on the first Fmoc cleavage. bAnalytical HPLC (0 min, 
95% A; 30 min 55% A). 
 
Synthesis of 1,4,7,10-tetraazacyclododecane-1,7-bis(tert-butyl acetate)-4,10-bis(glutaric 
acid 1-tert-butyl ester-5-benzyl ester) (6) 
To a stirred solution of 5 (0.8 g, 2 mmol) in dry acetonitrile (10 mL) was added K2CO2 (1.146 
g, 8 mmol) followed by the drop wise addition of racemic 1 (1.43 g, 4 mmol). After stirring 
for 18 h at room temperature, the mixture was filtered over Celite and concentrated under 
reduced pressure. Flash chromatography on silica gel 60 (CH2Cl2 / EtOH 9 : 1 followed by 
EtOH / NH3 95 : 5) yielded 6 (1.21 g, 63%) as a pale yellow oil. Rf: 0.54 (CH2Cl2 / EtOH 
9:1); MS-ESI: m/z (%): 953.7 [M+H]+ (11), 975.6 [M+Na]+ (100) ; 1H NMR (d6-DMSO) : δ 
(ppm) = 7.35 (m, 10H, Ar-H), 5.1 (m, 4H, CH2-Ar), 3.45 (m, 4H, -N-CH2-CO2C(CH3)3), 3.4 
(m, 2H, -N-CH(R)-CH2-CH2-COOBn), 3.2-2.0 (m, 16H, -N-CH2-CH2-N-), 2.41 (m, 4H, -N-
CH(R)-CH2-CH2-COOBn), 1.9 (m, 4H, -N-CH(R)-CH2-CH2-COOBn), 1.46 (m, 36H, -
C(CH3) 3); 13C NMR (d6-DMSO) : δ (ppm) = 172.8 (2C, -N-CH(R)-CH2-CH2-COOBn), 172.2 
(4C, -N-CH2-CO2C(CH3)3), 136.1 (2C, -CH2-C(Ar)), 128.4, 128.1, 128.0 & 127.9 (10C, -
C(Ar)), 81.4 & 81.6 (4C, -C(CH3)3), 64.5 (2C, -CH2-Ar), 63.2 (2C, -N-CH(R)-CO2C(CH3)3), 
56.5 (2C, -N-CH2-CO2C(CH2)2), 50-44 (8C, -N-CH2-CH2-N-), 32.0 (2C, -N-CH(R)-CH2-
CH2-COOBn), 27.4, 27.5, 27.6 & 27.8 (12C, -C(CH3)3), 23.5 (2C, -N-CH(R)-CH2-CH2-
COOBn). 
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Synthesis of 1,4,7,10-tetraazacyclododecane-1,7-bis(tert-butyl acetate)-4,10-bis(glutaric 
acid 1-tertbutyl ester) (7) 
To a solution of 6 (1 g, 1.05 mmol) in methanol (100 mL) was added 100 mg of 10% Pd/C 
suspended in 5 mL of H2O and H2 was bubbled through the solution under normal pressure. 
After completion of hydrogenation (as monitored by TLC), the catalyst was removed by 
filtration through Celite. The solvent was evaporated under reduced pressure and the residue 
obtained was triturated with diethyl ether. The solid crude product thus obtained was 
subjected to flash chromatography on silica gel 60 (EtOH / NH3 98 : 2 to 95 : 5) to yield 7 
(695 mg, 86%) as a white solid. Rf: 0.38 (EtOH / NH3 95 : 5) ; mp 206-208°C; MS-ESI: m/z 
(%) : 773.5 [M+H]+ (18), 795.6 [M+Na]+ (100); 1H NMR (d6-DMSO): δ (ppm) = 3.42 (m, 
2H, -NCH(R)-CH2-CH2-COOH), 2.74 & 3.46 (m, 4H, -N-CH2-CO2C(CH3) 3), 2.5 (m, 4H, -N-
CH(R)-CH2-CH2-COOH), 2.14 & 2.64 and 2.0 & 3.1 (m, 8H, -N-CH2-CH2-N-), 2.1 & 2.5 and 
2.35 & 3.0 (m, 8H, -N-CH2-CH2-N-), 1.63 & 1.9 (m, 4H, -N-CH(R)-CH2-CH2-COOH), 1.45 
(m, 36H, -C(CH3)3); 13C NMR (d6-DMSO): δ (ppm) = 174.9 & 174.7 (2C, -N-CH(R)-CH2-
CH2-COOH), 173.1 (4C, -N-CH2-CO2C(CH3)3), 81.8 (2C, -N-CH(R)-CO2C(CH3)3), 79.6 (2C, 
-N-CH2-CO2C(CH3)3), 59.8 (2C, -N-CH(R)-CO2C(CH3)3), 56.2 (2C, -N-CH2-CO2C(CH3)3), 
52.9 & 44.0 (4C, -N-CH2-CH2-N-), 48.5 & 47.2 (4C, -N-CH2-CH2-N-), 32.6 (2C, -N-CH(R)- 
CH2-CH2-COOH), 28.2, 27.8 & 27.7 (12C, -C(CH3)3), 19.4 (2C, -N-CH(R)-CH2-CH2-
COOH).  
 
General procedure for divalent conjugation (8 and 9) 
To a solution of prochelator 7 (10 mg, 13 μmol) in dry DMF (2 mL) was added purified 
peptide (28.6 μmol, 2.2 equivalents) and HATU (11 mg, 28.6 μmol) and adjusted the pH to 8 
using DIPEA. The mixture was stirred at room temperature overnight and DMF was 
evaporated under reduced pressure. The residue was triturated with diethyl ether, dried and 
subjected to t-Bu deprotection as described above. The divalent peptide-chelator conjugates 
were purified by semipreparative HPLC (0 min, 80% A, 30 min 40% A) and characterized by 
ESI-MS. 
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Molecular 
Formula M 
Yielda 
(%) 
Rtb 
(min) MS-ESI: m/z (%) 
(Lys3-BN)2-DOTA (8) C164H252N48O46S2 3696.18 48 21.99 1867.1 [M+K
]++
 (18) 
1245.2 [M+K]+++ (100) 
(Ahx-Bn(4-14))2-DOTA (9) C144H224N40O38S2 3188.08 55 22.88 1613.33 [M+K]
++ (35) 
1076.12[M+K]+++ (100) 
 
Table V.2   –  Analytical data for the divalent peptide conjugates (Lys3-
bombesin)2-DOTA (8) and (Ahx-bombesin(4-14))2-DOTA (9).         
aYields refer to the final divalent conjugation and deprotection 
steps. bAnalytical HPLC (0 min, 95% A; 30 min 55% A). 
 
V.2.2 Sample preparation 
A mixture of peptide-chelator conjugate (5 μmol) in 4 mL of sodium acetate buffer (0.4M, pH 
5) was incubated with 10 μmol Gd(OAc)3·6H2O at 95°C for 25 min, cooled to room 
temperature, and purified over a SepPak C18 cartridge preconditioned with 10 mL of methanol 
and 10 mL of water. The cartridge was eluted with 30 mL of sodium acetate buffer followed 
by 20 mL of methanol. The absence of free Gd(III) ions in methanol solution was verified by 
using xylenol orange indicator. The methanol was evaporated to afford the corresponding 
Gd(III) complexes (purity > 96% on HPLC), which were further characterized by MALDI-
MS. The well resolved MALDI-MS spectra of gadolinium conjugated peptides showed broad 
isotopic distribution. The broad isotope pattern is due to the fact that gadolinium has five 
main isotopes (14.80% of 155Gd, 20.47% of 156Gd, 15.65% of 157Gd, 24.84% of 158Gd, 21.86% 
of 160Gd) with similar abundance plus two isotopes of minor abundance.17 
 
The exact final Gd3+ concentration was measured by bulk magnetic susceptibility (BMS)18 at 
23.3°C on a Bruker DRX-400 (9.4 T, 400 MHz) spectrometer. This was performed by 
measuring the shift of the tert-butanol alkyl protons in the paramagnetic environment 
compared to the diamagnetic reference contained in a coaxial NMR tube. 
 
V.2.3 1H relaxivities 
T1 were determined by the inversion-recovery method19 using the following equipment : 
Stelar Spinmaster Fast Field Cycling (FFC) NMR relaxometer20 (2.35 · 10-4 to 0.47 T; 1H 
Larmor frequencies : 0.01 to 20 MHz) equipped with a VTC90 temperature control unit, 
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Bruker Minispec mq20 0.47 T (20 MHz), mq40 0.70 T (30 MHz), mq40 0.94 T (40 MHz) and 
mq60 1.41 T (60 MHz), Bruker Avance-200 console connected to a 2.35 T (100 MHz) and a 
4.7 T (200 MHz) cryomagnets, Bruker Avance-II 9.4 T (400 MHz). The spectrometers were 
equipped with Bruker BVT3000 temperature control units and Bruker BCU05 cooling units. 
All temperatures were measured by substitution techniques.21 The relaxation rates 1/T1 were 
corrected by diamagnetic contributions of 0.366 s-1 and 0.326 s-1 for 25°C and 37°C 
respectively. 
 
The 1/T1 NMRD profiles of the four complexes were measured at 25.0°C and 37.0°C with 
Gd3+ concentrations of 0.752 mM for {Lys3-BN[Gd(DOTA)(H2O)]} (4), 1.625 mM for {Ahx-
BN(4-14)[Gd(DOTA)(H2O)]} (5), 0.478 mM for {(Lys3-BN)2[Gd(DOTA)(H2O)]} (8) and 
1.618 mM  for {(Ahx-BN(4-14))2[Gd(DOTA)(H2O)]} (9). Samples in 7.5 mm tubes were 
used on Bruker mq40s and mq60 while samples sealed in glass spheres adapted for 10 mm 
NMR tubes were used for all other instruments. 
 
V.2.4 Data treatment 
The fitting of the 1H NMRD profiles using the Solomon-Bloembergen-Morgan theory 
(SBM)22-25 together with the Lipari-Szabo (LS) free-model approach for the internal 
rotation26,27 were performed on Visualiseur/Optimiseur28,29 running on a MATLAB© 7.3.0 
(R2006b) platform. The fitting of the 1H NMRD profiles using the “modified Florence 
approach”30-32 were performed with a version of the “modified Florence program”33 including  
Lipari-Szabo treatment of the internal rotation adapted to run on a MATLAB© 7.3.0 
(R2006b) platform. 
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V.3. Results and discussion 
V.3.1 Ligands and conjugates synthesis 
The synthesis of prochelator 7 containing two free carboxylic acid groups for the divalent 
vectorization of targeting peptides started from commercially available DO2A-tert-butyl ester 
5 (Figure V.4). N-alkylation of 5 with 2 equivalents of (R/S)-α-bromoglutaric acid 1-tert-butyl 
ester 5-benzyl ester 115 yielded 6 in 63%. Subsequent hydrogenation of 6 over 10% Pd/C 
catalyst followed by chromatographic purification yielded the prochelator 7 in 86%, which 
was further characterized by using ESI-MS and NMR (1D-1H, 1H-1H-COSY, 1D-13C and 1H-
13C-HSQC experiments). The new prochelator 7 exists in different isomeric forms (RR, SS, RS 
& SR) as it was synthesized by using racemic 1.34 The prochelator 2 containing one free 
carboxylic acid group was synthesized following the procedure described earlier.15  
 
The application of prochelator 7 for the divalent vectorization with peptide ligands has been 
demonstrated by synthesizing divalent bombesin analogues (Figure V.4). Analysis of HPLC 
fractions by MALDI-MS revealed the presence of considerable quantities of undesired 
modified divalent peptide conjugates produced by the HATU mediated nitrile formation via 
dehydration of the carboxamide side chain of asparagine and glutamine.35 
 
V.3.2 1H relaxivities of the four Gd-DOTA-bombesin conjugates 
The 1/T1 NMRD profiles of the four Gd-DOTA-BN complexes were measured at 25°C and 
37°C to characterize the 1H relaxivity properties of these potential MRI CAs. It should 
however be kept in mind that the relaxivities would drastically change when these compounds 
are bound to the targeted cells thanks to the bombesin-bombesin receptor interaction. This in 
vivo system would mainly affect two determining parameters : the rotational correlation time, 
related to the size of the entity, that would considerably increase and internal flexibility, 
which would be restricted.  
 
The NMRD profiles of the mono-peptide compounds {Lys3-BN[Gd(DOTA)(H2O)]} and 
{Ahx-BN(4-14)[Gd(DOTA)(H2O)]} are presented in Figure V.6. The relaxivity difference of 
the two compounds is most probably due to the more voluminous Lys3-BN compound, which 
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has three extra amino-acids (Figure V.5), and hence resulting in longer rotational correlation 
time. 
 
Figure V.6   –   NMRD profiles of the mono-peptide compounds {Lys3-
BN[Gd(DOTA)(H2O)]} (A) and {Ahx-BN(4-14)[Gd 
(DOTA)(H2O)]} (B) at 25°C (●) and 37°C (○), fitted with the 
SBM-LS theory (straight line) and the Florence approach (dashed 
line). 
 
The Figure V.7 presents the NMRD profiles of the two bis-bombesin compounds {(Lys3-
BN)2[Gd(DOTA)(H2O)]} and {(Ahx-BN(4-14))2[Gd(DOTA)(H2O)]}. The Lys3-BN complex 
holds this time six extra amino acids, resulting in a more marked relaxivity difference.  
 
Figure V.7   –  NMRD profiles of the bis-peptide compounds {(Lys3-
BN)2[Gd(DOTA)(H2O)]} (A) and {(Ahx-BN(4-14))2 [Gd 
(DOTA)(H2O)]} at 25°C (●) and 37°C (○), fitted with the SBM-
LS theory (straight line) and the Florence approach (dashed line). 
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Because the size of the compounds is substantial, implying a slow molecular tumbling, the 
simple electronic relaxation described by the SBM theory is not valid,36 resulting in a bad 
theoretical fit in the low field region, where the relaxivity is governed by the electron spin 
relaxation. The experimental data of the four complexes have therefore been fitted with the 
SBM-LS theory at high frequencies (≥ 7 MHz). The whole profiles have subsequently been 
fitted with the Florence approach,30,31 suitable for slowly rotating molecules. In the absence of 
17O NMR data, the activation enthalpy HΔ ‡  and the water exchange rate 298exk  cannot be 
reasonably fitted. Fitted values for the water exchange rate constant of [Gd(DOTA)(H2O)]- 
were therefore used to fix these parameters (the activation energy was calculated from the 
equation I.65).37 The Lipari-Szabo parameters S2 obtained from the SBM-LS fit have been 
used for the Florence fit. The best fitting parameters of the mono- and bis-bombesin 
conjugates are presented in Table V.3 and Table V.4 respectively. To allow direct 
comparison, the transient ZFS amplitude Δ  and static ZFS amplitude D obtained with the 
Florence fit, given in cm-1, have been converted into s-2 (equation III.3). 
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 {Lys3-BN[Gd(DOTA)(H2O)]} {Ahx-BN(4-14)[Gd(DOTA)(H2O)]} 
 SBM-LS  Florence SBM-LS  Florence 
HΔ ‡  / kJ mol-1 49.8 - 49.8 - 
aE  / kJ mol
-1
 
- 52.3 - 52.3 
298
exk  (1/ Μτ ) / 106 s-1 4.1 4.1 4.1 4.1 
RE  / kJ mol
-1
 9.5 ± 11.0 8.7 30.4 ± 17.0 32.1 
298
Rτ  / ps 1670 ± 560 1670 1140 ± 670 903 
lE  / kJ mol
-1
 32.4 ± 6.2 29.0 21.2 ± 8.5 22.8 
298
lτ  / ps 338 ± 23 330 240 ± 19 253 
Eν  / kJ mol
-1
 1 1 1 1 
298
ντ  / ps 21.0 ± 17.2 25.6 7.2 ± 3.3 47.6 
298
GdHD  / 10
-10
 m2 s-1 25 25 25 25 
DGdHE  / kJ mol
-1 20 20 20 20 
2Δ  / 1020 s-2 0.032 ± 0.006 0.044 0.10 ± 0.04 0.029 
2D  / 1020 s-2 - 0.417 - 0.185 
2S
 
0.08 ± 0.03 0.08 0.09 ± 0.06 0.09 
q
 
1 1 1 1 
stGdH 1r  / Å 3.1 3.1 3.1 3.1 
ndGdH 2r  / Å 3.6 3.6 3.6 3.6 
 
Table V.3   –  Best fitted parameters of the monovalent peptide compounds 
{Lys3-BN[Gd(DOTA)(H2O)]} and {Ahx-BN(4-14)[Gd(DOTA) 
(H2O)]} obtained with the SBM-LS theory and the Florence 
approach. Fixed values underlined. 
 
Let’s point out that the use of the Florence approach is questionable for mid-size molecules, 
particularly for the smaller {Ahx-BN(4-14)[Gd(DOTA)(H2O)]}, which is not fitted perfectly 
with this method (Figure V.6 B). The very small LS factors S2 < 0.1 denotes a high freedom 
for fast internal rotation and indicates that the bombesin analogue Lys3-BN is not more rigid 
than Ahx-BN. The global and local rotational correlation times are however actually shorter 
for the Ahx-BN(4-14) conjugate.  
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 {(Lys3-BN)2[Gd(DOTA)(H2O)]} {(Ahx-BN(4-14))2[Gd(DOTA)(H2O)]} 
 SBM-LS  Florence SBM-LS  Florence 
HΔ ‡  / kJ mol-1 49.8 - 49.8 - 
aE  / kJ mol
-1
 
- 52.3 - 52.3 
298
exk  (1/ Μτ ) / 106 s-1 4.1 4.1 4.1 4.1 
RE  / kJ mol
-1
 32.6 ± 3.7 38.2 39.2 ± 11.6 48.1 
298
Rτ  / ps 1835 ± 238 1725 2704 ± 909 2821 
lE  / kJ mol
-1
 50.9 ± 6.2 61.7 44.2 ± 6.1 52.2 
298
lτ  / ps 656 ± 60 722 487 ± 38 506 
Eν  / kJ mol
-1
 1 1 1 1 
298
ντ  / ps 17.5 ± 2.8 24.3 10.8 ± 2.1 14.1 
298
GdHD  / 10
-10
 m2 s-1 25 25 25 25 
DGdHE  / kJ mol
-1 20 20 20 20 
2Δ  / 1020 s-2 0.062 ± 0.003 0.061 0.13 ± 0.02 0.14 
2D  / 1020 s-2 - 0.375 - 0.654 
2S
 
0.32 ± 0.06 0.32 0.18 ± 0.04 0.18 
q
 
1 1 1 1 
stGdH 1r  / Å 3.1 3.1 3.1 3.1 
ndGdH 2r  / Å 3.6 3.6 3.6 3.6 
 
Table V.4   –  Best fitted parameters of the bis-peptide compounds {(Lys3-
BN)2[Gd(DOTA)(H2O)]} and {(Ahx-BN(4-14))2 [Gd(DOTA) 
(H2O)]} obtained with the SBM-LS theory and the Florence 
approach. Fixed values underlined. 
 
The global rotational correlation time is in the case of the bis-bombesin complexes 
surprisingly longer for the (Ahx-BN)2 conjugate. The local rotational correlation time is 
nevertheless still longer for the Lys3-BN constant. The S2 factors are two to three times higher 
for both bis-BN compounds. The lack of coherence of several fitting parameters, particularly 
the ones involved in the electronic treatment, arises most probably from the high correlation 
between the parameters in both fitting methods, which compensate during the fittings. The 
rotational activation energies ER are also unreasonable (too low for {Lys3-
BN[Gd(DOTA)(H2O)]} and too high for the three other compounds). This phenomenon will 
however not be investigated in this coarse analysis. 
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V.4. Conclusion 
With a view to develop targeted MRI contrast agents using the overexpression of peptide 
receptor by malignant tumor cell, the peptide neurotransmitter bombesin has been conjugated 
to the chelating unit DOTA. Two bombesin analogues, the Lys3-BN and the Ahx-BN, have 
been employed to synthesize mono- and bis-peptide compounds. After complexation with 
gadolinium, the 1/T1 NMRD profiles of the four compounds have been measured at 25°C and 
37°C and fitted with two different methods. 
 
Because the size of these BN-conjugated Gd3+ complexes is significant, the electron spin 
relaxation described by the SBM theory do not allow good relaxivity fitting at low magnetic 
field, where the electronic relaxation predominate the nuclear relaxation. The relaxometry 
data have therefore been treated with the SBM-LS for resonance frequencies ν > 7 MHz and 
with the Florence approach, using the Lipari-Szabo factor S2 obtained from the SBM-LS fit. 
The Florence approach turned out to be imperfect to treat mid-size molecules, and particularly 
the smallest compound {Ahx-BN(4-14)[Gd(DOTA)(H2O)]}. 
 
The most relevant information obtained from the NMRD profiles is the higher relaxivity for 
both Lys3-BN conjugates. This relaxivity enhancement is accredited to the bigger size of this 
peptide analogue, which comprises three amino acids more than the Ahx-BN(4-14). This was 
confirmed by the fitted rotational correlation times. The very low and similar S2 factors 
obtained from the fit of the mono-bombesin conjugates indicated respectively a high degree 
of freedom for the internal rotation and a similar rigidity of both compounds. Unsurprisingly, 
these parameters increased significantly for their dimeric analogues. The strong correlation 
between the fitted parameters led unfortunately to some incoherent values, particularly for the 
electronic relaxation and the rotational activation energies. 
 
One should however keep in mind that the relaxometry of the four systems would change 
radically when the compounds are bound to a cell thanks to the peptide-peptide receptor 
interaction. The rotational correlation times and the internal rotation would be the most 
affected parameters in such systems. 
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VI.1. Conclusions and perspectives 
From its invention in the early 70’s,1-3 the magnetic resonance imaging has increasingly 
become an incontrovertible method for medical diagnostic, thanks to its capability to 
differentiate different soft tissues of living bodies. The possibilities that offer this powerful 
tool, based on nuclear magnetic resonance pulsed field gradients, are almost infinite through 
the development of new NMR pulse sequences. Nowadays, the measurements of the water 
proton relaxation times T1 and T2 represent the great majority of MRI experiments. This 
imaging technique, like NMR, has however an important drawback : its low sensitivity, 
involving long examination times. This tedious time can be reduced through the use of MRI 
contrast agents, which decrease the relaxation times of water protons. Stable chelate 
complexes with the paramagnetic metal Gd3+, that reduce the longitudinal relaxation time 
though the interaction with the water proton are currently the most employed T1 contrast 
agents. 
  
As the relaxation rate enhancement depends on the concentration of the paramagnetic species, 
the notion of relaxivity, defined as the paramagnetic contribution to the relaxation rate divided 
by the concentration of the paramagnetic ion, has been introduced to define the efficiency of a 
contrast agent.4 This relaxivity is field-dependent and depends mainly on four parameters : the 
hydration number q, i.e. the number of water molecules in the inner sphere of the 
paramagnetic ion complex, the exchange rate of these water molecules kex, the rotational 
correlation time of the molecule τR, related to its size, and the electron spin longitudinal 
transverse relaxation rates 1/T1e and 1/T2e.5,6 
 
The development of T1 CAs can be achieved by many different ways, depending on the 
desired effect. For instance, the optimization of the relaxivity at 64 MHz (1.5 T) requires big 
and rigid molecules while mid-size and supple entities would allow to increase relaxivity at 
127 MHz (3 T) (Figure III.1).7 The unceasing evolution in the magnet technology constrains 
the development of high field contrast agents. Moreover, the progress in this field has to be 
achieved through responsive contrast agents, whose relaxivity allow the determination of 
some variable in their immediate environment, such as pH, temperature or metal ion 
Chapter VII 
170 
concentration, or through the development of targeted CA, that determines the geographic 
position of the target, such as tumors.8  
 
This work presented the synthesis, characterization and relaxometric properties of four new 
types of compounds developed as potential T1 CAs. 
 
Chapter II presented the mid-size trimeric Gd3+ complex {Mes[Gd(DO3A)(H2O)2}, 
developed as a high field CAs.9 The standard complexation method did allow the 
complexation of only two metal ions per molecule. This difficulty could arise from the 
important pH drop during the first complexations, which induces the protonation of the 
uncomplexing acetates and prevents the introduction of the third Gd3+. After restoring the pH 
to 5.8, the acetates are supposed to complex immediately the neighboring Gd3+ ions. This 
adjacent complexation leads to only one water molecule in the inner sphere of the two Gd3+. 
This was confirmed by relaxometry and 17O NMR measurements. A new complexation 
strategy, occurring at higher pH, has therefore been developed to sidestep this difficulty. 
Gadolinium, that forms insoluble hydroxides at pH higher than 6.2 could not be used directly. 
The alternative method was therefore achieved though pre-complexation with Mn2+ at pH 9 
and transmetallation with Gd3+ at pH 5.8. The complete complexation achieved with this 
method has been proved by elemental analysis and ICP-MS, and confirmed by NMRD 
profiles and 17O NMRD measurements. The hydration number of the Gd3+ in this fully 
complexed compound is two, as expected. The new complexation method turned out to be 
very efficient and can be helpful for the complexation of mid-size CAs. 
 
Chapter III dealt with another trimeric mid-size complex, {Ph4[Gd(DTTA)(H2O)2]-3}. This 
compound has however not been developed as a high-field CAs, but has been designed to 
form big entities through aggregation, most probably by π-stacking interaction of the aromatic 
core. The dynamic aggregations have been observed through exceptionally high relaxivity for 
such a mid-size molecule and the concentration dependence of this relaxivities. Thanks to the 
parameters obtained by a simultaneous fit of NMRD and 17O NMR data, the NMRD profiles 
of the compound at other concentrations have been fitted almost perfectly by varying only the 
global rotational correlation and the Lipari-Szabo factor S2 using two fit methods, the SB-LS-
RFB and the modified Florence approaches. From the obtained rotational correlation times, an 
approximation using the equation of Stokes-Einstein-Debye allowed us to determine that the 
monomer was predominantly present in diluted solutions and that aggregates were formed by 
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two or three molecules in more concentrated solutions. The small number of compounds in 
the aggregates, relatively to that of Costa et al. where the number of molecules in the 
aggregates was estimated to about ten, probably arises from steric hindrance of the chelate 
complexes, which prevents interactions of the central core. Its mono- or di-substituted 
analogues would probably leave enough space for chelate complexes and would perhaps lead 
to bigger aggregates and therefore higher relaxivities between 10 and 200 MHz. 
 
Chapter IV presented a strategy to couple covalently Gd3+ chelate complexes to the chitosan, 
a polysaccharide linear polymer with remarkable biological and biomedical properties. This 
was achieved through the amide bond formation between the deacetylated free amine of the 
chitosan with the pending butyrate arm of the compound [Gd(DTTA-N’but)(H2O)2]2-. The 
structural characterization, in terms of degree of acetylation, deacetylation and modification, 
was determined by elemental analysis and ICP-MS. This material was subsequently used to 
form hydrogel nanoparticles, or nanogels, via a folding induced by the interaction of the anion 
triphosphate TPP with the protonated chitosan amines. The nanogels, coated with the 
negatively charged polysaccharide alginate to stabilize the material at physiological pH, were 
characterized by DLS and TEM. Though the linear polymer presented interesting relaxivities, 
the relaxivities of the nanogel considerably drops. This might be due to the partial 
complexation of the Gd3+ by the pentaanion TPP, reducing the average hydration number of 
the complexes. The low quantity of available material, the high viscosity of concentrated 
solutions and the stability of the nanogel did unfortunately not allow to further investigate this 
system, typically by 17O NMR measurements. 
 
Chapter V presented potential targeted CAs composed by Gd3+ conjugated with the peptide 
neurotransmitter bombesin, whose receptors are overexpressed by a number of malignant 
tumor cells.10 To optimize the affinity of the compound with the targeted cells via bombesin-
bombesin receptor interaction, two bombesin analogues, the Lys3-BN and the Ahx-BN(4-14) 
were used to prepare the monovalent and the divalent peptide conjugates. These compounds, 
and particularly the divalent peptide conjugates, presented interesting relaxivities for a DOTA 
system with a hydration number of 1. One should however realize that such CAs are expected 
to be bound to the cell when measured, which would drastically influence the rotational 
correlation time and the internal rotation and therefore affect radically the relaxivity. The next 
step to optimize this family of potential targeted CAs composed by a Gd3+ complex bound to 
the bombesin would be achieved by increasing the number of chelate complexes. Though the 
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relaxivity would not, or nearly not, be affected, the relaxivity density would be enhanced, 
increasing the efficiency of the CA. Attempts to intercalate a dendron between the peptide and 
the chelating units have up to now not been successful, but seem to be a promising route to 
enhance the number of Gd3+ chelate complexes. 
 
To conclude, we can affirm that the field of MRI contrast agents has still numerous promising 
directions for its development, in which some major challenges remain, such as responsive, 
targeted or bimodal CAs. The fitting methods and the 17O NMR measurement can provide a 
number of essential information on the developed systems. The understanding of the meaning 
of the fitted parameters is therefore essential to tune and optimize the properties of newly 
developed potential CAs. 
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VII.1. General Appendix 
VII.1.1 Symbols 
β1 flip angle induced by the applied radiofrequency field 
χv volume magnetic susceptibility 
χM molar magnetic susceptibility 
χ(1+η2/3)1/2 nuclear quadrupole coupling constant 
Δ magnitude of the transient ZFS interaction (= a2T)  
ΔH‡ activation enthalpy 
ΔS‡ activation entropy 
Δσ chemical shift anisotropy 
ΔV(r) voxel of dimensions r 
ΔωM chemical shift difference in paramagnetic environment (rad s-1) 
ΔωOS chemical shift difference due to outer-sphere contribution (rad s-1) 
Δωr reduced chemical shift difference (rad s-1) 
δ chemical shift 
γI    gyromagnetic ratio of the particle I (generally the nucleus) 
γS  gyromagnetic ratio of the particle I (generally the electron) 
η asymmetry parameter of the electric field gradient 
η viscosity coefficient 
μ  magnetic moment 
ν frequency (s-1) 
ν0 nuclear Larmor frequency (s-1) 
ρ spin density 
τ variable delay 
τc correlation time 
τdi dipolar correlation time 
τg global rotational correlation time 
τl local rotational correlation time 
τM mean residence time in paramagnetic environment M 
τR
 rotational correlation time 
τR
298 rotational correlation time at 25°C 
τR
HW rotational correlation time of the water proton 
τR
OW rotational correlation time of the water oxygen 
τS0 electronic relaxation time at zero-field 
τsci scalar correlation time 
τv correlation time for transient ZFS 
Ω angular frequency of the applied radiofrequency pulse 
ω angular frequency (rad s-1) 
ω0 resonance angular frequency, angular Larmor frequency 
A/ħ scalar coupling constant (rad s-1) 
a2T second order transient ZFS parameter (= Δ) 
ak static ZFS parameter of order k = 2, 4, 6 (a2 = D) 
B magnetic field 
B0 static magnetic field 
B0 magnitude of the magnetic field B0 
B1 applied radiofrequency magnetic field 
Beff effective (experienced) magnetic field 
CSR spin-rotation constant 
CDD dipolar coupling constant 
COS outer-sphere empirical constant 
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D axial ZFS parameter (second order parameter for the static ZFS) (= a2) (cm-1) 
D translational diffusion coefficient 
d density 
d12 closest distance of approach of particles 1 and 2 
DGdH298 relative translational diffusion coefficient for diffusion of Gd and water proton at 25°C 
dH hydrodynamic diameter 
E energy 
Ea activation energy 
EDGdH translational diffusion activation energy for mutual diffusion of Gd and water proton 
El internal rotation activation energy 
Em energy of the nuclear spin state m 
eqzz electric field gradient along the z-axis 
ER rotational activation energy 
Ev transient zero-field splitting activation energy 
F torque 
G field gradient 
g Landé g-factor 
G(τ) correlation function 
ge Landé g-factor for free electron 
I spin angular momentum 
I nuclear spin quantum number 
Ir molecular inertia moment 
J(ω,τ) spectral density function 
kex298 exchange rate constant at 25°C 
M molar mass 
M  magnetization 
m magnetic quantum number 
M0 equilibrium magnetization along the z-axis 
Mxy magnetization component in the xy-plane 
Mz magnetization component along the z-axis 
N0 total number of spins 
Nm nuclear spin population in the spin state m 
Pm mole fraction of water bound to a metal ion 
Q nuclear quadropole moment 
q hydration number (number of water molecules in the inner sphere of a complex) 
r radius 
R1 longitudinal relaxation rate = 1/T1 
r1 relaxivity 
R2 transverse relaxation rate = 1/T2 
rIS interspin distance between the spins I and S 
rGdH water proton-gadolinium distance in the inner sphere of the complex (= rGdH 1st) 
rGdH 2nd water proton-gadolinium closest distance of the bulk water (= dGdH) 
rGdO water oxygen-gadolinium distance in the inner sphere of the complex 
S spin of the particle S 
S2 Lipari-Szabo parameter 
T temperature 
t time 
T1 longitudinal nuclear relaxation time 
T2 transverse nuclear relaxation time 
TiC (i = 1, 2) nuclear relaxation times due to Curie relaxation 
TiCSA (i = 1, 2)  nuclear relaxation times due to chemical shift anisotropy relaxation 
Tid (i = 1, 2) diamagnetic nuclear relaxation times  
TiDD (i = 1, 2) nuclear relaxation times due to dipolar relaxation 
Tie (i = 1, 2) electron spin relaxation times 
TiM (i = 1, 2) nuclear relaxation times in paramagnetic environment M (without chemical exchange) 
Tiobs (i = 1, 2) observed nuclear relaxation times 
Tip (i = 1, 2) paramagnetic nuclear relaxation times  
TiQ (i = 1, 2) nuclear relaxation time due to quadropolar relaxation 
Tiref (i = 1, 2) nuclear relaxation time of the reference 
Tir (i = 1, 2) reduced nuclear relaxation time 
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TiSC (i = 1, 2) nuclear relaxation times due to scalar relaxation 
TiSR (i = 1, 2) nuclear relaxation times due to spin-rotation relaxation 
wX mass fraction of the element X  
+ tert-butyl 
 
VII.1.2 Abbreviations 
Ar aromatic 
AUC analytical ultracentrifugation 
br s broad signal 
bisoxa(DO3A)26- bis(1,4-(1-(carboxymethyl)-1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)-1-cyclododecyl))-
1,10-diaza-3,6-dioxadecane 
BMS bulk magnetic susceptibility 
BN bombesin 
Bn benzyl 
BPO benzyl peroxide 
CA contrast agent 
Cbz carbobenzyle 
CCW counterclockwise 
Chi chitosan 
CPMG Carr-Purcell-Meiboom-Gill 
CSA chemical shift anisotropy 
CW  clockwise 
DA degree of acetylation 
DCM dichloromethane 
DD degree of deacetylation 
DD  dipole-dipole (or dipolar) interaction 
DIPEA diisopropylethylamine 
DLS dynamic light scattering 
DM degree of modification 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DO3A3- 1,4,7,10-tetraazacyclododecane-N,N’,N’’-triacetate 
DOSY diffusion ordered spectroscopy 
DOTA4- 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetate 
DTPA5- diethylenetriamine-N,N,N’,N’’,N’’-pentaacetate 
DTTA4- diethylenetriamine-N,N,N’’,N’’-tetraacetate 
DTTA-N’but5-  diethylenetriamine-N,N,N’’,N’’-tetraacetate-N’-propionic acetate 
DTTA-N’prop5- diethylenetriamine-N,N,N’’,N’’-tetraacetate-N’-butyric acetate 
DTPA-BA3- diethylenetriamine-N,N’’-bis amide-N’,N’,N’’-triacetate  
DTPA-CHD3- diethylenetriamine-N,N’’-cyclohexanediamide -N’,N’,N’’-triacetate 
DTPA-BMA3- 1,7-bis[(N-methylcarbonyl)methyl]-1,4,7-triazaheptane-1,4,7-triacetate 
EDC N-[3-(dimethylamino) propyl]-N’-ethylcarbodiimide hydrochloride 
EDTA4- 1,2-ethylenediamine-N,N,N’,N’-tetraacetate 
ELS  electrophoretic light scattering 
eq equivalent 
EPR electron paramagnetic relaxation 
ESI electron spray ionisation 
Et  ethyl 
EtOH ethanol 
FAB-MS fast atom bombardment mass spectroscopy 
FFC fast field cylce 
FID free induction decay 
Fmoc fluorenylmethyloxycarbonyl 
G (1-4)-linked α-L-guluronate 
GBCA gadolinium-based contrast agent 
hrs hours 
HP-DO3A 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-triacetic acid 
HPLC high pressure liquid chromatography 
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ICP-MS induced coupled plasma mass spectroscopy 
IR inversion recovery pulse sequence 
IS inner-sphere 
LS Lipari-Szabo 
M (1-4)-linked β-D-mannuronate 
MALDI matrix-assisted laser desorption 
Me methyl 
MeOH methanol 
Mes mesithylene 
min minutes 
MRI magnetic resonance imaging 
MS mass spectrometry 
mX(DO3A)26- 1,3-bis{[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl]methyl}benzene 
NBS N-bromosuccinimide 
NCF neutron-capture therapy 
NFS nephrogenic systemic fibrosis 
Ng nanogel 
NMR nuclear magnetic resonance 
NMRD  nuclear magnetic relaxation dispersion 
OS outer-sphere 
PAMAM poly(amido amine) 
PBS Phosphate Buffered Saline 
PdI polydispersity index 
PEG polyethylene glycol 
PRE paramagnetic relaxation enhancement 
pX(DO3A)26- 1,4-bis{[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl]methyl}-benzene 
RF radiofrequency 
RFB Rast-Fries-Belorizky 
SBM Solomon-Bloembergen-Morgan 
SC scalar (or Fermi contract) interaction 
SED Stokes-Einstein-Debye 
SOMO singly occupied molecular orbital  
SOP Standard Operating Procedures 
SPIO nanoparticular superparamagnetic ion oxides  
SPPS solid phase peptide synthesis 
Sulfo-NHS N-hydoxysulfosuccinimide 
t-Bu tert-butyl 
TEM transmission electron microscopy 
TOF time of flight 
TEA triethylamine 
TFA trifluoroacetic acid 
TPP triphosphate 
TTAHA6- N-tris(2-aminoethyl)amine-N’,N’,N’’,N’’,N’’’,N’’’-hexaacetate 
UV-Vis ultraviolet-visible 
vbr s very broad signal  
ZFS zero-field-splitting 
 
VII.1.3 Constants and numbers 
γe gyromagnetic ratio of the electron  -1.7609 · 1011  rad T-1 s-1 
γH gyromagnetic ratio of the proton  2.6751 · 108  rad T-1 s-1 
μ0  vacuum permeability    4π · 10-7  N A-2 
μB Bohr magneton    9.274 · 10-24 J T-1 
e Euler’s number     2.71828 
h Planck constant    6.6261 · 10-34 J s 
ħ Reduced Planck constant (= h / 2π)  1.054 · 10-34 J s 
kB Boltzmann constant    1.3807 · 10-34 J K-1 
NA Avogadro constant    6.022 · 10-23 mol-1  
R gas constant     8.3145  J K-1 mol-1  
Appendix 
183 
VII.2. Appendix to Chapter II 
VII.2.1. Transmetallation 
t / min T1obs / ms t / min T1obs / ms t / min T1obs / ms 
0 566.08 216 470.97 526 465.46 
5 537.08 226 471.07 536 465.66 
8 530.57 236 470.47 546 465.07 
10 527.00 246 469.56 556 465.17 
12 522.84 256 469.46 566 465.36 
14 519.74 266 468.85 576 465.07 
17 516.79 276 468.55 586 465.26 
23 512.92 286 468.65 596 464.97 
27 506.27 296 468.45 606 464.77 
33 500.83 306 468.25 616 464.87 
38 496.40 316 467.85 626 465.46 
40 495.16 326 467.85 636 464.97 
46 492.71 336 467.75 646 464.47 
47 491.60 346 467.35 656 465.17 
53 488.42 356 467.35 666 464.87 
56 487.77 366 467.15 676 464.77 
66 487.77 376 466.95 686 464.77 
76 484.10 386 467.25 696 464.67 
86 481.65 396 467.05 706 464.97 
96 479.64 406 466.95 716 465.07 
106 478.39 416 466.65 726 464.67 
116 476.72 426 466.26 736 464.67 
126 475.48 436 466.55 746 464.47 
136 474.75 446 466.75 756 464.47 
146 473.52 456 465.96 766 464.87 
156 474.44 466 465.96 776 464.08 
166 473.52 476 465.66 786 464.38 
176 473.01 486 466.26 796 464.57 
186 472.29 496 465.56 806 464.47 
196 471.48 506 465.66   
206 471.28 516 465.46   
 
Table VII.1  –  Relaxation times T1 at 25°C, 30 MHz of the system Gd3+ / 
{Mes[Gd(DO3A)(H2O)2]3} during transmetallation 
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VII.2.2. Normalized peak areas as a function of pH 
pH normalized peak area @ 7.09 ppm normalized peak area @ 7.52 ppm 
1.15 0 1 
2.95 0.17 0.83 
5.60 0.72 0.28 
9.18 0.85 0.15 
13.29 0.97 0.03 
 
Table VII.2  –  Normalized aromatic peak areas of isomers A and B of the bis-Gd 
complex {Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- as a function of 
pH. 
 
VII.2.3. 17O NMR data of {Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- 
T / °C 1000/T / K-1 ln (1/T1r) ln (1/T2r) Δωr / 106 rad s-1 
89.6 2.76 9.226 12.48 -0.5686 
76.4 2.86 9.461 12.83 -0.5686 
66.9 2.94 9.559 12.68 -0.6053 
58.4 3.02 9.754 12.79 -0.6039 
55.7 3.04 9.813 12.93 -0.6583 
44.4 3.15 10.04 13.19 -0.6583 
38.6 3.21 10.18 13.66 -0.6726 
29.4 3.31 10.33 14.24 -0.6398 
17.5 3.44 10.67 14.70 -0.5653 
2.0 3.63 11.07 14.87 -0.3912 
 
Table VII.3  –  Variable temperature reduced relaxation rates (1/Tir, i = 1, 2) and 
chemical shifts Δωr of the water 17O of the bis-Gd complex 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- ([Gd3+] = 20.15 mM). 
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VII.2.4. 17O NMR data of {Mes[Gd(DO3A)(H2O)2]3} 
T / °C 1000/T / K-1 ln (1/T1r) ln (1/T2r) Δωr / 106 rad s-1 
89.6 2.76 8.893 12.24 -0.4682 
76.4 2.86 9.155 12.60 -0.5540 
66.9 2.94 9.380 13.00 -0.5532 
58.4 3.02 9.657 13.16 -0.6044 
55.7 3.04 9.751 13.21 -0.5946 
44.4 3.15 9.949 13.51 -0.5946 
38.6 3.21 10.21 13.52 -0.6622 
29.4 3.31 10.41 13.93 -0.6421 
17.5 3.44 10.64 14.39 -0.5790 
2.0 3.63 11.14 14.76 -0.4597 
 
Table VII.4  –  Variable temperature reduced relaxation rates (1/Tir, i = 1, 2) and 
chemical shifts Δωr of the water 17O of the tris-Gd complex 
{Mes[Gd(DO3A)(H2O)2]3} ([Gd3+] = 20.61 mM). 
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VII.2.5. 1H NMRD data of bis-Gd and tris-Gd complexes  
r1 / mM-1 s-1 
Bis-Gd Tris-Gd 
{Mes(H2DO3A)[Gd(DO3A)(H2O)]2}- {Mes[Gd(DO3A)(H2O)2]3} 
ν (1H) / MHz 
25.0°C 37.0°C 25.0°C 37.0°C 
0.0100 7.70 6.78 16.04 13.80 
0.0144 7.71 6.78 16.06 13.72 
0.0208 7.73 6.78 16.09 13.72 
0.0298 7.70 6.78 16.07 13.77 
0.0428 7.71 6.78 16.06 13.72 
0.0616 7.73 6.79 16.01 13.80 
0.0887 7.72 6.79 16.01 13.85 
0.127 7.82 6.80 16.03 13.81 
0.183 7.84 6.81 16.04 13.89 
0.264 7.92 6.83 16.10 13.89 
0.379 7.92 6.85 16.12 13.91 
0.546 7.94 6.88 16.07 13.96 
0.785 7.90 6.91 16.05 13.70 
1.13 7.80 6.94 15.63 13.97 
1.62 7.83 6.95 15.60 13.91 
2.34 7.80 6.90 15.28 13.80 
3.36 7.87 6.74 14.71 13.49 
4.83 7.83 6.44 14.10 13.13 
6.95 7.47 6.13 13.63 11.94 
10 7.00 5.99 13.19 11.15 
12 6.93 5.99 13.04 10.48 
14 7.05 6.01 13.09 10.37 
16 7.23 6.03 13.16 10.37 
18 7.31 6.05 13.82 10.32 
20 7.45 6.07 13.65 10.23 
30 7.73 6.09 14.08 10.68 
40 7.97 6.06 14.21 10.63 
60 7.73 5.98 14.33 10.52 
100 7.52 5.85 13.87 10.23 
200 6.69 5.63 13.42 9.80 
400 5.91 5.17 11.14 8.96 
 
Table VII.5  –  Water proton relaxivities r1 at 25°C and 37°C of the bis-Gd 
complex ([Gd3+] = 5.53 mM) and the tris-Gd complex ([Gd3+] = 
12.79 mM) as a function of the proton Larmor frequency. 
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VII.3. Appendix to Chapter III 
VII.3.1 Relaxivity of {Ph4[Gd(DTTA)(H2O)2]-3} as a function of [Gd3+] 
[Gd3+] / mM T1 / s r1 / mM-1 s-1 
1.515 0.01535 42.76 
1.264 0.01870 42.02 
0.999 0.02480 39.98 
0.746 0.03430 38.61 
0.508 0.05348 36.11 
0.295 0.09880 33.03 
0.146 0.2109 29.98 
0.0740 0.4057 28.38 
0.0486 0.5855 27.62 
0.0237 0.9790 27.62 
0.00938 1.649 25.63 
18.92 48.14 48.14 
18.18 50.56 50.56 
9.906 48.19 48.19 
4.235 44.98 44.98 
1.838 43.06 43.06 
0.947 41.71 41.71 
0.471 36.81 36.81 
0.226 32.14 32.14 
0.103 27.05 27.05 
0.0478 26.35 26.35 
0.0227 24.89 24.89 
0.0103 25.63 25.63 
 
Table VII.6  –  Water proton relaxation times T1 and relaxivities r1 at 25°C, 
30MHz of two {Ph4[Gd(DTTA)(H2O)2]-3} systems resulting from 
different synthesis batches as a function of the Gd3+ concentration. 
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VII.3.2 1H NMRD data of {Ph4[Gd(DTTA)(H2O)2]-3} 
 r1 / mM-1 s-1 
[Gd3+] / mM 18.18 1.838 0.101 
ν (1H) / MHz 25.0°C 37.0°C 25.0°C 37.0°C 25.0°C 
0.0100   37.78 32.37 28.39 
0.0137   37.44 32.31 28.92 
0.0190   37.61 32.12 29.03 
0.0262   37.22 32.26 28.99 
0.0360   37.16 32.12 28.97 
0.0497   37.36 32.36 29.29 
0.0686   37.22 32.32 28.98 
0.0943   37.22 32.20 28.76 
0.130   37.27 31.76 28.78 
0.180   36.91 31.99 28.91 
0.247   36.62 31.82 28.76 
0.341   36.73 31.31 28.39 
0.469   35.86 31.17 28.60 
0.647   34.95 30.58 27.91 
0.892   34.14 29.32 26.98 
1.23   32.88 28.55 25.40 
1.69   31.35 27.13 24.92 
2.33   29.60 25.60 23.95 
3.22   27.91 24.32 22.61 
4.43   26.59 22.68 20.94 
6.11   26.14 22.01 19.97 
8.42   28.45 23.18 20.05 
11.6   32.11 25.40 21.28 
16   35.72 27.71 22.38 
20 46.67 38.28 38.52 29.68 22.84 
30 50.55 41.64 42.47 32.32 24.67 
40 53.15 44.16 43.49 33.26 25.27 
60 47.75 40.80 42.16 32.32 25.27 
100 34.61 32.72 31.69 27.27 23.76 
200 15.01 17.43 16.74 16.72 17.63 
400 7.51 7.86 7.94 8.40 9.97 
800 4.17 4.00 4.17 4.19 4.70 
 
Table VII.7  –  Water proton relaxivities r1 at 25°C and 37°C of 
{Ph4[Gd(DTTA)(H2O)2]-3} at different concentrations as a 
function of the proton Larmor frequency. 
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VII.3.3 17O NMR data of {Ph4[Gd(DTTA)(H2O)2]-3} 
T / °C 1000/T / K-1 ln (1/T1r) ln (1/T2r) Δωr / 106 rad s-1 
25.2 3.35 11.66 14.00 -0.763 
44.2 3.15 11.30 13.66 -0.783 
61.8 2.99 10.89 13.15 -0.678 
89.9 2.75 10.50 12.28 -0.582 
79.6 2.83 10.48 12.59 -0.674 
70.4 2.91 10.72 12.88 -0.668 
52 3.08 11.14 13.45 -0.790 
35.3 3.24 11.39 13.83 -0.805 
14 3.48 11.85 14.17 -0.687 
2 3.63 11.88 14.10 -0.423 
-2 3.69 11.83 14.08 -0.369 
 
Table VII.8  –  Variable temperature reduced relaxation rates (1/Tir, i = 1, 2) and 
chemical shifts Δωr of the water 17O of {Ph4[Gd(DTTA)(H2O)2]-3} 
([Gd3+] = 15.37 mM). 
 
VII.3.4 Relaxivities of {Ph4[Gd(DTTA)(H2O)2]-3} as a function of pH 
pH [Gd3+] / mM T1 / ms r1 / mM-1 s-1 
7.07 0.756 31.53 41.45 
5.7 0.767 31.64 40.73 
4.71 0.792 31.06 40.19 
4.47 0.763 32.10 40.35 
4.16 0.763 31.96 40.50 
4.07 0.761 31.20 41.62 
 
Table VII.9  –  Water proton relaxivities r1 of {Ph4[Gd(DTTA)(H2O)2]-3} ~ 0.8 
mM at 25°C, 20 MHz as a function of pH 
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VII.3.5 Relaxivities time evolution of {Ph4[Gd(DTTA)(H2O)2]-3} vs.  [PO43-] 
 r1 / mM-1 s-1 
[PO43-] / mM  /  t / h 0.17 24 48 72 96 120 144 
0 54.94 54.74 54.74 54.40 54.09 54.36 54.77 
11.5 55.26 52.72 51.67 51.10 50.46 50.84 51.13 
21.2 54.96 51.61 49.26 48.24 47.49 47.29 47.21 
50.9 53.74 47.01 39.02 35.75 33.62 31.42 30.24 
115.6 49.77 33.29 13.34 8.42 5.27 3.72 2.99 
221.7 42.84 16.58 2.50 1.80 1.31 1.13 1.06 
506.8 32.42 4.56 1.36 1.24 1.19 1.02 1.00 
 
Table VII.10 –  Time evolution of the water proton relaxivities r1 at 25°C, 30 MHz 
of {Ph4[Gd(DTTA)(H2O)2]-3} ([Gd3+] = 2.25 mM) as a function of 
the phosphate concentration. 
 
VII.3.6 Relaxivities time evolution of {Ph4[Gd(DTTA)(H2O)2]-3} in human serum 
t / h r1 / mM-1 s-1 
0.17 60.51 
24 59.03 
48 58.01 
72 57.55 
96 57.18 
120 56.69 
144 56.18 
168 56.77 
 
Table VII.11 –  Time evolution of the water proton relaxivities r1 at 25°C, 30 MHz 
of {Ph4[Gd(DTTA)(H2O)2]-3} ([Gd3+] = 2.25 mM) in 32% w/w 
human serum. 
 
 
 
 
 
 
 
 
Appendix 
191 
VII.4. Appendix to Chapter IV 
VII.4.1. ICP-MS instrumentation parameters and performance report 
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VII.4.2. ICP-MS experimental data 
 isotope concentr. ppm 
3+
3+
Gd
Eu
  
  
 
I 
cps 
Gd
Eu
I
I
 
blank
Gd
blank
Eu
I
I
 
151Eu 0.2974  13852135.4   
155Gd  481.6 0.00003477  Blank 
157Gd 
0 
 472 0.00003407  
151Eu 0.3011 14831723   
155Gd 13173741 0.88821 0.88818 Standard 1 
157Gd 
0.9763 
3.242 
15266177 1.02929 1.02926 
151Eu 0.2907 14720575   
155Gd 4123073 0.28009 0.28005 Standard 2 
157Gd 
0.2885 
0.9924 
4786912 0.32519 0.32515 
151Eu 0.2904  15780928   
155Gd 0.64428 0.2188 9616625 0.60938 0.60935 Sample 
157Gd 0.64400 0.2178 11141001 0.70598 0.70595 
 
Table VII.12 –  Experimental values of ICP-MS intensities, in counts per seconds, 
for the isotopes 151Eu, 155Gd and 157Gd at precise concentrations to 
determine [Gd3+] for 10.54 mg of sample in 5.00533 g of solution. 
Bold values obtained from linear fit of experimental points (Figure 
VII.1) 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
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Figure VII.1 –  Linear fits, allowing the determination of the Gd3+ concentration, 
for corrected 155Gd (●) and 157Gd (○) intensities with respect to the 
internal reference 151Eu. 
 
y = 0.31831 (± 0.00285) x 
R2 = 0.99984 
y = 0.27463 (± 0.00231) x 
R2 = 0.99986 
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VII.4.3. 1H NMRD data of [Gd(DTTA-N’but)(H2O)2]2- and [Gd(DTTA-Me)(H2O)2]-  
r1 / mM-1 s-1 
[Gd(DTTA-N’but)(H2O)2]2- [Gd(DTTA-Me)(H2O)2]- ν (1H) / MHz 
25.0°C 37.0°C 25.0°C 37.0°C 
0.0100 15.34 12.29 12.31 10.58 
0.0137 15.34 12.19 12.34 10.49 
0.0190 15.32 12.25 12.28 10.54 
0.0262 15.32 12.28 12.22 10.58 
0.0360 15.35 12.32 12.25 10.51 
0.0497 15.35 12.31 12.29 10.53 
0.0686 15.36 12.28 12.34 10.48 
0.0943 15.25 12.25 12.33 10.44 
0.130 15.26 12.22 12.30 10.45 
0.180 15.34 12.10 12.25 10.51 
0.247 15.21 12.21 12.23 10.39 
0.341 15.25 12.21 12.24 10.45 
0.469 15.18 12.22 12.22 10.38 
0.647 15.16 12.13 12.17 10.38 
0.892 15.10 12.10 12.09 10.28 
1.23 14.89 11.98 11.96 10.24 
1.69 14.62 11.77 11.79 9.98 
2.33 14.20 11.44 11.62 9.92 
3.22 13.50 10.85 11.17 9.55 
4.43 12.45 10.18 10.30 8.92 
6.11 11.55 9.67 9.71 8.41 
8.42 10.87 8.70 8.82 7.48 
11.6 10.02 7.99 7.95 6.94 
16 9.44 7.30 7.48 5.97 
20 9.02 7.01 7.21 5.54 
30 8.67 6.52 6.92 5.30 
40 8.52 6.34 6.74 5.10 
60 8.62 6.30 6.77 4.96 
100 8.47 6.30 6.43 4.80 
200 8.60 6.40 6.45 4.77 
400 8.04 6.08 6.18 4.61 
 
Table VII.13 –  Water proton relaxivities r1 at 25°C and 37°C of [Gd(DTTA-
N’but)(H2O)2]2- ([Gd3+] = 2.55/3.50 mM) and  [Gd(DTTA-
Me)(H2O)2]- ([Gd3+] = 3.30/2.97 mM) as a function of the proton 
Larmor frequency. 
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VII.4.4. 1H NMRD data of {Chi[Gd(DTTA-N’but)(H2O)2]-} and Ng{Chi[Gd(DTTA-
N’but)(H2O)2]-} 
r1 / mM-1 s-1 
{Chi[Gd(DTTA-N’but)(H2O)2]2-} Ng{Chi[Gd(DTTA-N’but)(H2O)2]2-} ν (1H) / MHz 
25.0°C 37.0°C 25.0°C 
0.0100 32.93 27.76 24.86 
0.0137 32.85 27.70  
0.0190 32.81 27.99 24.83 
0.0262 32.58 27.94  
0.0360 32.61 28.13 24.62 
0.0497 32.44 28.12  
0.0686 32.63 27.76 24.66 
0.0943 32.35 27.47  
0.130 32.51 27.38 22.44 
0.180 32.17 27.37  
0.247 32.08 27.32 21.81 
0.341 31.66 26.90  
0.469 31.61 26.33 21.26 
0.647 30.32 26.29  
0.892 29.64 25.41 20.08 
1.23 28.34 24.57  
1.69 27.42 23.62 18.54 
2.33 26.73 22.98  
3.22 25.26 21.54 15.37 
4.43 23.11 20.18  
6.11 22.71 19.11 13.97 
8.42 23.86 19.09  
11.6 25.46 20.49 13.38 
16 27.83 21.87  
20 29.52 22.51 16.72 
30 32.69 25.38 18.27 
40 33.64 26.03 18.12 
60 32.52 24.94 17.25 
100 24.59 20.11 13.27 
200 17.38 14.96 11.07 
400 11.81 10.33 8.61 
 
Table VII.14 –  Water proton relaxivities r1 of {Chi[Gd(DTTA-N’but)(H2O)2]-} 
([Gd3+] = 0.97/0.65 mM) and  Ng{Chi[Gd(DTTA-N’but)(H2O)2]-} 
([Gd3+] = 0.13 mM) as a function of the proton Larmor frequency. 
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VII.4.5. Relaxivities of {Chi[Gd(DTTA-N’but)(H2O)2]2-} as a function of [Gd3+] 
[Gd3+] / mM  [Chi] / %(w/w) r1 / mM-1 s-1 
1.05 0.57 28.60 
0.835 0.45 28.72 
0.629 0.34 29.07 
0.415 0.23 28.94 
0.205 0.11 27.15 
0.103 0.056 26.58 
 
Table VII.15 –  Water proton relaxivities r1 at 25°C, 20 MHz as a function of the 
Gd3+ and chitosan concentration. 
 
VII.4.6. Relaxivities time evolution of {Chi[Gd(DTTA-N’but)(H2O)2]2-} 
time / day r1 / mM-1 s-1 
0 29.52 
1 29.92 
2 29.64 
3 30.27 
4 29.80 
7 29.84 
14 29.83 
31 29.66 
 
Table VII.16 –  Water proton relaxivities r1 at 25°C, 20 MHz as a function of time. 
 
VII.4.7. ZetaSizer Nano-ZS parameters of the Standard Operating Procedures (SOP) 
Parameters  
Equilibrium time  / s 180 
Temperature / °C 25 
Refractive index 1.59 
Absorption 0.0 / 0.3 (samples in DMEM) 
Dispersant Water 
Number of measures 3 
Runs Automatic 
Angle 173° - Backscatter (size) 
Model Smoluchowski (zeta) 
 
Table VII.17 –  Parameters of the SOP for the analysis of nanogel size distribution 
and zeta potential in the ZetaSizer Nano-ZS. 
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VII.4.8. DLS size distribution of Ng{Chi[Gd(DTTA-N’but)(H2O)2]-} 
size dH / nm intensity / % size dH / nm intensity / % 
 modified Ng standard Ng  modified Ng standard Ng 
0.7195 0 0 91.28 0 0 
0.8332 0 0 105.7 0 0 
0.9649 0 0 122.4 0 0 
1.117 0 0 141.8 0 0 
1.294 0 0 164.2 0.133 0 
1.499 0 0 190.1 1.467 0 
1.736 0 0 220.2 3.967 0.6 
2.01 0 0 255 7.233 1.9 
2.328 0 0 295.3 10.5 4 
2.696 0 0 342 13.067 6.5 
3.122 0 0 396.1 14.4 8.9 
3.615 0 0 458.7 14.167 10.8 
4.187 0 0 531.2 12.6 12 
4.849 0 0 615.1 9.933 12.2 
5.615 0 0 712.4 6.8 11.6 
6.503 0 0 825 3.833 10.1 
7.531 0 0 955.4 1.533 8.2 
8.721 0 0 1106 0.3 6 
10.1 0 0 1281 0 3.9 
11.7 0 0 1484 0 2.1 
13.54 0 0 1718 0 0.9 
15.69 0 0 1990 0 0.2 
18.17 0 0 2305 0 0 
21.04 0 0 2669 0 0 
24.36 0 0 3091 0 0 
28.21 0 0 3580 0 0 
32.67 0 0 4145 0 0 
37.84 0 0 4801 0 0 
43.82 0 0 5560 0 0 
50.75 0 0 6439 0 0 
58.77 0 0 7456 0 0 
68.06 0 0 8635 0 0 
78.82 0 0 10000 0 0 
 
Table VII.18 –  Intensity frequencies of Ng{Chi[Gd(DTTA-N’but)(H2O)2]-} 
(modified Ng) and unmodified nanogels as a function of the 
hydrodynamic diameter. 
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VII.5. Appendix to Chapter V 
VII.5.1. 1H NMRD data of monovalent peptide conjugates 
r1 / mM-1 s-1 
{Lys3-BN[Gd(DOTA)(H2O)]} {Ahx-BN(4-14)[Gd(DOTA)(H2O)]} ν (1H) / MHz 
25.0°C 37.0°C 25.0°C 37.0°C 
0.0100 21.15 18.35 18.74 15.24 
0.0144 21.16 18.34 18.71 15.14 
0.0208 21.16 18.26 18.75 15.10 
0.0298 21.13 18.20 18.72 15.08 
0.0428 21.11 18.21 18.77 14.97 
0.0616 21.14 18.21 18.79 14.95 
0.0887 21.12 18.17 18.72 14.95 
0.127 21.13 18.14 18.72 14.91 
0.183 21.06 18.11 18.71 14.88 
0.264 20.98 18.11 18.60 14.72 
0.379 20.76 17.86 18.44 14.64 
0.546 20.39 17.56 18.15 14.67 
0.784 19.99 17.17 17.68 14.41 
1.13 19.23 16.43 17.11 13.76 
1.62 17.97 15.35 16.05 13.03 
2.34 16.41 13.99 14.71 11.90 
3.36 14.71 12.55 13.11 10.48 
4.83 13.41 11.39 11.55 9.21 
6.95 12.58 10.57 10.34 8.20 
10 12.23 9.99 9.23 7.79 
14 12.27 10.16 8.98 7.70 
18 13.03 10.46 9.31 7.65 
30 12.76 9.66 9.53 7.20 
40 11.98 9.29 9.41 7.04 
60 11.60 8.82 9.33 6.91 
100 10.76 8.10 8.83 6.46 
200 8.96 7.02 7.67 5.87 
400 6.48 5.62 6.05 5.28 
 
Table VII.19 –  Water proton relaxivities r1 of {Lys3-BN[Gd(DOTA)(H2O)]} 
([Gd3+] = 0.75 mM) and {Ahx-BN(4-14)[Gd(DOTA)(H2O)]} 
([Gd3+] = 1.63 mM) as a function of the proton Larmor frequency. 
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VII.5.2. 1H NMRD data of divalent peptide conjugates 
r1 / mM-1 s-1 
{(Lys3-BN)2[Gd(DOTA)(H2O)]} {(Ahx-BN(4-14))2[Gd(DOTA)(H2O)]} ν (1H) / MHz 
25.0°C 37.0°C 25.0°C 37.0°C 
0.0100 27.40 21.55 21.71 21.71 
0.0144 27.03 21.54 21.70 21.70 
0.0208 27.21 21.52 21.64 21.64 
0.0298 27.22 21.52 21.59 21.59 
0.0428 27.15 21.48 21.69 21.69 
0.0616 27.23 21.45 21.65 21.65 
0.0887 27.33 21.46 21.64 21.64 
0.127 26.75 21.44 21.61 21.61 
0.183 27.27 21.42 21.35 21.35 
0.264 27.46 21.30 21.36 21.36 
0.379 26.97 20.87 21.24 21.24 
0.546 26.03 20.39 20.74 20.74 
0.784 25.07 19.78 19.95 19.95 
1.13 23.23 18.84 18.93 18.93 
1.62 22.17 17.63 17.82 17.82 
2.34 19.42 15.93 16.51 16.51 
3.36 17.21 14.33 14.48 14.48 
4.83 16.56 13.24 13.35 13.35 
6.95 16.72 13.01 12.97 12.97 
10 17.53 13.06 13.33 13.33 
14 19.05 13.88 14.03 14.03 
18 20.00 14.84 14.82 14.82 
30 20.24 15.42 16.48 16.48 
40 20.07 15.30 16.41 16.41 
60 19.22 14.75 15.83 15.83 
100 15.83 12.86 13.70 13.70 
200 10.80 9.41 10.03 10.03 
400 6.27 6.09 6.40 6.40 
 
Table VII.20 –  Water proton relaxivities r1 of {(Lys3-BN)2[Gd(DOTA)(H2O)]} 
([Gd3+] = 0.48 mM) and {(Ahx-BN(4-14))2[Gd(DOTA)(H2O)]} 
([Gd3+] = 1.62 mM) as a function of the proton Larmor frequency. 
 
199 
Hugues Jaccard 
 
 
 
 
 
 
Education 
  
 
 
 
 
 
 
 
Professional Experience  
  
 
 
 
Test 
• 1 
• 2 
• 3 
•  
 
 
 
 
 
 
 
 
 
 
 
 
Skills 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rue de Bourg 11 
1003 Lausanne 
Switzerland 
+41 79 371 40 10 
hugues.jaccard@epfl.ch 
 
PhD in Chemistry (19.07.2011), Ecole Polytechnique Fédérale de Lausanne (EPFL), 
Switzerland 
Master of Science MSc in Molecular and Biological Chemistry, EPFL 
Maturité Fédérale Type C, Yverdon-les-Bains, Switzerland 
 
PhD in the field of MRI contrast agents, Group of Inorganic and Bioinorganic 
Chemistry, Prof. Lothar Helm, EPFL. (Title : “Development and understanding of novel 
compounds designed as potential MRI contrast agents”) 
• Organic synthesis of poly(amino carboxylate) chelating units 
• Inorganic complexation, analytical chemistry 
• NMR measurements and theoretical treatment of relaxometric properties of 
paramagnetic ion complexes. 
 
Teacher of Mathematics, Physics and Sciences at Secondary School, Etablissement 
Secondaire Léon Michaud, Yverdon-les-Bains, Switzerland 
Research assistant in molecular and cellular biology in the field of protozoan parasites, 
Prof. Nicolas Fasel, Université de Lausanne, Switzerland 
Laboratory assistant, Green Coffee Laboratory, Nespresso, Orbe, Switzerland 
Master project in organic chemisty and biochemistry, Prof. Kai Johnsson, Laboratory 
of Protein Engineering, EPFL (Title : “New Substrates for Specific Quenching of hAGT 
for in vivo experiments”) 
 
 
Chemistry Multli-stage organic synthesis 
 NMR analytical methods, theoretical analysis 
Purification (chromatography, HPLC) and analytical techniques (NMR, 
potentiometry, MS, LC-MS, ICP-MS, HPLC, UV-Vis, DLS) 
Biochemistry Molecular biology / biochemistry methods (Western blot, PCR, ELISA) 
Sterile culture of mammalian and protozoan cells 
 
Languages French : mother tongue 
English : fluent 
German : good (C1 level, ZMP Goethe Institut, 2006) 
Italian : basic (A1 level, EPFL, 2008) 
Informatics Standard office and graphics software, Origin, Matlab, ChemDraw, 
Topspin, XWinNMR 
33 years old 
27.10.1977 
Single 
Swiss citizenship 
 
 
 
 
 
2007-2011 
 
 
1998-2004 
 
1993-1996 
 
 
 2007-2011 
 
• Organic  
• Inorganic  
• NMR. 
 
 
2006-2007 
 
 
2004-2005 
 
 
2004 
 
2003-2004 
 
 
 
 
 
200 
 
Publications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patents 
 
 
 
 
 
 
 
 
 
 
Posters Presentations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P. Miéville, H. Jaccard, F. Reviriego, R. Tripier, L. Helm, Synthesis, complexation and 
NMR relaxation properties of Gd3+ complexes of Mes(DO3A)3, Dalton Transactions 
2011, 40(16), 4260-4267. 
K. Abiraj, H. Jaccard, M. Kretzschmar, L. Helm, H.R. Maecke, Novel DOTA-based 
prochelator for divalent peptide vectorization: Synthesis of dimeric bombesin analogues 
for multimodality tumor imaging and therapy, Chemical Communications 2008, (28), 
3248-3250. 
A. Juillerat, C. Heinis, I. Sielaff, J. Barnikow, H. Jaccard, B. Kunz, A. Terskikh, K. 
Johnsson, Engineering substrate specificity of O-6-alkylguanine-DNA alkyltransferase 
for specific protein labeling in living cells, Chembiochem, 2005, 6(7), 1263-1269. 
 
“Mutants of human O6-alkylguanine-DNA alkyltransferase with improved properties” 
J. Barnikov, C. Chidley, T. Gronemeyer, C. Heinis, H. Jaccard, K. Johnsson, A. 
Juillerat, A. Keppler. (EPFL Ecole Polytechnique Fédérale de Lausanne, Switz.). PCT 
Int. Appl. (2005), WO 2005085431. 
“Specific substrates for O6- alkylguanine-DNA alkyltransferase”; H. Jaccard, K. 
Johnsson, M. Kindermann, I. C. Sielaff, (EPFL Ecole Polytechnique Fédérale de 
Lausanne, Switz.). WO 2005085470. 
 
COST Action D38 Annual Meeting 2008 – Sacavém, Portugal, April 27-29th 2008,    
H. Jaccard, C. Cannizzo, C.R. Mayer, L. Moriggi, L. Helm “Surprisingly high 
relaxivities of the [Ph4{Gd(DTTA)(H2O)2}3]3- complex”  
Swiss Chemical Society Fall Meeting 2008 – Zurich, Switzerland, September 11th 
2008, H. Jaccard, C. Cannizzo, C.R. Mayer, L. Moriggi, L. Helm “Remarkably high 
T1 relaxivities of the complex [Ph4{Gd(DTTA)(H2O)2}3]3-” 
 
COST Action D38 Working Group 2 Annual Meeting 2009 – Delft, Netherlands, 
February 19-20th 2009, P. Miéville, H. Jaccard, R. Tripier, L. Helm “Synthesis and 
relaxation properties of the conformation-switching complex 
[Mes{Gd(DO3A)(H2O)2}3]”  
 
COST Action D38 Annual Meeting 2009 – Warsaw, Poland, April 25-27th 2009,   
P. Miéville, H. Jaccard, R. Tripier, L. Helm “Synthesis and relaxation properties of the 
conformation-switching complex [Mes{Gd(DO3A)(H2O)2}3]”  
 
Swiss Chemical Society Fall Meeting 2009 – Lausanne, Switzerland, September 4th 
2009, P. Miéville, H. Jaccard, R. Tripier, L. Helm “New complexation strategy and 
relaxation properties of the conformation-switching complex 
{Mes[Gd(DO3A)(H2O)2]3}” 
 
COST Action D38 Annual Meeting 2010 – Thessaloniki, Greece, June 20-22nd 2010,    
H. Jaccard, L. Helm “Highly-controlled coupling of the MRI contrast agent DTTA-
Gd(III) on the polysaccharide chitosan”  
 
 
 
 
 
201 
 
 COST Action D38 Working Groups 2-6 Annual Meeting 2011 – Torino, Italy, March 
24-26th 2011, H. Jaccard, C. Cannizzo, C.R. Mayer, L. Helm “Dynamic aggregation of 
the mid-size gadolinium complex [Gd3(Ph4DTTA3)(H2O)6]3-”  
 
 
 
 
